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Abstract 
 
 Alcoholism is a complex neuropsychiatric disease that is characterized by 
compulsive alcohol use and intensifying cravings and withdrawals, often culminating in 
physiologic dependency. Fundamental alterations in brain chemistry underlie the 
transition from initial ethanol exposure to repetitive excessive use. Key mediators of this 
adaptation include changes in gene expression and signal transduction. Here we 
investigated gene expression pathways in prefrontal cortex and nucleus accumbens 
following acute or chronic ethanol treatment, to identify genes with potentially conserved 
involvement in the long-term response of the corticolimbic system to repeated ethanol 
exposure. We investigated Gsk3b, which encodes glycogen synthase kinase 3-beta, as 
a highly ethanol responsive gene associated with risk for long-term maladaptive 
responses to ethanol. On the level of the protein, we found that GSK3B and to a lesser 
extent the GSK3A isoform showed robust increases in inhibitory phosphorylation 
following acute ethanol. This inhibition may underlie aspects of the behavioral response 
to acute ethanol, as pre-treatment with a GSK3B inhibitor (tideglusib) augmented 
ethanol’s locomotor effects. Following long term ethanol exposure, we re-tested GSK3B 
phosphorylation and found that its ethanol response is blunted, consistent with 
molecular tolerance as a corollary to increased consumption. As the prefrontal cortex 
(PFC) plays a vital role in the reward pathway via its glutamatergic projections to the 
nucleus accumbens, we investigated the role of the Gsk3b gene specifically in PFC and 
in glutamatergic neurons. Overexpression of Gsk3b in the PFC robustly increased 
ethanol consumption, while deletion in Camk2a-positive neurons significantly attenuated 
ethanol consumption. Pharmacologic antagonism of GSK3B also decreased drinking in 
xvi 
 
a model of binge-like consumption. Collectively this data implicates GSK3B as a 
mediator of excessive ethanol intake via its kinase activity, wherein inhibition of the 
kinase via phosphorylation exerts a protective effect in the context of acute ethanol, but 
desensitizes with repeated exposure. 
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Chapter 1  
Introduction 
 
 Alcohol Use Disorder (AUD) is a chronic relapsing disease characterized 
by compulsive use of alcohol, negative consequences due to alcohol use, and a 
negative emotional state when not using. The DSM-5 (2013) classifies AUD as a 
spectrum disorder with severity ranging from mild, i.e. problem drinking, to 
severe, i.e. alcohol dependence, based on clinical criteria. Alcohol dependence is 
marked by physiological symptoms upon its withdrawal, including hallucinations, 
tremors, and seizures. In some cases this alcohol withdrawal syndrome can be 
fatal (Finn and Crabbe, 1997). The level of central nervous system (CNS) 
dysfunction associated with the mere removal of ethanol at this point in AUD 
pathophysiology demonstrates the extent of fundamental adaptation that has 
occurred with chronic exposure. 
 While alcohol dependence represents a primary disease endpoint in itself, 
adverse outcomes occur all along the pathophysiological process. In 2014, 
alcohol contributed to more than 200 diseases, according to the World Health 
Organization. Nearly 6% of all global deaths were attributable to alcohol, with the 
largest share of these (29.6%) coming from unintentional injuries (such as motor 
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vehicle accidents), followed by cancers (21.6%), and liver cirrhosis (16.6%) 
(Organization, 2014). In the United States, alcohol is the third leading 
preventable cause of death, after tobacco and poor diet (Mokdad et al, 2004). 
AUD has an extremely high co-morbidity with other addictions (Hakkarainen and 
Metso, 2009), as well as psychiatric disorders more generally (Tomasson and 
Vaglum, 1998). Alcohol may exacerbate or even cause certain symptoms of 
bipolar disorder (BD) and post-traumatic stress disorder (PTSD) (Jaffee et al, 
2009; Nickerson et al, 2014), and greatly increases the risk of overdose deaths 
from respiratory depressant effects when combined with opioids and/or other 
sedatives (Health and Human, 2015).  
According to the 2015 NSDUH, 6% of adults in the U.S. meet the clinical 
criteria AUD (SAMHSA, 2015). Moreover, 26.9% of adults reported binge 
drinking in the past month, which may represent a temporary loss of control over 
ethanol consumption, and a potential precursor for AUD (SAMHSA, 2015). Given 
that the large majority of adults (>85%) have at least tried alcohol at some point 
in their lifetimes while only 10% of these develop AUD, a critical priority for 
intervention regards the mechanisms mediating transition from casual social 
drinking to compulsive injurious consumption. Genetic predisposition has been 
found to play a substantial role (Kendler et al, 2012), explaining 49% of the 
variance according to twin and adoption studies (Verhulst et al, 2015). However, 
identifying specific genetic variants which contribute meaningfully to the 
neuropsychiatric—as opposed to metabolic—phenotype has proven arduous 
(Tawa et al, 2016).  Similarly ill illuminated are specific neurobiological 
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mechanisms which underlie the risk of relapse, which can occur even years after 
last use (Vaillant, 2003). While current pharmacologic or psychodynamic 
interventions can contribute (in relatively equivocal measure) toward decreasing 
problematic alcohol use (Weisner et al, 2003), less than 20% of alcoholic patients 
remain abstinent even with treatment (Thompson et al, 2017). Given such poor 
responses, there is a great need for development of more targeted AUD 
treatments. Identifying novel treatments based on defined neurobiological targets 
is one arm of the pharmacogenetic endeavor. The other is a more precision-
based approach in the application of treatments, i.e. predicting successes based 
on an as-yet-undefined genetic panel (Ragia and Manolopoulos, 2017). Together 
these arms converge on the goal of defining how ethanol interacts with genetic 
risk alleles to manifest molecular mechanisms promoting its use, and targeting 
these accordingly.  
 Aspects of ethanol’s acute molecular sites of action have been 
characterized, but repeated ethanol exposure leading to AUD evokes 
mechanisms still only poorly defined  (Starkman et al, 2012).  The primary action 
of acute ethanol is CNS depression, which occurs through the combinatorial 
effect of ethanol on ion channel proteins, including (1) positive allosteric 
modulation of the GABAA receptor and (2) negative allosteric modulation of the 
NMDA receptor (Weight et al, 1992). Consequences of these primary actions 
vary spatiotemporally, but include increased dopamine release along the 
mesolimbic and mesocortical pathways (Soderpalm and Ericson, 2013). The 
former of these dopaminergic pathways projects from the Ventral Tegmental 
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Area (VTA) to the Nucleus Accumbens (NAC) and seems to assign 
reward/salience to stimuli (Saddoris et al, 2015), and the latter projects from the 
VTA to the prefrontal cortex (PFC), the region largely responsible for executive 
function, and thereby informs decision-making according to reward/salience 
(Jenni et al, 2017). These pathway-specific increases in dopaminergic signaling 
are pathognomonic for drugs of abuse (Koob and Le Moal, 1997). With repeated 
ethanol exposures there emerge homeostatic responses, such as tolerance to 
the dopaminergic effect (Diana et al, 1993) and neuronal hyperexcitability upon 
each withdrawal from the depressant action (Grant et al, 1990). On a behavioral 
level, more ethanol must be consumed to achieve the same intoxicating effect. 
What accounts for this attempt at homeostasis? There are opportunities for 
adaptation at perhaps every known level of a biological system. Neuronal 
excitability may be altered by an immediate change in the level of activity of a 
particular receptor (Bespalov et al, 2016), or a change in receptor density or 
subunit composition at the synapse over time (Casarett and Doull, 1975; Harms 
et al, 2005). A given receptor subunit may be regulated as a functional protein, 
post-translationally, translationally, transcriptionally, or epigenetically (Lempradl 
et al, 2015; Zong et al, 2017). It seems likely that these different layers of 
regulation can operate cooperatively on different time-scales. More permanent 
adaptations might be expected following persistent regulation on a more transient 
level—for example, lowered transcriptional activity of a gene might follow a 
period of low functional activity of its protein. Elucidating the means of such 
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cross-talk is a continuing directive of systems biologists and molecular 
geneticists.  
 In the case of alcoholism, we hypothesize that there are fundamental 
shifts in responsiveness of the CNS which occur from initial ethanol exposure to 
chronic, repeated ethanol exposures. Further we hypothesize that this transition 
underlies altered behavioral responses to ethanol, including promotion of 
maladaptive excessive ethanol intake. To test this hypothesis we have developed 
the following specific aims: (1) To characterize acute and chronic responses to 
ethanol in the corticolimbic reward pathway at the level of gene expression. (2) 
To determine whether acute and chronic ethanol show differential effects on the 
protein activity of a previously identified genetic hub of ethanol response in PFC, 
Gsk3b. (3) To determine whether genetic or pharmacologic modulation of Gsk3b 
alter ethanol-related behaviors, particularly ethanol consumption.  
Thus, this dissertation begins by comparing genome-wide expression 
analyses of the effect of a single acute dose of ethanol vs. chronic intermittent 
ethanol (CIE) on gene expression changes in PFC and NAC across a 
recombinant inbred panel of mice (Crabbe et al, 1994). The effect of genetic 
variation across the mice strains on ethanol-induced expression changes is 
assessed via the identification of expression quantitative trait loci (eQTLs) (Doss 
et al, 2005) which may represent critical regulatory hot-spots of 
pharmacogenomic effect. 
 Gene expression networks are a means of understanding large scale 
genomic responses as the perturbations of many genes in tandem. Network hubs 
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represent points of highest interconnectivity, that is genes whose changes in 
expression correlate to those of many other network members at once. One such 
hub that emerged from prior network analyses of ethanol-responsive genes 
(Wolen et al, 2012) was glycogen synthase kinase 3-beta (Gsk3b). Gsk3b 
encodes one of two isoforms of glycogen synthase kinase 3 (GSK-3), an enzyme 
uniquely suited to integrate cellular signals and direct subsequent cellular 
response (Grimes and Jope, 2001). To assess its response to ethanol-induced 
changes in neuronal activity specifically, we characterize the phosphorylation 
state of its major regulatory site, serine-9 (S9), following acute ethanol treatment, 
withdrawal from long-term ethanol, and acute ethanol challenge after long-term 
ethanol. Based on prior studies we hypothesize that acute ethanol increases 
phosphorylation at S9 (Neznanova et al, 2009), but that chronic ethanol alters the 
response at this phospho-site.  
 GSK3B has been found to play a role in mechanisms of learning and 
memory generally (Kimura et al, 2008; Nelson et al, 2013), as well as behavioral 
conditioning in the context of drugs of abuse (Dobashi et al, 2010; Miller et al, 
2014). Given the hub-like nature of the Gsk3b gene in the context of acute 
ethanol in the prefrontal cortex, we expect that each successive ethanol 
exposure may have continual downstream effects, with consequences on 
ethanol-related behavioral adaptations. The hypothesis that genetic modulation 
of Gsk3b in mouse medial prefrontal cortex (mPFC) alters ethanol self-
administration is thoroughly investigated, using a viral over-expression vector 
and two methods of gene deletion. Finally, pharmacologic agents targeting 
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GSK3B protein are explored pre-clinically, with emphasis on the FDA Phase II 
approved small molecule inhibitor tideglusib (Lovestone et al, 2015).  
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Chapter 2  
Background and Significance 
 
2.1 Primary Binding Sites of Ethanol 
Historically, the observation that alcohols and other general anesthetics 
exhibited a linear relationship of potency to lipid solubility led to the hypothesis 
that these agents acted by non-specific disruption of membranes (Janoff et al, 
1981). Membrane-bound ion channels would then be altered secondary to 
disruption of the phospholipid bilayer. However significant weaknesses in this 
theory would eventually become evident, including differences in the anesthetic 
potency between stereoisomers with equal lipid solubilities, and the sudden loss 
of anesthetic effect with increasing chain lengths of alcohols or alkanes (Liu et al, 
1993). Moreover, alcohols were found capable of modifying the activity of 
luciferase, a soluble enzyme, and this effect too showed distinct cut-off lengths  
(Moss et al, 1991). This latter finding is consistent with the “cut-off effect” 
reflecting size constraints of hydrophobic pockets wherein alcohols bind and 
modulate protein activity, rather than a loss of membrane solubility above a 
certain carbon chain length. Subsequent experiments have provided mounting 
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evidence that ethanol exerts its psychoactive effects by specific binding to 
proteins and consequent functional changes (Harris et al, 2008). 
 However, while ethanol binds specifically, it also binds promiscuously. 
Many proteins have been confirmed, and many more theorized, to contain 
ethanol binding sites (Howard et al, 2011). Furthermore, the molecule’s small 
size and polarity make it freely diffusible and only transiently bound in a given 
hydrophobic pocket. Thus ethanol’s global action can be seen as the spatial and 
temporal sum of many transient displacements of disordered water molecules 
from protein pockets (Klemm, 1998). Each of these displacements allows for 
allosteric effects on protein functioning, with ethanol varying in its potency and 
efficacy between its varied targets.  
 At pharmacologically relevant concentrations, ethanol is an efficacious 
positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor, 
and negative allosteric modulator of the N-methy-D-aspartate (NMDA) glutamate 
receptor.  Ethanol’s GABAergic agonism accounts for its anxiolysis (Weight et al, 
1992) and at higher doses, sedative effects (Lu and Greco, 2006); while NMDA 
antagonism likely accounts for the dissociative anesthetic effects (Krystal et al, 
1998), and some degree of motor and memory impairment (Khanna et al, 1993). 
While these are not the only membrane-bound receptors bound by ethanol, they 
are each thought to contribute significantly to its reinforcing effects (Koob et al, 
1998). 
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2.1.1 GABAA Receptors 
 GABAA receptors are pentameric ligand-gated ion channels which allow 
for the selective influx of chloride (Cl-) ions into the neuron upon GABA binding. 
The resulting hyperpolarization increases the threshold for firing an action 
potential, thereby accounting for GABA’s famed status as the major inhibitory 
neurotransmitter of the nervous system. Allosteric to the ligand-binding site there 
exists a well-characterized benzodiazepine-binding site, between the α- and γ- 
subunits of α- and γ-subunit containing GABAA receptors (Sigel, 2002). 
Benzodiazepine binding induces a conformational change which results in a 
greater affinity of GABA for the GABAA receptor, and thus a greater frequency of 
channel opening and subsequent neuronal hypoexcitability (Sigel, 2002). This 
GABA potentiation accounts for the anxiolytic and sedative effects of 
benzodiazepines—effects which show cross-tolerance with ethanol (Khanna et 
al, 1998). Some degree of mechanistic conservation in the CNS adaptations to 
benzodiazepines and ethanol is suggested by this cross-tolerance.  
 Evidence for the primary site of ethanol action comes from studies of site 
specific mutagenesis and chimeric receptors. Mihic et al. (1997) used the 
observation that alcohols and anesthetics increase GABAA activity but decrease 
the activity of GABAA receptors composed totally of rho1 subunits, to create a 
series of chimeric constructs.  Differential modulation of these allowed for the 
identification of a region necessary and sufficient for alcohols’ enhancement of 
GABAA receptor function. The region contained transmembrane domains (TM) 2 
and 3—homologous between GABAA and glycine receptors—and particular 
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amino acid residues on these domains were found to be critical for alcohol and 
anesthetic enhancement of GABAA and glycine receptor function (Mihic et al, 
1997). Subsequent studies have confirmed the role of TMs 2 and 3 while also 
providing some evidence of the involvement of TMs 1 and 4 (Lobo et al, 2008; 
Lobo et al, 2004; Lobo et al, 2006; Wick et al, 1998). 
Significant differences in ethanol responsiveness have been observed 
between GABAA receptors based on their subunit composition, which dictate 
differences in spatial effects of ethanol, both on the microscopic (i.e. synaptic vs. 
extrasynaptic) and macroscopic (i.e. brain region) scales. The most common 
isoforms of GABA receptors are pentamers of 2α, 2β, and one γ or δ subunit. It 
has been found that γ subunit  containing receptors are relatively insensitive to 
ethanol (Wallner et al, 2006), while δ-containing receptors are ethanol-
responsive even at low doses, consistent with levels achieved in moderate social 
consumption (Santhakumar et al, 2007).  GABAA receptors containing δ subunits 
are restricted to extrasynaptic sites, which exert tonic inhibitory effects on the 
neuron, as opposed to γ-containing receptors, which cluster within postsynaptic 
densities and mediate phasic bursts of inhibition (Nusser et al, 1998; Wei et al, 
2004). As might be expected, low doses of ethanol preferentially enhance tonic 
inhibition over phasic inhibition, and the effect is most robust in neuronal cell 
types enriched for δ subunits, including cortical interneurons (Glykys et al, 2007), 
as well as granule cells of the dentate gyrus and cerebellum (Wallner et al, 2006; 
Zhang et al, 2007).  
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2.1.2 NMDA Receptors 
 Glutamate, the major excitatory neurotransmitter of the CNS, binds three 
receptor subtypes: NMDA receptors (NMDAR), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, and metabotropic receptors. Of the 
two former, ionotropic subtypes, AMPA receptors mediate an immediate 
response while NMDA ion channels open after an initial (AMPA-mediated) 
depolarization (Blanke and VanDongen, 2009). NMDA receptors are further 
distinguished by their Mg2+-gating, permeability to Ca2+, and sensitivity to ethanol 
antagonism (Lovinger et al, 1989; Moykkynen and Korpi, 2012) 
 The inhibitory actions of ethanol on NMDA-activated ion currents have 
been demonstrated throughout the brain (Hoffman et al, 1990), although the 
precise nature of ethanol-receptor binding is less well understood.  The very 
rapid reduction in channel activity in response to ethanol suggests direct 
interaction of ethanol on NMDAR subunits (Ron and Wang, 2009). The NMDAR 
is a heteromeric complex made up of three subunits: NR1, NR2, and NR3. In turn 
each subunit has multiple subtypes, determined either by genetic variants or by 
alternative splicing from a single gene (Blahos and Wenthold, 1996). NR1/NR2B 
transmembrane segments contain the binding pockets for uncompetitive NMDAR 
antagonists such as ketamine and memantine (Johnson and Kotermanski, 2006). 
It may be speculated that ethanol exerts its effects through similar action (Bonnet 
and Scherbaum, 2015) but the ethanol binding site remains undefined.  
 What is well-characterized is the dynamic response of NMDARs to 
repeated ethanol exposures. Given the critical role of NMDARs in memory and 
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neuroplasticity (Blanke et al, 2009), it makes sense that these receptors would 
underlie aspects of ethanol tolerance and long-term facilitation, an activity-
dependent increase in synaptic strength (Ron et al, 2009). Still, it makes them 
attractive targets for addiction medicine, insofar as addiction may be conceived 
as maladaptive learning (Lewis, 2017). Acutely, NMDARs can develop resistance 
in 1-2 hours to the depressive effects of ethanol on long-term-potentiation (LTP) 
(Tokuda et al, 2007). Upregulation of NMDAR function in a period following 
ethanol exposure may actually serve to better encode the reinforcing aspects of 
the behavior (Everitt and Robbins, 2005). Chronically, NMDARs show 
hyperactivity upon ethanol withdrawal, to the point of seizures and NMDA-
mediated excitotoxicity (Gillman and Lichtigfeld, 1997); this aspect of NMDAR 
response could contribute to neuronal loss observed in late-stage alcohol 
patients (Moselhy et al, 2001). 
 One mechanism underlying NMDA receptor tolerance to ethanol may be 
via NR2 phosphorylation by Src family protein tyrosine kinases, particularly Fyn 
(Ron et al, 2009). Acute tolerance to ethanol inhibition of NMDAR channel 
activity is not observed in Fyn deletion (Fyn-/-) mice, while it is intact in Fyn 
heterozygotes (Fyn+/-); correspondingly, NR2B phosphorylation is increased in 
Fyn+/- mice but this increase is not observed in the Fyn-/- mice (Miyakawa et al, 
1997). Thus as ethanol negatively modulates NMDAR function, a compensatory 
increase in activity, mediated by Fyn kinase phosphorylation of the NR2B 
subunit, is the intact response. This mechanism was further elucidated when it 
was revealed that, in the hippocampus, the scaffolding protein RACK1 localizes 
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Fyn kinase to the NR2B subunit (Yaka et al, 2002). Under basal conditions 
RACK1 prevents Fyn phosphorylation of NR2B; however activation of the 
cAMP/PKA pathway (such as by ethanol) leads to the dissociation of the 
molecular complex, allowing the kinase action of Fyn and subsequent 
upregulation of NMDAR channel activity (Yaka et al, 2003a). On a behavioral 
level, the regulation of ethanol sensitivity by the actions of Fyn kinase is 
evidenced by the longer ethanol-induced sleep time in Fyn-/- mice than 
heterozygous Fyn+/-; and the increase in sleep time in Fyn+/+ mice to the same 
level of the Fyn-deletion mice upon systemic administration of the NR2B inhibitor 
ifenprodil (Miyakawa et al, 1997; Yaka et al, 2003b). Farris and Miles (2013) 
showed that Fyn-/- mice might additionally show longer ethanol-induced sleep 
time due to severe disruptions in myelin-related gene expression.  
 While Fyn kinase deletion produces increased sensitivity to the sedative-
hypnotic effects of ethanol, it does not alter rewarding properties of ethanol, as 
measured by the acquisition of conditioned place preference (CPP) (Yaka et al, 
2003b). NR2A deletion or heterozygosity, however, does ablate ethanol induced 
CPP compared to wild-type NR2A+/+ mice (Boyce-Rustay and Holmes, 2006). 
Taken together it would appear that NR2A subunit activity is necessary for the 
rewarding aspects of ethanol, whereas NR2B subunit activity is necessary for 
ethanol sensitivity but not necessarily ethanol reward. Similarly to the scaffolding 
protein RACK1 localizing Fyn to the NR2B subunit, PSD-95 appears to anchor 
Fyn and other protein tyrosine kinases (PTK) to NR2A (Tezuka et al, 1999). 
Unlike RACK1, this interaction does not appear to be inhibitory but rather 
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facilitates phosphorylation (Zhao et al, 2015). Given the homeostatic response of 
Fyn kinase phosphorylation of NR2B to regulate ethanol sensitivity, it may be 
postulated that compensatory changes in NR2A activity, possibly through PSD-
95/PTK, would underlie tolerance to the rewarding effects of ethanol. What is 
unclear is the level of NR2A activity that is necessary for ethanol induced 
reward—ethanol itself is a negative modulator of NMDAR activity, but full deletion 
of the NR2A subunits ablates ethanol induced CPP. If it is rebound activity of 
NR2A-containing NMDARs that encodes ethanol reward-related learning, then 
presumably increased PSD-95/PTK activity would serve to increase the 
rewarding effects of ethanol, i.e. sensitization.  
  
2.1.3 Intracellular Signaling Enzymes 
It should be noted that there is also evidence that ethanol directly binds certain 
intracellular targets. There are numerous enzymes that may contain ethanol 
binding sites, although not necessarily with a direct impact on the CNS. For 
example, alcohol dehydrogenase (ADH) has a well delineated binding site 
(Hammes-Schiffer and Benkovic, 2006) but outside of its obvious relevance of 
ethanol metabolism generally, it seems unlikely that ethanol binding ADH per se 
produces changes in neurotransmitter signaling (Inoue et al, 1981).  
 Adenylate cyclase (AC) plays a regulatory role in essentially all cells via 
production of 3’,5’-cyclic AMP (cAMP) from ATP. Among the various isozymes of 
AC, ethanol has been observed to exert varying degrees of effect on function, as 
measured by intracellular cAMP levels (Yoshimura and Tabakoff, 1995).  On the 
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extremes, AC3 shows no ethanol response, while AC7 shows a several-fold 
increase in activity. Chimeric studies on utilizing these isoforms would go on to 
reveal two ethanol binding domains in adenylate cyclase (Yoshimura et al, 2006). 
While the degree of allosteric modulation varies between isoforms, those 
showing ethanol response (AC2, AC5, AC6, and AC7) are activated. The 
downstream effects that would be predicted by AC activation—most immediately, 
an increase in intracellular cAMP and thereby activation of cAMP-dependent 
protein kinase (protein kinase A)—are consistent with empirical observations of 
ethanol’s acute effects in neurons (Newton and Messing, 2006).  In GABAA 
receptor expressing neurons in the VTA, a potentiation of inhibitory post-synaptic 
currents was observed for days after a single ethanol exposure in mice, and this 
effect could be further enhanced with the adenylate cyclase activator forskolin or 
decreased with a PKA inhibitor (Melis et al, 2002). While it cannot be said the 
extent to which direct ethanol action on AC contributed to the observed 
potentiation, it is plausible that ethanol-induced AC activation would have at least 
enhanced the normal response to upstream G-protein signaling: in essence, 
turning up the “gain” on extracellular signals. Such interactions may account for 
plasticity changes beyond those mediated by receptors alone. 
An enzyme which has received significant attention in the alcohol literature 
is protein kinase C (PKC). In particular, two isoforms of PKC have been shown to 
mediate robust and opposite effects in rodent gene knockout studies. Mice 
lacking PKCδ show decreased sensitivity to ethanol’s GABA potentiation and 
increased ethanol self-administration (Harris et al, 1995). Conversely, PKCε 
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knockout exhibit increased sensitivity to ethanol’s sedative effects, and double 
the GABA-induced Cl- influx compared with ethanol-treated wild-type mice 
(Hodge et al, 1999; Proctor et al, 2003). PKCε activity is inhibited by 
pharmacologically relevant concentrations of ethanol, and experiments 
employing photoactive alcohols and mass spectroscopy have identified an 
alcohol-binding site in a cysteine-rich regulatory region of PKCε (C1B), which is 
also its activator-binding domain (Das et al, 2009). These findings provide strong 
support that ethanol inhibits PKCε activity via direct binding. Again, to what 
extent a direct ethanol-enzyme interaction modulates the ethanol’s effect on the 
GABAergic system is unclear. There is evidence that active PKCε 
phosphorylates the γ2 subunit of GABAA receptors, and that this mediates a 
suppression of allosteric activation (Qi et al, 2007). Thereby ethanol’s inhibition of 
PKCε would serve to sensitize its own response. Increases in the active, 
phosphorylated form of PKCε have been shown to modulate acute functional 
tolerance (Wallace et al, 2007), perhaps representing a homeostatic cellular 
response to ethanol’s inhibition of the enzyme.  
 PKCε also plays a crucial role in the surface expression of GABAA 
receptors. The adaptor protein 2 (AP2) interaction site on β1-3 GABAA subunits 
is phosphorylated by PKC, which regulates cell surface stability and endocytosis 
(Smith et al, 2012). Furthermore specific phosphorylation by PKCε activates the 
vesicular ATPase and trafficking factor, N-ethylmaleimide-sensitive factor (NSF) 
(Chou et al, 2010), which then translocates to the plasma membrane and to 
synapses, where it reduces the expression of GABAA receptors.  Receptors of 
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different subunit composition show differential sensitivity to PKC-induced 
internalization (Connolly et al, 1999). Ethanol has been shown to alter GABAA 
receptor expression and subunit composition via PKC-γ and PKA-dependent 
mechanisms (Carlson et al, 2013; Kumar et al, 2010). Specific ethanol induced 
alterations in GABAA subunit composition potentially mediated by the ε isoform of 
PKC have not, to our knowledge, been reported—despite its role in mediating 
ethanol sensitivity. Regardless, these intracellular kinases collectively represent 
a potential means of neuronal adaptation to repeated ethanol exposures, 
including through cellular feedback to the synapse via receptor regulation.  
 
2.2 Glycogen Synthase Kinase 3 
In some cases ethanol has been shown to modulate protein kinase activity in the 
absence of an identified binding site. For example, at this point there is no 
evidence of ethanol directly targeting the serine-threonine kinase glycogen 
synthase kinase-3, however there is mounting evidence of ethanol-induced 
changes in GSK3 activity and downstream effects (French and Heberlein, 2009; 
Luo, 2010; Neznanova et al, 2009; Velazquez-Marrero et al, 2016).  
 
2.2.1 GSK3B and Plasticity 
 An integrator of cellular signaling, glycogen synthase kinase-3 is also 
increasingly recognized as a major mediator of synaptic plasticity (Bradley et al, 
2012; Peineau et al, 2008). There are two isoforms of GSK3, alpha and beta, 
encoded by different genes: GSK3A and GSK3B respectively (Woodgett, 1990). 
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These protein isoforms show a high degree of homology in their kinase domains 
but differ in other regions (Peineau et al, 2008). Each is analogously regulated by 
inhibitory phosphorylation of an N-terminal serine: Ser-21 in the case of GSK3A, 
Ser-9 for GSK3B (Sutherland and Cohen, 1994; Sutherland et al, 1993). 
Depending on the stimulatory context, this upstream phosphorylation can be 
carried out by Akt, protein kinase A, or protein kinase C (Fang et al, 2000; Tsujio 
et al, 2000). Dephosphorylation, resulting in activation of GSK3, is carried out by 
protein phosphatases 1 (PP1) and 2A (PP2A) (Salcedo-Tello et al, 2011). There 
is a secondary phosphorylation site on GSK3, Tyr216 and Tyr279, with a 
reported activating effect on the kinase activity (Frame et al, 2001). There is 
evidence that this tyrosine represents an autophosphorylation site and may be 
secondary to GSK3 activity (Cole et al, 2004).  
 Deletion of each GSK3 isoform produces distinct substrate 
phosphorylation profiles in mammalian cortical tissue, providing evidence for 
substrate specificity (Soutar et al, 2010). It should be said that nearly 100 
proteins are at least proposed to be substrates for GSK3 (Sutherland, 2011), and 
so a full accounting of isoform-specific effects would require a costly 
phosphorylation panel. Regardless, Soutar et. al found that phosphorylation of 
tau and CRMP seemed to depend specifically on the beta isoform of GSK3, while 
c-Myc and β-catenin were regulated by both isoforms to an equivalent degree 
(Soutar et al, 2010). Both GSK3A and GSK3B are highly expressed in brain, 
particularly cortex and hippocampus (Salcedo-Tello et al, 2011). In adult rodents, 
GSK3B is the more abundant isoform in hippocampus (Lee et al, 2006), and is 
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more often investigated for its roles in long-term potentiation (LTP) and long-term 
depression (LTD) than the alpha isoform (Peineau et al, 2008). LTP and LTD 
constitute the two major of forms synaptic plasticity understood to underlie 
information storage in the CNS, accounting for synaptic strengthening or 
weakening based on recent patterns of activity. Most mechanisms of LTP and 
LTD have been studied (via electrophysiology) in the hippocampus, but appear to 
be utilized widely in the brain (Bliss et al, 2007).  
 The great majority of LTP- and LTD-exhibiting synapses are glutamatergic 
(Peineau et al, 2008). Synapses show NMDAR-dependent bidirectionality in 
synaptic response, with differing NMDA activity patterns inducing either LTP or 
LTD (Malenka and Bear, 2004). Using patch electrodes with a modifiable input 
and an output read-out of excitatory post-synaptic potential (EPSP), low 
frequency stimulation (LFS) can reliably induce LTD, an effect which is blocked 
by NMDA antagonism (Oliet et al, 1997). Peineau et al. (2007) have found that 
GSK3B activity is also necessary for this LFS induced LTD. The GSK3B inhibitor 
SB41528 showed no effect on baseline synaptic activity in rat hippocampal slices 
as measured by field EPSP, but 60 minutes after LFS, control slices showed 
synaptic activity of 65% (±5%) of baseline, while SB41528-treated slices 
maintained 103% (± 2%) of their baseline field EPSP (Peineau et al, 2007). The 
experimenters validated these findings using the GSK3B inhibitor kenpaullone 
which also abolished the LTD, and multiple doses of the less specific GSK3B 
inhibitor lithium, which showed dose dependent effects on LTD (Peineau et al, 
2007). Using Western blots for the phospho-Ser9 form of GSK3B, Peineau et al. 
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found a decrease in inhibitory phosphorylation, indicating heightened GSK3B 
activity, in the CA1 area of the hippocampus during LTD. This effect lasted at 
least 20 minutes following the delivery of LFS, indicating heightened GSK3B 
activity may play a role in the maintenance of LTD (Peineau et al, 2007). 
 Perhaps the best characterized form of LTD depends on NMDAR activity 
as the stimulus and AMPA receptor regulation as the response. Phosphorylation 
and the subsequent removal of AMPA receptors from the synapse is the primary 
mechanism of the decrease in post-synaptic excitability observed in LTD 
(Kessels and Malinow, 2009). PSD-95, an abundant scaffolding protein in the 
post-synaptic density, mediates interactions of NMDA and AMPA receptors with 
the structure of the synapse (Scannevin and Huganir, 2000).  Nelson et al. 
(2013) have provided evidence that the effect of GSK3B on LTD described above 
depends at least in part on the phosphorylation of PSD-95 on its threonine-19 
(T19) residue. In rat hippocampal neurons, phospho-PSD-95-T19 was increased 
with LTD, while this effect was attenuated by pharmacologic suppression of 
GSK3B (Nelson et al, 2013). A non-phosphorylatable PSD-95 mutant (T19A) was 
found to resist internalization from dendritic spines, and overexpression of PSD-
95-T19A led to impaired AMPA receptor internalization and impaired induction of 
LTD (Nelson et al, 2013). In combination with the Peineau et al. findings, it 
seems that low-frequency NMDAR stimulation increases GSK3B activity, which 
in turn phosphorylates the AMPA receptor anchor PSD-95, and phospho-PSD-
95-T19 subsequently internalizes its associated AMPA receptors, thereby 
decreasing the synaptic strength.    
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 A very similar mechanism has been described at GABAergic synapses, 
wherein GSK3B targets a unique phosphorylation site, Ser270, on the GABAA 
receptor scaffolding protein gephyrin (Rui et al, 2013; Tyagarajan et al, 2011). 
Tyagarajan et al. (2011) introduced point mutations to a then-uncharacterized 
phospho-site on gephyrin: S270A, a non-phosphorylatable mutant, and S270E, a 
phosphomimetic mutant. Neurons expressing these gephyrin mutants were 
assessed for dendritic gephyrin clustering and GABAergic activity. The non-
phosphorylatable S270A mutant was associated with significantly higher degrees 
of gephyrin surface expression and corresponding GABAergic activity as 
measured by miniature inhibitory postsynaptic currents (mIPSCs) (Tyagarajan et 
al, 2011). Multiple protein kinase inhibitors were tested for their effect on 
gephyrin clustering in the gephyrin-270A transfected cells, and the GSK3B 
inhibitor GSK3-IX was found to reverse the aberrant phenotype (Tyagarajan et al, 
2011). Rui et al. (2013) built upon these findings by transfecting a constitutively 
active GSK3B non-phosphorylatable mutant (GSK3B-S9A) into hippocampal 
neurons, and finding a decrease in GABAA receptor surface expression, which 
was rescued by the GSK3B inhibitory peptide GID5-6. Moreover, this decrease in 
GABAA surface expression corresponded with overall dendritic shrinkage in the 
GSK3B-S9A neurons—also rescued by GID5-6 (Rui et al, 2013). The authors 
contend that neurotrophin signaling normally acts to inhibit GSK3B via Ser9 
phosphorylation and promote dendritic growth. Bath application of brain-derived 
neurotrophic factor (BDNF) to hippocampal neurons elevated phospho-GSK3B-
S9 in the somatodendritic compartment, indicating BDNF inhibits GSK3B activity 
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(Rui et al, 2013). This increase in inhibitory phosphorylation was blocked with an 
inhibitor (K252a) of Trk, the BDNF receptor (Rui et al, 2013). (Rui et al, 2013).  
 Another BDNF-GSK3B interaction has been reported in the context of 
synaptic plasticity. The endocytosis enzyme dynamin 1 mediates activity 
dependent bulk endocytosis (ADBE), a method of large-scale synaptic vesicle 
(SV) retrieval via invagination of the presynaptic membrane (Clayton and Cousin, 
2009). This is the dominant form of SV retrieval during high-intensity firing, 
presumably because it more efficiently recycles neurotransmitters from the 
synapse to maintain a stock supply in the highly active, neurotransmitter-
releasing neuron (Clayton et al, 2010). To trigger ADBE, dynamin 1 must be de-
phosphorylated by the calcium-dependent phosphatase calcineurin (Clayton et 
al, 2009). When the firing is complete, dynamin I is re-phosphorylated by cyclin 
dependent kinase 5 (cdk5) and GSK3B (Clayton et al, 2010; Evans and Cousin, 
2007). This re-phosphorylation is what “loads” dynamin I to be ready to initiate 
ADBE upon the next instance of high-intensity firing (Smillie et al, 2013). Smillie 
et al. (2010) found that extracellular BDNF prevents this re-phosphorylation event 
by inhibition of GSK3B. Thus BDNF prevents the “run-down” of post-synaptic 
activity by arresting the usual recycling of neurotransmitters from the synapse 
back into the pre-synaptic membrane (Smillie et al, 2013). This indicates that 
when BDNF is released during high-frequency firing, neurotransmission is 
strengthened, albeit at the risk of neurotransmitter depletion in the pre-synaptic 
neuron.  
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Figure 2.1. Regulation of pre- and post-synaptic dynamics by GSK3B. 
GSK3B phosphorylation of Dnm1 regulates activity dependent bulk endocytosis 
subject to regulation by BDNF. GSK3B phosphorylation of gephyrin and PSD95 
is necessary for turnover of these scaffolding proteins.  
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 In light of the above findings, a picture emerges of GSK3B as a consistent 
regulator of synaptic plasticity (Figure 2.1). At both the post-synaptic and pre-
synaptic membranes, GSK3B can regulate fundamental dynamics of membrane  
turnover in response to neuronal signaling. If there is a consistent directionality, it 
would be that GSK3B inhibition seems to correspond to a more stable synapse, 
while high GSK3B activity seems to correspond to a more dynamic synapse, 
characterized by receptor turnover. Oversimplification, however, must be 
cautioned against. It is unlikely that the role of GSK3B at the synapse is 
unidirectional. Regardless, GSK3B can function both pre- and post-synaptically 
to modify neurotransmission. The actual predominant action would be dependent 
on the type of synapse, state of activity, and coincident modulators (e.g. BDNF). 
These mechanisms discussed above should be kept in mind when considering 
the emerging evidence of GSK3B’s role in addictive disorders.  
 
2.2.2 GSK3B in Addiction and Neuropsychiatric Disorders 
Miller et al. have demonstrated that cocaine activates GSK3B in the caudate 
putamen and nucleus accumbens (NAC) core, and that GSK3B activation is 
necessary for cocaine conditioned place preference (Miller et al, 2014). Inhibitory 
phosphorylation of GSK3B and the activating phosphorylation of the upstream 
kinase Akt were both decreased 30 minutes after an acute cocaine injection, 
while phospho-GSK3A-S21 was not significantly altered (Miller et al, 2014). The 
Akt de-phosphorylation, which would correspond to its disinhibition of GSK3B, 
was blocked by a D2 receptor antagonist specifically, while the GSK3B de-
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phosphorylation was blocked by antagonists at D1, D2, or glutamatergic NMDA 
receptors (Miller et al, 2014). These results suggest that cocaine’s activation of 
GSK3B occurs through convergent pathways, one of which is a D2-mediated 
inhibition of Akt. Moreover, Miller et al. found that administration of the GSK3B 
inhibitor SB216763 prevented the development of cocaine induced place 
preference, while showing no effect on acquisition of a contextual fear 
conditioning response. Thus cocaine’s activation of GSK3B is not an incidental 
effect but rather a critical step in reward-based learning. As an extension of this 
work, Shi et al. studied the Akt/GSK3 pathway in the context of cocaine cue-
induced memory reconsolidation, following conditional place preference (Shi et 
al, 2014). In mice that we re-exposed to an environment previously paired with 
cocaine, levels of phospho-Akt-T308, phospho-GSK3A-S21 and phospho-
GSK3B-S9 were decreased in the NAC and hippocampus (Shi et al, 2014), 
indicating that re-exposure inhibited Akt and thus activated GSK3. Mice would 
typically re-exhibit a conditioned place preference for the previously cocaine-
paired chamber, however treatment with SB216763 abrogated this response (Shi 
et al, 2014). Together with the above, these results suggest that GSK3B 
activation plays a key role in both the consolidation and re-consolidation of 
cocaine-associated memory.  
 The effects of GSK3B activity on reward-based learning serve as an 
additional layer atop previously established evidence for its role in the 
hyperlocomotor effects of cocaine and other stimulant drugs. Pharmacologic 
inhibition of GSK3B has been shown to attenuate hyperactivity produced by 
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acute injection of cocaine or amphetamine (Enman and Unterwald, 2012; Miller 
et al, 2009); and injection of a peptide decreasing S9 phosphorylation of GSK3B 
into the NAC enhances cocaine-induced hyper-locomotor activity while leaving 
basal locomotor activity unchanged (Kim et al, 2013). Urs et al. found that 
selective Gsk3b gene deletion from D2 receptor-expressing neurons attenuated 
amphetamine induced hyperlocomotion, while deletion from D1 receptor positive 
neurons had no effect on this phenotype (Urs et al, 2012). Thus it would seem 
that the D2-Akt-GSK3B pathway found to be activated by cocaine (Miller et al, 
2014) might also underlie amphetamine induced hyperlocomotion.  
 In addition to stimulants, GSK3B has been studied in the context of 
morphine. Tolerance to the antinociceptive effects of a 10 mg/kg morphine dose 
for 8 days develops by 8 days of repeated administration, in Wistar rats assessed 
by tail-flick assay (Parkitna et al, 2006).  This tolerance effect was prevented 
when morphine injections were preceded by an intrathecal administration of 
either the GSK3 inhibitor 216763 or the cdk5 inhibitor roscovitine (Parkitna et al, 
2006). Moreover, a single administration of either inhibitor restored the 
antinociceptive effect of morphine in a dose-dependent manner, in rats 
previously tolerant to the morphine (Parkitna et al, 2006).  These experiments 
seem to indicate that GSK3B activity underlies the development and 
maintenance of morphine tolerance. A subsequent study confirmed that chronic 
morphine treatment activates GSK3B in midbrain (Dobashi et al, 2010). Dobashi 
et al. also demonstrated that valproate, an anticonvulsant with GSK3B inhibition 
as one of many effects, can serve to attenuate morphine tolerance.  
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 Psychomotor stimulants and morphine have all been found to activate 
GSK3B in brain, with this activation underlying some aspect of neuroadaptation. 
However, GSK3B activation does not appear to be a defining feature of drugs of 
abuse, as all reports of ethanol in adult brain find inhibition of GSK3B. 
Neznanova et al. found that an acute intraperitoneal (i.p.) injection of ethanol 
significantly increased phospho-GSK3B-S9 in rat medial PFC (Neznanova et al, 
2009). The effect was observed in both alcohol accepting (AA) and alcohol non 
accepting (ANA) selectively bred rat lines, but the effect was more marked in the 
AA rat line—possible due to higher baseline GSK3B activity (Neznanova et al, 
2009).  Neasta et al. studied mouse NAC and similar found a significant increase 
in p-GSK3B-S9 as well as p-GSK3A-S21, after an acute i.p. injection of ethanol 
and to a lesser extent after long-term ethanol drinking (Neasta et al, 2011). 
Cheng et al. (2016) investigated distinct D1 and D2 receptor-dependent 
pathways in the dorsomedial striatum (DMS) following repeated cycles of binge-
like ethanol consumption, and found that chronic ethanol increased GSK3B 
phosphorylation. This decrease in GSK3B activity occurred in conjunction with an 
enhancement of GABAergic signaling in this D2 receptor expressing neurons of 
the DMS, presumably through increased GABAA receptor surface expression 
(Cheng et al, 2016). Further, the authors delineated the D1 receptor dependent 
pathway as promoting ethanol consumption (“Go”) whereas the D2 receptor 
dependent pathway suppressed ethanol consumption (“No-Go”) (Cheng et al, 
2016). The D2 agonist quinpirole applied to the DMS was found to decrease 
ethanol drinking as well as decrease GABAergic IPSPs, indicating disinhibition of 
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the No-Go pathway. Concurrent administration of the GSK3B inhibitor SB216763 
attenuated both of these effects, indicating that D2-mediated activation of GSK3B 
normally serves to decrease GABAA receptor surface expression and activate the 
No-Go pathway (Cheng et al, 2016). When this pathway is disrupted via repeated 
ethanol binges, GSK3B is inhibited and in turn, the entire No-Go pathway is 
inhibited, via GABAA receptor build-up in D2 receptor positive neurons of the 
DMS (Cheng et al, 2016). It is interesting to consider that cocaine’s activation of 
D2 receptor mediated activation of GSK3B underlies its rewarding effects, 
whereas ethanol’s inhibition of GSK3B in D2-receptor neurons promotes ethanol 
consumption. How these seemingly disparate behavioral effects might relate to 
one another remains to be elucidated.  
 In developing neurons, there is evidence that high GSK3B activity 
sensitizes neurons to ethanol induced neurotoxicity. Ethanol induces excitotoxic 
cell death in Drosophila olfactory neurons, however genetic deletion or 
pharmacologic inhibition of GSK3B protects against this neurotoxic effect (French 
et al, 2009). Similarly, lithium is protective against ethanol induced 
neuroapoptosis in an animal model of fetal alcohol spectrum disorder (FASD) 
(Luo, 2010). It remains to be determined whether or to what extent ethanol 
induced excitotoxicity in sensitive neurons might actually serve to re-enforce 
ethanol self-administration.  
 Aside from ethanol-specific contexts, the role of GSK3B in 
neurodegeneration has been of significant clinical interest (Salcedo-Tello et al, 
2011). The GSK3B mediated effects on tau phosphorylation are particularly 
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relevant to Alzheimer’s Disease, the pathology of which is partially defined by 
hyperphosphorylated tau. Following pre-clinical studies of the novel GSK3B 
inhibitor tideglusib (Sereno et al, 2009), the FDA approved this drug for Phase II 
trials of Alzheimer’s Disease and subsequently Progressive Supranuclear Palsy 
(Lovestone et al, 2015; Tolosa et al, 2014). Unfortunately, tideglusib did not 
achieve clinical efficacy through any of its primary endpoints, although it was 
determined to be well-tolerated, with the only adverse outcome a transient 
elevation of liver enzymes (Lovestone et al, 2015; Tolosa et al, 2014). There is 
evidence that oral tideglusib reduced the progression of brain atrophy in patients 
with progressive supranuclear palsy, as assessed by MRI, although this was as 
part of a secondary exploratory analysis (Hoglinger et al, 2014). At the time of 
this writing, tideglusib is in clinical trials for Autism Spectrum Disorders (ASD) 
(Anagnostou, 2018). 
 Preclinical studies have certainly pointed to GSK3B as a potential 
therapeutic target for psychiatric disorders (Jope and Roh, 2006). In 1996, it was 
discovered that lithium acts to potently inhibit GSK3B, while not inhibiting protein 
kinases generally (Klein and Melton, 1996). This would prove to be a 
precipitating finding for a line of investigation of the role of GSK3B in bipolar 
disorder, which has been largely born out (Luykx et al, 2010). Cortical GSK3B 
has consistently been shown to play a key role in mood-related phenotypes 
(Latapy et al, 2012; Urs et al, 2012). GSK3 is hyperactive in the hippocampus 
and cerebral cortex of Fmr1 knockout mice, and these mice show anxiety-like 
behavior during social interaction, which is ameliorated with chronic lithium 
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treatment (Mines et al, 2010). GSK3B inhibition, either pharmacologic or genetic, 
also rescued aberrant mood-related behaviors in Tph2 knockin mice, which are 
serotonin-deficient in striatum, frontal cortex, and hippocampus (Beaulieu et al, 
2008). Latapy et al. (2012) generated a CamKIIcre-floxGSK3B mouse to delete 
the Gsk3b gene postnatally in forebrain. These mice were shown to exhibit a 
marked reduction in basal anxiety via the open field test and light-dark 
emergence test (Latapy et al, 2012). A number of other studies have found that 
GSK3B inhibitors mimic the actions of antidepressants in the tail suspension test 
and forced swim test (Beaulieu et al, 2008; Can et al, 2011; Du et al, 2010; Gould 
et al, 2004; Kaidanovich-Beilin et al, 2004). 
 It should be noted that patients with psychiatric disorders are also at a 
much greater risk of developing substance use disorders and AUD, although 
extricating causality is complex. Overall, individuals with any mental disorder are 
2.7 times more likely to have some addictive disorder (Regier et al, 1990). 
Among patients with alcohol dependence, the odds ratios of having a mood 
disorder is 3.6, bipolar disorder is 6.3, and generalized anxiety disorder is 4.6 
(Kessler et al, 1996). Given the above findings in preclinical models, GSK3B 
activity in response to ethanol may correspond to a particularly relevant signaling 
pathway underlying addiction in patients with co-morbid psychiatric disorders.  
  
2.3 Modeling Alcohol Use Disorder 
 Studies on ethanol exposure in animal models and AUD in humans have 
found a strong predictive relationship between responses to acute ethanol and 
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risk for long-term excessive consumption or abusive intake (Schuckit, 1994). 
Thus studies on initial sensitivity to ethanol in animals can provide insight into 
potential risk conferring pathways in humans. For example, low basal myelin 
expression confers ethanol sensitivity to mice (Farris et al, 2013; Kerns et al, 
2005a), and so genotypes associated with altered myelin genes in humans might 
be predicted to confer risk for AUD.  
 Repeated cycles of ethanol exposure in mice, such as through the chronic 
intermittent ethanol (CIE) vapor model are associated with changes in gene 
expression (Smith et al, 2016), synaptic plasticity (Holmes et al, 2012), and gross 
changes in anatomic structure of cortical neurons (Beaudet et al, 2016). Together 
these neuroadaptations are believed to underlie the escalation in drinking (Griffin 
et al, 2009), tolerance to aversive symptoms of intoxication (Lopez et al, 2012) 
and withdrawal-like symptoms (Werner et al, 2009) observed in mice having 
undergone this model. However, it is a limitation of the model that it relies on 
involuntary exposures to ethanol vapor rather than allowing AUD-type 
pathogenesis to develop purely in the context of self-administration.  
 In mice strains with a predisposition to drink ethanol freely, such as 
C57BL/6J mice, a number of paradigms to intensify this phenotype have been 
explored (Crabbe, 2014). Generally these are modifications of two-bottle choice 
procedures, wherein mice have access to one water bottle and one bottle 
containing an ethanol solution. Drinking-in-the-dark (DID) paradigms utilize the 2 
or 4-hour period of high activity early in the dark cycle, to give limited access of 
either a single ethanol bottle or a two-bottle choice period (Barkley-Levenson and 
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Crabbe, 2014). Intermittent ethanol access (IEA) allows for a full 24 hour period 
of ethanol access, using 2-bottle-choice, which leads to a substantial escalation 
in ethanol preference over water in C57BL/6J mice as well as C3H/HeJ mice 
(Barkley-Levenson et al, 2014). In either case the intermittent schedule 
encourages binge-like consumption that is not observed under constant ethanol 
access, 2-bottle-choice (Hwa et al, 2011). 
 Using these paradigms to model AUD-related behaviors, genetic 
techniques can be used to explore the role AUD candidate risk genes. Genetic 
deletion, or knockout (KO) mice allow for the study of a complete genetic loss of 
function, as in the case of µ-opiate receptor KO and CB1 receptor KO mice, both 
which have shown reduced ethanol consumption and preference (Hall et al, 
2001; Thanos et al, 2005). Given innumerable potential compensatory 
mechanisms during development in the brains of constitutive KO mice, gene 
manipulation techniques which provide spatiotemporal specificity are preferred. 
Cre-loxP manipulation is widely used as a means to selectively delete (or 
express, by deletion of a stop cassette) genes of interest at a given time and in a 
cell-specific manner (Pina and Cunningham, 2017; Sauer, 1993). Cre 
recombinase is a bacteriophage-derived enzyme which performs site specific 
recombination at DNA recognition sites known as loxP sites. DNA located 
between these loxP sites is referred to as “floxed” and will be excised from the 
chromosome following Cre-mediated recombination (Nagy, 2000). To achieve 
deletion, animals with loxP sites selectively added, in order to flox a gene of 
interest, must be exposed to Cre. Cre can be delivered as a gene insert in a viral 
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vector: injection of the vector into tissue will result in transduction of the viral 
genome and subsequent Cre expression. In this case regional specificity is 
provided by the location of injection itself. Cellular specificity can be conferred by 
the viral serotype of the vector (Howard et al, 2008) and by the promoter driving 
the Cre transgene (Liu et al, 2008). However, size constraints can limit the 
effective use of many eukaryotic promoters (Shinohara et al, 2016).  
 An alternative Cre delivery is by chemically mediated induction. The most 
common of these are the tetracycline-inducible Cre-LoxP system and the 
tamoxifen-inducible Cre-loxP system (Feil et al, 2009); we will focus on the latter. 
The tamoxifen-inducible system uses a modified estrogen receptor (ER) with a 
strong affinity for tamoxifen, fused to Cre. In the absence of treatment the ER is 
sequestered in the cytosol by heat shock protein 90 (Hsp90) (Gunschmann et al, 
2014). Upon tamoxifen treatment, tamoxifen binds the ER, releasing Hsp90, and 
the Cre-ER fusion protein translocates to the nucleus. In the nucleus Cre 
recombines the floxed gene, resulting in a knockout (Gunschmann et al, 2014). 
Under this system a high degree of cellular specificity is possible because the 
inducible Cre-ER gene can be inserted into the region of any promoter of interest 
(Feil et al, 2009). Selective breeding is then required to cross mice bred to carry 
floxed alleles with those bred to carry the Cre-ER gene under the promoter of 
interest. The convergence of a Cre-mediated knockout with specific cellular 
promoters allows the experimenter to investigate the role of a candidate gene as 
it functions only in a particular cell type. Furthermore when this method is 
complimented with viral-vector mediated studies, the combination of regional and 
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cellular specific readouts can serve to delineate a prospective pathway. In this 
dissertation we follow these lines of evidence in the context of GSK3B function in 
glutamatergic projection neurons and the promotion of excessive ethanol intake.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
 
 
Chapter 3  
Effects of Acute and Chronic Ethanol on the Genome 
 
3.1 Introduction 
Alcohol-use disorder is the complex result of a multitude of central 
nervous system (CNS) adaptations following long-term, repeated episodes of 
heavy ethanol consumption and withdrawal. Although AUD is a uniquely human 
trait possibly requiring decades to develop, key facets of ethanol-induced 
behaviors and cognate molecular adaptations following acute ethanol exposure 
can be studied across a spectrum of animal models including monkeys, mice, 
rats, flies, and worms (Becker and Hale, 1993; Bettinger et al, 2012; Bhandari et 
al, 2009). Each of these organisms demonstrates some type of tolerance to 
ethanol’s effects, indicating a conserved tendency of the CNS to restore 
homeostasis. Changes in stress reactivity, gene expression, and neuronal 
signaling all accompany acute ethanol exposure and have been postulated to 
lead to chronic adaptation—essentially an allostatic imprint on the CNS (Costin et 
al, 2013; McBride et al, 2005). 
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In comparing biological pathways potentially mediating acute-to-chronic 
adaptation, it may be postulated that there exist several distinct response 
profiles:  
(1) pathways which are acutely perturbed, but under tight homeostatic pressure 
to return to a baseline.  
(2) pathways showing acute alterations which, upon repeated exposures, 
continue to show alterations, i.e. adapt to a new baseline.  
(3) pathways which do not show any acute response, but are only induced upon 
chronic exposure. 
The habituation of the hypothalamic-pituitary-adrenal (HPA) axis to stress 
is a quintessential example of the first type of response, with an induction of 
immediate early genes (i.e. c-fos) observed following an acute stressor, but a 
diminished or even absent response following repeated stressors (Melia, 
Ryabinin, Schroeder, Bloom, & Wilson, 1994). In the context of ethanol, its 
corticosterone-increasing effect has also been found to show such habituation 
(Seeley, Hawkins, Ramsay, Wilkinson, & Woods, 1996) as has the ethanol 
induced activation of serum glucocorticoid kinase 1 (Sgk1) (Costin et al 2013). 
Brain-derived Neurotrophic Factor (BDNF) has garnered considerable interest in 
mediating addictive aspects of ethanol, and its expression is acutely induced in 
the striatum, with a long-term blunting of this response following repeated ethanol 
exposure (Logrip, Janak, & Ron, 2009).  
BDNF in the frontal cortex is an example of the second type of response. 
Its expression shows ethanol-induced reductions during intoxication, but unlike in 
striatum, these cortical perturbations can persist through chronic exposure and 
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withdrawal (Logrip et al, 2009; Smith et al, 2016). Wolstenholme et al. (2017) 
have found long-term changes in myelin-related gene expression in the PFC of 
mice repeatedly exposed to ethanol during adolescence. Mag, Cnp, Pten, and 
Mpp showed expression changes immediately following repeated adolescent 
exposure, which persisted into adulthood even without subsequent exposures 
(Wolstenholme et al, 2017).  
The third type of response profile—changes observed only upon chronic 
exposure—is well evidenced by changes in the expression and localization 
GABA and NDMA receptors following chronic ethanol (Carpenter-Hyland et al, 
2004; Papadeas and Grobin, 2001). While acute ethanol directly targets these 
receptors, it is only after long-term repeated exposures that changes in 
expression level and localization are observed.   
The focus of this chapter will be on gene expression changes fitting 
response profiles (2) and (3). Genome-wide expression changes following an 
acute ethanol exposure will be compared to changes observed following chronic 
ethanol exposure, in the corticostriatal pathway. They will be assessed for 
overlap to identify transcriptional changes which are conserved from acute to 
chronic ethanol exposure, as well as those unique to the chronic treatment 
condition. The acute condition consisted of a single i.p. injection of ethanol (1.8 
g/kg) or saline, while the chronic condition used the chronic intermittent ethanol 
(CIE) vapor model.  
The chronic intermittent ethanol vapor model (CIE) has been widely used 
in rodent studies (Lopez and Becker, 2005; Lopez et al, 2012; O'Dell et al, 2004; 
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Roberts et al, 2000) as a tool to approximate the repeated cycles of heavy 
consumption and withdrawal that are seen in humans during development of 
AUD. CIE-exposed rats or mice will show alterations in the amount and pattern of 
ethanol consumption, generally increasing their ethanol consumption following 
CIE vapor exposure (Becker, 2013; Griffin et al, 2009; Lopez et al, 2005; O'Dell 
et al, 2004). Genomic studies have correlated patterns of gene expression 
following CIE with coincident changes in ethanol consumption (Osterndorff-
Kahanek et al, 2013). 
The CIE model provides a powerful tool for discovery and hypothesis 
testing of processes and mechanisms underlying progressive ethanol 
consumption. Its application to the recombinant inbred (RI) panel of BXD mice 
allows for additional insights to be made into genetic variation underlying 
changes in gene expression. The BXD panel, generated from crosses between 
C57BL/6J and DBA/2J, is currently the largest and best-characterized RI line, 
allowing for genomic mapping of quantitative traits to loci of allelic variation 
(Andreux et al, 2012). In this experiment we have used ethanol-induced 
expression change as the quantitative phenotype, thus generating expression 
quantitative trait loci (eQTLs) in both acutely and chronically treated animals.  
Because variation in initial sensitivity to ethanol has itself been shown to 
confer risk in human alcoholism (Schuckit, 1994), identification of acutely 
ethanol-responsive genes might in itself be helpful in identifying human 
susceptibility loci. Assessing acutely responsive genes for overlap with chronic 
ethanol responsive genes might further identify those initial sensitivity genes with 
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continuing roles in CNS adaptation. Finally, analysis of ethanol-responsive genes 
within human genetic data provides a direct application of candidate gene 
discoveries to a patient population. This chapter concludes with this type of 
application, based on a gene network centered on Gsk3b. 
 
3.2 Materials and Methods 
Animals. Male and female C57BL/6J and DBA/2J mice for CIE experiments 
were purchased from Jackson Laboratory at 10 weeks old (Bar Harbor, ME). 
After 1-week acclimation to the animal facility, mice were singly housed for 72 h 
prior to the drinking experiments. Male and female BXD RI strains for CIE (n = 43 
strains) at 12–16 weeks old were supplied by the University of Tennessee Health 
Sciences Center (Memphis, TN). BXD mice were single-housed immediately, 
and began the drinking experiments after 72-h acclimation to single housing. All 
mice were housed individually in an AALAC-accredited facility under 12-h 
light/dark cycles with free access to food and water. All animal housing and care 
was conducted in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (Council, 2011). 
Chronic Intermittent Ethanol. Chronic intermittent ethanol procedures were 
performed at Medical University of South Carolina with approval by the 
Institutional Animal Care and Use Committee, according to well-established 
procedures shown to cause increased ethanol consumption (Lopez et al, 2005). 
Since the CIE model is a complex and time-consuming behavioral analysis, as 
an initial genetic analysis of CIE-evoked behaviors and gene expression 
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alterations, we utilized a design where single animals per strain/treatment were 
used for most strains to maximize the number of strains for genetic and genomic 
analysis. After 6 weeks of limited access (2 h/day) baseline drinking with 2-bottle 
choice 15% v/v ethanol and water, mice (n = 119) representing 43 BXD RI strains 
and progenitors were divided into two groups: CIE and control. CIE mice 
received ethanol vapor in Plexiglas® inhalation chambers (60 × 36 × 60 cm) for 
16 h/day for 4 days. Control mice were also placed in the inhalation chambers for 
16 h/day for 4 days, but did not receive ethanol vapor. After 4 days in the 
inhalation chamber, mice underwent 72 h of complete ethanol abstinence, 
followed by 5 days limited-access drinking (2-bottle choice 15% v/v ethanol and 
water, 2 h/day) (Lopez et al, 2005). This cycle was repeated such that BXD mice 
underwent four sessions of inter-cycle ethanol consumption and five sessions of 
inhalation chamber exposure. Ethanol levels in the inhalation chambers were set 
to produce blood ethanol concentrations of 200–300 mg/dL. Prior to each vapor 
chamber session, mice were injected intraperitoneally (i.p.) with 1 mmol/kg 
pyrazole, an alcohol dehydrogenase inhibitor used to stabilize blood ethanol 
concentration. Blood was collected from mice after the 3rd day in the inhalation 
chamber during each inhalation chamber cycle. Mice were sacrificed 72 h after 
the 5th inhalation chamber session. A schematic of the CIE protocol employed 
here is given in Fig. 3.1. 
 
42 
 
 
 
Fig. 3.1. Schematic of Chronic Intermittent Ethanol (CIE) model. Following 
6 weeks baseline drinking, male and female BXD mice and their progenitors 
(n = 48) underwent 4 cycles of CIE by Plexiglas® vapor chamber 
16 h/day × 4 days, 72 h ethanol abstinence, then 2-bottle choice drinking 
2 h/day × 5 days. After the final cycle of CIE, mice were sacrificed 72 h after a 
5th vapor-chamber session (van der Vaart et al, 2017). 
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Tissue Harvesting and RNA Isolation. Surviving mice (n = 72) were sacrificed 
72 h after CIE procedures by cervical dislocation and decapitation. Brains were 
immediately removed, and specific regions dissected using a brain punch micro-
dissection and snap freezing in liquid nitrogen. Tissue samples were shipped on 
dry ice to Virginia Commonwealth University, and stored at −80 °C until RNA 
isolation. Total RNA was isolated from prefrontal cortex (PFC) and nucleus 
accumbens (NAC), as described (Kerns et al, 2005b; Wolen et al, 2012). Briefly, 
brain tissue from individual mice (n = 72) was ground with a glass homogenizer, 
and RNA extracted using Stat 60 (AMS Biotechnology, Abingdon, UK). RNA 
quality was assessed by capillary gel electrophoresis with the Experion™ 
Automated Electrophoresis System (BioRad Laboratories, Hercules, CA). 
Samples showing poor RNA quality (i.e., RIN < 8, n = 2 for NAC, n = 3 for PFC) 
were eliminated from analysis. 
For qPCR validation of Dmn3, NAC brain tissue from separate cohorts of 
C57BL/6J and DBA2/J mice having undergone the same CIE with drinking 
procedure described were used. Brain regions were harvested using brain punch 
micro-dissection as previously described (Kerns et al, 2005b). Brain tissues were 
immediately snap frozen in liquid nitrogen, and stored long-term at −80 °C. NAC 
tissue was lysed using Stat 60, and RNA was extracted with the Qiagen 
miRNeasy Mini Kit. RNA quality was assessed with the ExperionTM System and 
RNA yield was determined using a NanoDrop 2000 UV spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA). 
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CIE gene expression microarray analysis. Gene expression was quantified 
with Affymetrix GeneChip® Mouse Genome 430 2.0 arrays (Affymetrix, Santa 
Clara, CA). Arrays were run on PFC and NAC from 70 mice comprised of 19 
BXD RI strains, C57BL/6J and DBA/2J progenitors, and C57BL/6J + DBA/2J F1 
(n = 1–2 per strain per treatment group for BXDs, B6D2F1, C57BL/6UT, and 
DBA/2J; n = 6 CIE C57BL/6J; n = 8 CTL C57BL/6J; Supplemental Table 3.1). 
RNA samples from PFC and NAC were processed separately using standard 
protocols outlined by Affymetrix. RNA samples were randomized for cRNA 
preparation, and re-randomized before hybridization and scanning to minimize 
batch effects. 
Mouse Genome 430 2.0 arrays were initially analyzed using Affymetrix 
Expression Console software. Array quality was assessed based on average 
background, scaling factor, present probesets, and 3′/5′ ratios of Actin and 
Gapdh. Robust multichip analysis (RMA) with quantile normalization was 
performed within the R statistical package for generation of normalized 
expression values from control and CIE-treated animals (Irizarry et al, 2003). 
CIE-responsive genes were identified within each brain region by using the 
Significance-score (S-score) algorithm (GeneNetwork Accession: GN:299 for 
PFC and GN:407 for NAC) (Kennedy et al, 2006; Kerns et al, 2003; Zhang et al, 
2002). The S-score is a method developed to measure change in expression 
between compared oligonucleotide microarrays using probe-level data, and so is 
particularly suited to comparisons of smaller numbers of chips. The algorithm 
uses relative changes in probe-pair intensities to essentially create z scores 
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centered around zero for individual probesets, with values reflecting significance 
of expression change in the positive or negative direction. Thus, while not 
technically a measure of magnitude of expression change, S-scores generally 
correlate to fold change. S-scores were generated using the S-score R package 
from each BXD RI strain, C57BL/6J, DBA/2J, and C57BL/6J + DBA/2J F1 mice 
separately. Because only one CIE and one control sample was available for most 
BXD RI strains, significance of gene expression response across the BXD cohort 
was determined using Fisher’s Combined Probability Test with S-scores as 
previously described (Wolen et al, 2012). Ethanol-“responsive” genes were 
identified as probesets with a q value < 0.05. 
Comparison of CIE and acute ethanol genomic responses in BXD mice. CIE 
responsive genes identified by Fisher’s Combined S-scores in the PFC and NAC 
were compared to probesets previously identified as responsive to acute ethanol 
exposure (4 h, 1.8 g/kg i.p., 6–8/strain) across 29 or 36 strains of the BXD RI 
cohort in PFC and NAC, respectively (GEO: GSE28515, GeneNetwork 
Accession: GN:137 for PFC and GN:154 for NAC) (Wolen et al, 2012). Overlap 
analyses were performed using GeneWeaver (Baker et al, 2012) and visualized 
with Venny (Oliveros, 2007). Overlaps of interest were Acute PFC vs. CIE PFC, 
Acute NAC vs. CIE NAC, and overlap between all four groups (two brain regions 
each with two treatment paradigms). Probesets exclusively regulated in the PFC 
with CIE, and exclusively regulated in the NAC with CIE, were also examined. 
Significance of overlap between pairwise combinations was determined using 
Fisher’s test for count data (Fisher, 1922). 
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Pathway enrichment and gene ontology analyses of ethanol-responsive 
gene sets. ToppGene (http://toppgene.cchmc.org/), an open-source gene 
ontology analysis tool, was used for gene-set enrichment analysis for Gene 
Ontology (GO) terms among the Biological Process, Molecular Function, and 
Cellular Component categories. GO analyses were performed in June 2016. 
Results were filtered for FDR < 0.05 for all the comparisons to increase 
stringency of the analysis. Results were further filtered to remove terms 
containing fewer than two genes or greater than 1000 genes, and terms with 
similar definitions and gene lists were trimmed for clarity. Gene Ontology results 
were then summarized using REVIGO (http://revigo.irb.hr/). REVIGO reduces 
and summarizes GO results by clustering redundant terms into overarching 
categories representing biological functions (Supek et al, 2011). Ingenuity 
Pathways Analysis (Ingenuity Systems Inc., Redwood City, CA) was used to 
identify gene networks coordinately regulated exclusively by CIE in the PFC and 
NAC, or by acute ethanol and CIE within the PFC or NAC. Ingenuity Pathway 
Analysis (IPA) was also used to identify over-represented potential upstream 
regulators such as transcription factors that may be responsible for regulating 
expression of genes in the set. Networks were limited to 35 molecules, and 
scored by IPA based on the hypergeometric distribution, calculated using the 
right-tailed Fisher’s exact test. Results were reported as the negative log of this 
value, such that a score of 20 indicates that there is a 1 in 1020 chance of 
producing a network containing at least the same number of genes of interest 
from 35 randomly chosen genes. 
47 
 
eQTL analyses of ethanol-responsive gene sets. Gene expression data in the 
form of S-score values for significant ethanol-responsive probesets (acute and 
CIE) were used as the quantitative trait values to be analyzed across the BXD 
cohort, and are accessible in GeneNetwork (GN299 for PFC and GN407 for 
NAC, www.genenetwork.org). GeneNetwork web-based tool sets were used for 
genetic mapping, and correlation of quantitative traits such as gene expression 
data and behavioral parameters (Wang et al, 2003). GeneNetwork employs 
genotype data from 3809 markers, selected based on their being informative 
(i.e., different between progenitor strains). GeneNetwork outputs peak “likelihood 
ratio statistic” (LRS) locations for each trait, which can be directly converted to 
log odds ratios (LOD) by dividing by 4.61. In our analysis, we defined 
“suggestive” eQTLs as markers with an LRS > 10 (LOD > 2.17) (Williams, 2012). 
This lenient threshold allowed for a high number of associations between 
genomic loci and ethanol-responsive transcripts, useful for an exploratory 
genetical genomics analysis. Within the subsets of suggestive eQTLs for a given 
brain region and treatment paradigm, significance of individual eQTLs was 
determined using permutation testing, wherein 5000 random reassignments of 
genotypes and trait values are compared to the actual observation. Genes were 
considered significant in the permuted data analysis at p < 0.05 (Williams and 
Broman, 2010). Cis-eQTLs were defined as loci within 5 Mb of the gene showing 
associated ethanol-responsive expression. To identify genomic regions 
regulating large numbers of ethanol-responsive genes, the genome was split into 
10-Mb bins and the numbers of significant or suggestive eQTLs were counted 
48 
 
within each bin. In the absence of cis-eQTLs, QTLminer (Alberts and Schughart, 
2010), which integrates gene annotations, expression, and single nucleotide 
polymorphisms (SNPs), was used within GeneNetwork to identify candidate 
regulatory genes. Within QTLminer, our interval was set as 1 Mb on either side of 
the peak LRS of interest; the strains for nsSNPs were set as DBA/2J and 
C57BL6/J. Input datasets were expression data from treatment of interest (acute 
or CIE). Dataset 1 used S-score, while Datasets 2 and 3 used RMA values of 
ethanol-treated and control animals, respectively. 
(http://www.genenetwork.org/webqtl/main.py?FormID=qtlminer) 
Correlation of gene expression with ethanol-drinking behavior. To assess 
the relationship between ethanol-responsive gene expression and ethanol-
drinking behavior across the BXD cohort, we correlated the average ethanol 
intake over the 5-day period of 2-bottle choice following the 3rd and 4th cycles of 
ethanol or air vapor exposure to gene expression (RMA values) in ethanol vapor-
exposed (CIE, PFC GN:791, NAC GN:795) or air-exposed (control, PFC GN:789, 
NAC GN:793) mice. RMA values were generated using an SNP mask to remove 
probes and probesets that target regions of known SNPs between the D2 and B6 
strains. Additionally, the RMA files were corrected for possible batch effects 
using the ComBat function (Johnson, 2007). These RMA files allowed us to 
identify probesets whose expression correlated with ethanol-drinking behavior in 
the ethanol-exposed animals, but not in controls. In each comparison, Spearman 
correlations were used, with p values for each probesetʹs correlation coefficient 
calculated using a two-tailed t test. The probesets were then ranked in ascending 
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order from the smallest p value. Spearman correlations with a p value < 0.05 
were considered significant. GO analysis was performed using the ToppGene 
Suite (as described above) on the lists of significantly correlated genes in the air-
exposed or the CIE-exposed mice in both the PFC and the NAC. 
We also queried GeneNetwork for other BXD phenotypes related to 
ethanol consumption after the 3rd cycle of ethanol vapor treatment (GN:12967). 
The top 500 Spearman correlations were filtered for the term “ethanol” and 
p values < 0.05 were considered significant. 
Quantitative real-time reverse transcription – qPCR. Total RNA (1 μg) from 
18 DBA/2J and 20 C57BL/6J mice (n = 4–5/group) was reverse transcribed into 
cDNA using an iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR 
was performed using iQ SYBR Green Supermix and the CFX system (Bio-Rad), 
according to manufacturer’s instructions. Three technical replicates were 
performed for each cDNA, and relative abundance of target transcripts were 
normalized to Ppp2a and Ublcp1 as reference genes using GeneNorm in the 
CFX software. Primers were designed to minimize secondary structure formation 
and cross intron-exon boundaries to reduce genomic DNA amplification. Primers 
were validated to produce a single PCR product via DNA gel electrophoresis (not 
shown). 
Gsk3b Network Derivation. Microarray data for derivation of the acute ethanol 
Gsk3b correlation network have been previously reported (Putman et al, 2016; 
Wolen et al, 2012). Briefly, prefrontal cortex tissue samples were derived from a 
total of 468 animals across the BXD panel of inbred mice. An average of 8 mice 
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per strain were treated with either saline or 1.8g/kg ethanol. Four hours following 
treatment, animals were rapidly sacrificed by cervical dislocation, brains 
removed, chilled, microdissected and processed for RNA isolation (Kerns et al, 
2005a). Affymetrix M430 type 2.0 microarrays were used for hybridization 
utilizing standard procedures. Expression response to ethanol was derived using 
the S-score method to compare ethanol vs. saline expression from pairs of 
arrays for each strain (Farris and Mayfield, 2014; Kerns et al, 2003; Zhang et al, 
2002). The S-score is a method developed for Affymetrix oligonucleotide arrays 
that is particularly suited to comparing expression on a small number of chips. 
The S-score output for each probe set measures the change in expression 
between compared arrays is essentially a z-score centered around zero, with 
positive or negative S-scores reflecting ethanol-induced increases and decreases 
in gene expression, respectively. Genes correlating with Gsk3b at defined 
Pearson correlation cutoffs and random networks of genes of the same size were 
determined using weighted gene correlation network analysis (WGCNA) as 
described previously (Smith et al, 2016). The hub-like nature of Gsk3b (Wolen et 
al, 2012) in an ethanol responsive gene network was assessed and illustrated by 
selecting genes with an S-Score correlation greater than 0.9 and calculating 
edge weights between these genes using WGCNA (Langfelder and Horvath, 
2008). Randomly selected groups of genes of the same number were also 
assessed with WGCNA. A minimum edge weight threshold of 0 was used so that 
all edge weights among 10000 random permutations of gene groups could be 
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counted and compared (after normalization) to the Gsk3b gene group. Graphics 
were created in the R statistical framework using ggplot2 (Wickham, 2009).  
Set-based Human Association Analysis. The Collaborative Study on the 
Genetics of Alcoholism (COGA) is a family-based study of alcohol dependence 
(Bierut et al, 2002). Full acknowledgement of COGA investigators is included 
below. COGA provided genotype information for this study but no new human 
subjects were recruited nor individual identifier information disclosed. Alcohol-
dependent probands were identified through inpatient or outpatient alcohol 
treatment programs at seven sites around the United States (Reich, 1996). All 
individuals aged 18 or older were interviewed using the Semi-Structured 
Assessment for the Genetics of Alcoholism (SSAGA) (Bucholz et al, 1994; 
Hesselbrock et al, 1999). From this sample, an independent case-control sample 
was selected for a genome-wide association study (GWAS), with genotyping 
conducted by the Center for Inherited Disease Research using the Illumina 1 
million SNPchip platform. Genome wide data was generated on 2000 individuals, 
1905 (1022 males 883 females) of which remained after all data cleaning (Bierut 
et al, 2010).  All 1205 cases met criteria for DSM-IV Alcohol Dependence, as 
assessed by the SSAGA, and all 700 controls were screened against Alcohol 
Dependence and related substance use disorders. The program Plink (Purcell et 
al, 2007) was used to conduct all association tests.  Logistic regression 
association analyses were conducted using an additive genetic model. Sex and 
two principal components to adjust for race were used as covariates in analyses. 
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 Human homologs of genes correlating with Gsk3b in ethanol-induced 
microarray expression change in mouse mPFC were selected for association 
analysis. Groups of genes correlating ≥ .80, ≥ .85, ≥ .90, and ≥ .95 with S-scores 
of Gsk3b responses to ethanol were assessed for risk-conferring SNPs, with a p-
value<0.05 defined as significant in these gene group-based analyses. SNPs 
located within the genes, as well as SNPs 2Kb up and downstream from the 
genes were included. For analyses on individual genes, a slightly stricter p-value 
of <0.01 defined as risk-conferring. P-values of SNP sets were determined 
empirically by random resampling (10000 permutations).   
 
3.3 Results 
Identification of significant ethanol-responsive gene expression following 
CIE. Chronic intermittent ethanol by vapor chamber significantly affected gene 
expression across the BXD cohort in both the PFC and NAC. In all, the 
expression of 759 genes in the PFC and 867 genes in NAC were ethanol-
responsive by CIE at a significance level of q < 0.05 (Supplemental Table 3.2). 
We previously found that an acute dose of ethanol significantly altered 1479 
genes in PFC and 1373 genes in NAC (Wolen et al, 2012), using a similar 
genomic and statistical approach. In this study, we compared the probesets 
altered by acute ethanol to our CIE findings (Fig. 3.2, Supplemental Table 3.3) to 
gain potential insights into conserved vs. unique mechanisms of CIE-induced 
expression changes. The degree of overlap between ethanol-responsive 
probesets was significant (p < 0.05) by Fisher’s exact test, when comparing 
treatment paradigms (Acute PFC vs. CIE PFC, Acute NAC vs. CIE NAC). In the  
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Fig. 3.2. CIE-responsive genes overlap with acute ethanol responsive 
genes. Gene expression response to CIE or acute ethanol was measured by 
Fisher’s combined S-scores in the PFC and NAC. Ethanol-responsive genes 
were defined as those with p values ≤ 0.05. CIE-responsive genes identified 
were compared to probesets previously identified as responsive to acute ethanol 
exposure across the BXD RI cohort in PFC and NAC. Both pairwise and 
hierarchal overlap was examined. Significance of overlap between each pairwise 
combination was determined using Fisher’s test for count data (Fisher, 1992). 
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PFC, ~35% of CIE-responsive probesets were also significantly responsive to 
acute ethanol (n = 269 probesets), while in NAC ~26% of CIE-responsive 
probesets were also responsive to acute ethanol (n = 225 probesets). We found 
224 probesets unique to the CIE PFC, and 378 unique to CIE NAC, representing 
effects specific to brain region and to chronic ethanol.  
Bioinformatic analyses of gene sets in the PFC and NAC following CIE or 
acute ethanol. Bioinformatic analysis using ToppGene or Ingenuity Pathway 
Analysis was performed to identify significantly over-represented biological 
themes within gene sets (see Supplemental Tables 3.4–3.8). Five gene sets 
developed from our overlap analyses were queried: (1) genes unique to 
CIE PFC, (2) genes unique to CIE NAC, (3) overlapping genes between acute 
PFC and CIE PFC, (4) overlapping genes between acute NAC and CIE NAC, 
and (5) overlapping genes between both treatment conditions in PFC and NAC. 
(1) Genes exclusively regulated by chronic ethanol in the PFC 
224 probesets were modulated by only CIE and exclusively in the PFC 
(Supplemental Fig. 3.1 and Supplemental Table 3.4). Five molecular functions 
were significantly over-represented: protein complex binding, cytoskeletal protein 
binding, MHC II receptor activity, cell adhesion molecule binding, and calmodulin 
binding. Of the 51 Biological Process categories identified, the major themes are 
involved in action potentials and synaptic transmission, antigen processing and 
presentation, dopamine receptor signaling, and brain developmental processes, 
including locomotor behavior and learning. 
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Fig. 3.3. Network of genes exclusively regulated by CIE in the PFC. Gene 
network was generated by Ingenuity Pathways Analysis (www.ingenuity.com). 
Solid arrowheads reflect “acts on” interactions while lines without arrows indicate 
binding interactions only. Solid and dotted lines indicate, respectively, direct vs. 
indirect interactions. 
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Ingenuity Pathway Analysis (IPA) generated several novel networks, one of 
which (Fig. 3.3) contained CaM kinase II and two myelin-associated genes (Mag 
and Mal), with Akt as the major integration point. Two types of collagen and 
N-Cadherin were also in this pathway. The top upstream regulators of this gene 
set were Huntingtin (HTT), which regulates 32 of the 193 genes analyzed 
(p = 1.22 × 10−15), and β-estradiol, which may regulate 39 out of 193 genes in the 
set (p = 4.06 × 10−10). 
(2) Genes exclusively regulated by chronic ethanol in the NAC 
378 probesets were exclusively altered by ethanol in the NAC only 
following CIE (Supplemental Fig. 3.2 and Supplemental Table 3.5). Only three 
Molecular Function categories were significantly over-represented: neuropeptide 
hormone activity, phorbol ester receptor activity, and protein heterodimerization 
activity. Substantially more Biological Processes were identified (55 categories) 
and can be described by the main themes of synaptic transmission, negative 
regulation of cell death, neuron projection development, behavior, including 
behavioral fear response, learning or memory, and regulation of nervous system 
development. The 10 significant Cellular Component categories reflect many 
parts of the neuron or synapse including the synapse, axon, dendrite, and 
synaptic vesicles. An additional category from ToppFun is the Mouse Phenotype. 
For genes altered by ethanol in NAC of CIE BXD mice, significant results in the 
Mouse Phenotype category highlight potential problems in neurological function: 
abnormal fear/anxiety-related behavior, synaptic transmission, increased 
susceptibility to induction of seizure, abnormal learning/memory/conditioning, and 
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locomotor activation. These phenotypic categories are consistent with the gene 
ontology findings discussed above. 
IPA analysis identified gene networks that involved genes within the 
synapse, BDNF, and GABA receptor subunits. CREB1 was identified as the top 
upstream regulator with 34 genes potentially regulated out of 304 in the analysis 
(p = 1 × 10−14). 
(3) Genes regulated by both acute and chronic ethanol in PFC 
In the PFC, 269 probesets were in common after overlapping gene sets 
from the CIE protocol and acute ethanol (Supplemental Fig. 3.3 and 
Supplemental Table 3.6). Thirty-eight identified Molecular Functions included 
some rather diverse categories, including mRNA binding, syntaxin binding, 
GABA-A receptor activity, calcium-dependent protein binding activity, voltage-
gated potassium channel activity, toll-like receptor 4 binding, and structural 
constituent of the myelin sheath. Over-represented Biological Processes (109 
categories) were complementary to the Molecular Function categories and 
included synaptic transmission, mRNA processing, learning or memory and 
cognition, neurotransmitter secretion, and axon development. Similarly, the 43 
categories from the Cellular Component analysis identified many specific parts of 
the neuron (somatodendritic compartment, synapse, dendrite, neuronal body, 
dendritic spine, and post-synaptic membrane). These also included ion channel 
complexes, voltage-gated potassium channel, SWI/SNF family complex, GABA-A 
receptor, nuclear chromatin and myelin sheath, and axonal region. Mouse 
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Phenotypes identified abnormalities in synaptic transmission, specifically 
miniature EPSCs, learning, memory and cognition, and abnormal gait. 
(4) Genes regulated by both acute and chronic ethanol in the NAC 
In the NAC, 225 probesets were similarly regulated by ethanol following 
acute ethanol and the CIE protocol (Supplemental Fig. 3.4 and Supplemental 
Table 3.7). Surprisingly, no Molecular Functions were significantly over-
represented in the ToppFun analysis. However, 91 categories in the Biological 
Processes were significantly over-represented. These categories included such 
processes as synaptic transmission, neurotransmitter secretion, behavior, CNS 
development, and glutamate receptor signaling. Again, categories identified in 
the Cellular Component analysis (29 categories) identified many parts of the 
neuron including neuron projection, synapse, clathrin-coated vesicles, GABA and 
glutamate transport vesicles, dendritic spine, and neuronal cell body. Similar to 
the PFC, Mouse Phenotypes identified were primarily abnormalities in learning 
and memory, synaptic transmission, miniature EPSCs, and synaptic depression. 
The novel networks identified by IPA were again similar in theme and 
generated networks containing calcium-channel and glutamate-receptor subunits 
along with synapse structural components (Fig. 3.4). Upstream regulators of 
these genes were similar to the regulators of PFC genes regulated by CIE and 
acute ethanol: HTT (28 genes/191 analyzed, p = 2.6 × 10−12), BDNF 
(18 genes/191 analyzed, p = 5.8 × 10−11) and HDAC4 (11 genes/191 analyzed, 
p = 1.12 × 10−9). 
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Fig. 3.4. Top-ranked network in the NAC, regulated by both acute and 
chronic ethanol. Gene network enriched in genes involved in synapse structural 
components and calcium channels was generated by Ingenuity Pathways 
Analysis (www.ingenuity.com). Solid arrowheads reflect “acts on” interactions 
while lines without arrows indicate binding interactions only. Solid and dotted 
lines indicate, respectively, direct vs. indirect interactions. 
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(5) Genes regulated by acute and chronic ethanol in both PFC and NAC 
We were also interested in examining the genes which were in common 
between both PFC and NAC in regulation by acute ethanol and CIE 
(Supplemental Fig. 3.5 and Supplemental Table 3.8). We reasoned that this 
group might reflect genes with a particular sensitivity to ethanol pharmacology, 
based on their regulation across region and paradigm. Eighty-eight probesets 
were similarly regulated by both ethanol protocols in both brain regions (Fig. 3.2). 
GO analysis identified 16 Biological Process categories (enzyme regulator 
activity, protein-domain specific binding, SMAD binding, voltage-gated cation 
channel activity, calmodulin binding, and GTPase regulator activity). The 56 
Molecular Function categories were similar in theme to the previous gene set 
comparisons and included synaptic transmission, neurotransmitter transport, 
signal release, regulation of calcium ion transport, and regulation of hormone 
levels, as well as learning and memory. However, there were unique categories 
that included receptor clustering and DNA methylation. Mouse Phenotypes found 
abnormalities in synaptic transmission, miniature EPSCs, and learning and 
memory. 
Each of the top novel networks generated by IPA contained either 
CREBBP, FOS and NEDD4, or voltage-gated potassium channel subunits and 
structural components of the synapse. Importantly, the genes regulated by CIE 
and acute ethanol in the PFC and NAC shared several upstream regulators with 
the PFC or NAC alone and included HTT (15 genes/78 analyzed, p = 9.5 × 10−9), 
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BDNF (10 genes/78 analyzed, p = 7.35 × 10−8), and HDAC4 
(6 genes/78 analyzed, p = 1.64 × 10−6). 
eQTL analyses of ethanol-responsive genes. In addition to assessing overlap 
of the mRNA transcripts with ethanol-induced expression changes, we sought to 
define genetic intervals associated with genome-wide expression changes, 
following acute or chronic ethanol in either the PFC or NAC. Cis eQTLs are 
chromosomal regions associated with altered expression of genes located within 
the same region (<10 megabases), while trans eQTLs are chromosomal regions 
associated with gene expression changes across the genome (distal to the 
genetic variant).  
PFC 
We used S-scores as a measure of ethanol-induced expression change. 
When S-scores were analyzed as a quantitative genetic trait, we found that 633 
probesets with significant ethanol responses in the CIE PFC showed at least a 
suggestive (LRS ≥ 10) eQTL, with 15 of these reaching empirical significance 
(p < 0.05, Supplemental Table 9). S-scores avoid the potential false-positive 
cis-eQTLs that can result from genetic polymorphisms affecting probeset 
hybridization performance (Wolen et al, 2012). In PFC, none of the observed 
eQTLs were cis-regulated. Top trans eQTLs in PFC from CIE or acute ethanol 
(Wolen et al, 2012) treatment are shown in Table 3.1, ranked by LRS. There was 
no overlap between the two lists of top-ranked eQTLs. 
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Table 3.1: PFC—ten highest ranked eQTLs (by LRS), CIE and acute. All significant eQTLs 
identified in the PFC were trans. 
CIE     
Probeset Gene Location (Chr: Mb) Max 
LRS 
Max LRS Location (Chr: Mb) 
1438012_at Ppm1l Chr3: 69.358475 23.3 Chr16: 97.799871 
1422546_at Ilf3 Chr9: 21.198197 23.3 Chr16: 11.886515 
1432269_a_at Sh3kbp1 ChrX: 156.266314 23.1 Chr16: 97.617114 
1423506_a_at Nnat Chr2: 157.387623 22.8 Chr7: 67.179978 
1436098_at Bche Chr3: 73.439883 22.6 Chr7: 57.048459 
1426543_x_at Endod1 Chr9: 14.160201 22.6 Chr16: 97.799871 
1448380_at Lgals3bp Chr11: 118.254260 22.2 ChrX: 48.285597 
1458263_at Cugbp2 Chr2: 6.494081 21.9 Chr1: 194.086272 
1460218_at Cd52 Chr4: 133.649510 21.7 ChrX: 56.488673 
1418580_at Rtp4 Chr16: 23.613274 21.6 ChrX: 48.285597 
Acute     
1442026_at Zbtb16 Chr9: 48.460145 26.4 Chr7: 35.483869 
1418508_a_at Grb2 Chr11: 115.505490 26.4 Chr13: 54.980446 
1431028_a_at Pank1 Chr19: 34.886667 23.7 Chr11: 58.057819 
1427345_a_at Sult1a1 Chr7: 133.816669 22.1 Chr2: 162.978274 
1448534_at Ptpns1 Chr2: 129.456079 22 ChrX: 70.273782 
1450056_at Apc Chr18: 34.477683 21.9 Chr16: 67.888886 
1417409_at Jun Chr4: 94.716397 21.7 Chr1: 20.623897 
1451403_at Ppp1r37 Chr7: 20.116409 21.7 Chr13: 52.866221 
1434661_at Syngr1 Chr15: 79.949377 21 Chr13: 54.980446 
1452958_at Asphd2 Chr5: 112.814574 20.4 Chr7: 25.722934 
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Fig. 3.5. PFC—eQTLS regulated by acute and CIE. Histograms of significant or 
suggestive eQTLs (LRS > 10) across the genome, divided into 10-Mb bins. In the 
eQTL analyses, transcripts were filtered by significant ethanol response 
(p < 0.05) in PFC following acute or chronic ethanol. Ethanol vs. control S-score 
was used as the trait of interest. 
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Histograms of the number of ethanol-responsive genes with suggestive or 
significant eQTLs in 10-Mb chromosomal bins are shown in Fig. 3.5. In the 
CIE PFC experiment, large peaks representing “trans-bands” were seen on Chr3  
(peak LRS: 39.9 Mb) and Chr16 (peak LRS: 97.8 Mb). Highly suggestive 
(LRS > 18) trans-regulated genes at the Chr3 locus were Ube2b, Cplx2, and 
Smarca4. Significant trans-regulated genes at the Chr16 locus were Ppm1l, Ilf3, 
Shk3kbp1, Endod1, and Syn2. Analysis by QTLminer within GeneNetwork 
suggested that the highest-ranked candidate regulatory gene within 1 Mb of the 
Chr3 peak was the cell adhesion molecule, FAT tumor suppressor homolog 4 
(Fat4). The highest-ranked candidate gene for the Chr16 peak was Down 
syndrome cell adhesion molecule (Dscam). There was minimal overlap between 
the acute PFC eQTL bands and the CIE PFC bands, which may indicate distinct 
sites of genomic regulation of ethanol-responsive transcripts in acute vs. chronic 
ethanol in the PFC. All ethanol-responsive eQTLs in PFC with LRS ≥ 10 following 
acute or CIE ethanol treatment are given in Supplemental Tables 3.9–3.10. 
NAC 
In CIE NAC, 699 probesets with significant ethanol response showed at 
least a suggestive eQTL with 69 of these reaching empirical significance 
(p < 0.05, Supplemental Table 11). There was one significant cis-eQTL, Nuclear 
Receptor Subfamily 2, Group C, Member 2 (Nr2c2) (eQTL map shown in 
Fig. 3.6). There were four suggestive cis-eQTLs: Pcolce, Dnm3, Gfap, and 
Fbxo39. Top-ranked eQTLs from CIE treatment are compared to those from 
acute ethanol (Wolen et al, 2012) in Table 3.2. 
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Table 3.2: NAC—ten highest ranked eQTLs (by LRS), CIE and acute. 
 
CIE     
Probeset Gene Location (Chr: Mb) Max LRS Max LRS Location (Chr: Mb) 
1420957_at Apc Chr18: 34.472690 31.9 Chr6: 92.514677 
1452360_a_at Jarid1a Chr6: 120.362354 28.6 Chr6: 94.596952 
1419127_at Npy Chr6: 49.773622 28.5 ChrX: 147.758346 
1456656_at Lin7a Chr10: 106.859723 27.4 Chr6: 94.596952 
1422164_at Pou3f4 ChrX: 108.010303 27.1 Chr4: 16.419441 
1424504_at Rab22a Chr2: 173.530582 26 Chr6: 94.596952 
1435635_at Pcmtd1 Chr1: 7.150977 25.3 Chr6: 92.514677 
1421738_at Gabra2 Chr5: 71.352858 24.2 Chr6: 94.596952 
1425014_at¥ Nr2c2¥ Chr6: 92.117447 24.2 Chr6: 92.514677 
1431020_a_at Fgfr1op2 Chr6: 146.546009 24.2 Chr19: 28.477768 
Acute     
1440901_at Dgkb Chr12: 38.863144 26.9 Chr3: 10.327101 
1447454_at Kif5c Chr2: 49.485000 26.7 Chr18: 3.516538 
1425382_a_at Aqp4 Chr18: 15.551957 26.2 Chr3: 10.327101 
1429882_at Cdh11 Chr8: 19.687909 26 Chr18: 3.516538 
1438069_a_at Rbm5 Chr9: 107.662114 24.9 Chr3: 10.327101 
1421933_at Cbx5 Chr15: 103.026753 24.8 Chr12: 28.507707 
1433413_at Nrxn1 Chr17: 91.488263 24.2 Chr3: 10.327101 
1440439_at Jazf1 Chr6: 52.961885 23.9 Chr18: 3.516538 
1421905_at Ncoa6ip Chr4: 3.502142 23.8 Chr3: 10.018672 
1445717_at Luc7l2 Chr6: 38.548642 23.1 Chr17: 27.985169 
¥ = cis eQTL  
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Fig. 3.6. NAC—eQTLS regulated by acute and CIE. (Top) Histograms of 
significant or suggestive eQTLs (LRS > 10) across the genome, divided into 
10-Mb bins. In the eQTL analyses, transcripts were filtered by significant ethanol 
response (p < 0.05) in NAC following acute or chronic ethanol. Ethanol vs. 
control S-score was used as the trait of interest. (Bottom) Mapping of Nr2c2 S-
Score shows significant peak at its own locus (purple triangle at bottom of peak), 
demonstrating a cis eQTL.  
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Histograms of the number of ethanol-responsive genes with suggestive or 
significant eQTLs in 10-Mb bins are shown in Fig. 3.6. In CIE NAC, a large peak, 
corresponding to 109 ethanol-responsive transcripts, was observed on Chr6:90–
100Mb. This locus was also the site of the significant Nr2c2 cis-eQTL, indicating 
that this gene may play a role in regulating the ethanol-induced expression 
changes of a large number of genes. 34 trans-eQTLs were significantly linked to 
this region, including Apc, Gabra2, Slc1a2, and Homer1. All significant eQTLs at 
this locus are shown in Table 3.3.  
In both the acute and chronic treatments, a trans-band was observed at 
Chr1:160–170Mb; however, the ethanol-responsive transcripts regulated at this 
site differed between the treatment conditions. The suggestive cis-eQTL 
Kidins220 was located at this site following acute ethanol, whereas the 
suggestive cis-eQTL Dnm3 was found at this site in the CIE NAC data. All 
ethanol-responsive eQTLs in NAC with LRS ≥ 10 following acute or CIE ethanol 
treatment are given in Supplemental Tables 3.11–3.12. 
Correlation of gene expression with ethanol-drinking behavior. As an initial 
effort to genetically correlate gene expression to behavioral outcomes of CIE 
treatment, we generated Spearman correlation analyses between ethanol 
consumption (g/kg averaged over a 5-day drinking period) following the 3rd and 
4th cycles of air or CIE treatment versus RMA expression values from the same 
treatment groups. Our premise was that expression correlated with ethanol 
consumption following CIE should reveal a different biological function 
“signature” than seen with air-treated controls. PFC gene lists for correlations  
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Table 3.3: All significant eQTLs in CIE NAC, Chr6:90-95 Mb trans-band 
Probeset Gene Location (Chr, 
Mb) 
Max 
LRS 
Max LRS Location 
(Chr: Mb) 
1420957_at Apc Chr18: 34.472690 31.9 Chr6: 92.514677 
1452360_a_at Jarid1a Chr6: 120.362354 28.6 Chr6: 94.596952 
1456656_at Lin7a Chr10: 
106.859723 
27.4 Chr6: 94.596952 
1424504_at Rab22a Chr2: 173.530582 26 Chr6: 94.596952 
1435635_at Pcmtd1 Chr1: 7.150977 25.3 Chr6: 92.514677 
1421738_at Gabra2 Chr5: 71.352858 24.2 Chr6: 94.596952 
1425014_at Nr2c2¥ Chr6: 92.117447 24.2 Chr6: 92.514677 
1439940_at Slc1a2 Chr2: 102.623749 24.1 Chr6: 92.570486 
1455998_at G630041M05Rik Chr1: 135.556378 23.8 Chr6: 92.514677 
1417736_at Smc6l1 Chr12: 11.298458 23.2 Chr6: 94.596952 
1426259_at Pank3 Chr11: 35.599852 23 Chr6: 92.514677 
1439450_x_at Kiaa1033 Chr10: 83.053882 22 Chr6: 92.514677 
1457361_at Zfp804a Chr2: 82.097416 21.9 Chr6: 92.570486 
1436023_at Bclaf1 Chr10: 20.043434 21.7 Chr6: 92.570486 
1453612_at Nek1 Chr8: 63.533396 21.6 Chr6: 92.514677 
1457625_s_at Cdkl2 Chr5: 92.453971 21.5 Chr6: 92.514677 
1419277_at Usp48 Chr4: 137.172327 21.4 Chr6: 94.596952 
1421768_a_at Homer1 Chr13: 94.119180 21.4 Chr6: 92.514677 
1449120_a_at Pcm1 Chr8: 42.415987 21.2 Chr6: 94.596952 
1452470_at 4933409L06Rik Chr1: 157.791229 21 Chr6: 94.596952 
1452708_a_at Luc7l Chr17: 26.403234 21 Chr6: 94.596952 
1456088_at Birc4 ChrX: 39.460010 21 Chr6: 92.570486 
1429432_at 1810043M20Rik Chr1: 164.640706 20.9 Chr6: 92.514677 
1445081_at Scai Chr2: 38.928170 20.9 Chr6: 92.514677 
1423184_at Itsn2 Chr12: 4.642424 20.9 Chr6: 92.514677 
1457891_at Cugbp2 Chr2: 6.487216 20.3 Chr6: 94.596952 
1434643_at Tbl1x ChrX: 74.900816 20.3 Chr6: 92.570486 
1422842_at Xrn2 Chr2: 146.853329 20.1 Chr6: 92.514677 
1424658_at Taok1 Chr11: 77.349717 20 Chr6: 92.514677 
1450051_at Atrx ChrX: 103.072338 20 Chr6: 92.514677 
1459984_at Mia3 Chr1: 185.000000 19.9 Chr6: 92.514677 
1453414_at E130113K08Rik Chr11: 86.752656 19.5 Chr6: 92.514677 
1440437_at Herc1 Chr9: 66.315187 19.1 Chr6: 92.514677 
1460729_at Rock1 Chr18: 10.119892 19 Chr6: 94.596952 
1437502_x_at Cd24a Chr10: 43.303878 18.4 Chr6: 90.308023 
¥ = cis eQTL 
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Table 3.4: PFC—Spearman correlations of gene expression (RMA) with ethanol 
consumption after the 3rd and 4th cycles of vapor chamber exposure 
 
*Cycle column: reveals if the probeset was significantly correlated with ethanol consumption after 
the 3rd or 4th cycle.  If the probeset was significantly correlated after both cycles, then the row is 
labeled BOTH and the cycle with the strongest correlation is listed and the cycle is denoted in 
parenthesis.  
 
CIE-treated     
Probeset Gene Pval.corr Corr.Spear Cycle* 
1458499_at Pde10a 9.47E-05 0.712173913 BOTH (4th) 
1421860_at Clstn1 0.00091914 0.632173913 BOTH (3rd) 
1425833_a_at Hpca 0.001181409 0.62173913 BOTH (3rd) 
1439618_at Pde10a 0.002053437 0.597391304 BOTH (3rd) 
1442019_at Gas7 0.003023388 0.579130435 BOTH (3rd) 
1416562_at Gad1 0.003799673 0.567826087 BOTH (4th) 
1425810_a_at Csrp1 0.003932856 0.566086957 BOTH (4th) 
1430449_at Kidins220 0.005147076 0.552173913 BOTH (3rd) 
1425281_a_at Tsc22d3 0.005676965 0.546956522 3rd 
1429859_a_at Arl2bp 0.005769573 0.546086957 BOTH (3rd) 
1449932_at Csnk1d 0.005769573 0.546086957 BOTH (3rd) 
1420899_at Rab18 0.00635219 0.540869565 3rd 
1436713_s_at Meg3 0.006874531 0.536521739 4th 
1418586_at Adcy9 0.007548179 0.531304348 BOTH (4th) 
1449264_at Syt11 0.007665626 0.530434783 BOTH (3rd) 
Air-treated     
Probeset Gene Pval.corr Corr.Spear Cycle* 
1439196_at Hook3 0.000319626 -0.696216827 BOTH (4th) 
1444435_at 1110014F16Rik 0.001608394 -0.631846414 4th 
1427150_at Mll3 0.001962023 -0.622811971 4th 
1427319_at A230046K03Rik 0.002110577 -0.619424054 4th 
1427353_at Clasp1 0.002868941 -0.604743083 4th 
1437020_at Ep400 0.003364405 -0.596837945 4th 
1417754_at Topors 0.00428699 -0.584415584 4th 
1416501_at Pdpk1 0.004572405 -0.581027668 4th 
1452187_at Rbm5 0.004771353 -0.578769057 4th 
1423559_at Kcnc1 0.005083271 -0.575381141 4th 
1430820_a_at Bbx 0.005190943 -0.574251835 4th 
1450401_at Ncoa6ip 0.005411987 -0.571993224 4th 
1426327_s_at Zfp91 0.005758193 -0.568605308 4th 
1453512_at Mbnl2 0.006248242 -0.564088086 4th 
1460417_at AB041803 0.006248242 -0.564088086 4th 
70 
 
from CIE- or air-treated animals are contained in Supplemental Table 3.13. Only 
four genes were in common between the CIE (n = 58) and air (n = 170) gene  
lists. Table 3.4 shows the top 15 correlated genes in PFC for ethanol  
consumption in CIE-treated and air-treated animals. Bioinformatic (GO) analysis 
of PFC genes significantly correlated to 3rd- and 4th-cycle drinking after CIE 
exposure revealed enrichment for Biological Processes related to neuron 
ensheathment, sodium ion channel activity, and neuron projection development 
(Supplemental Table 3.14). Highly correlated genes after CIE exposure included 
Mobp and Mbp (components of the myelin sheath), Scn2b, Scn4b, Kcnma1, and 
Gad1. In contrast, bioinformatic (GO) analysis of PFC genes significantly 
correlated to 3rd- and 4th-cycle drinking after air exposure revealed enrichment 
for Molecular Processes related to DNA and RNA polymerase binding, biological 
processes related to synaptic transmission and neurotransmitter secretion, 
cellular processes related to the synapse and neuronal projection, and mRNA 
splicing and processing (Supplemental Table 3.15). Highly correlated genes after 
air exposure included Hook3, Trpm7, Clasp1, and Kcnc1. 
A similar correlation analysis was conducted for gene expression in NAC 
of air- or CIE-treated animals (Supplemental Table 3.16). There was an overlap 
of 13 genes between the CIE (n = 150) and the air (n = 160) gene lists. 
Interestingly, multiple genes involved in neurodevelopment (including Smarca5, 
Ddx6, Qk, and Ndrg1) were highly correlated to drinking in the NAC after the 3rd 
and 4th cycles of air exposure, but were not significantly correlated with drinking 
after CIE exposure. Dnm3, a hub gene that emerged from IPA network analysis  
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Fig. 3.7. Dnm3 expression and ethanol drinking. Correlation of RMA 
expression values for Dnm3 [1436875_at] in the NAC and total ethanol 
consumption after the 3rd cycle of ethanol vapor exposure (g/kg). Spearman 
correlation across microarray expression values for 26 strains of mice from the 
BXD cohort. The red dots represent the drinking and expression values for each 
respective strain of mouse. There was a significant (p = 0.00287) positive 
correlation (rho = 0.561) using the Spearman rank order test. 
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Table 3.5: NAC—Spearman correlations of gene expression (RMA) with ethanol 
consumption after the 3rd and 4th cycles of vapor chamber exposure 
CIE-treated     
Probeset Gene Pval.corr Corr.Spear Cycle* 
1450769_s_at Stard5 0.00030775 -0.651965812 4th 
1417943_at Gng4 0.000359169 -0.646495726 3rd 
1449571_at Trhr 0.000531398 -0.632136752 BOTH (4th) 
1446176_at Mrg1 0.001404264 0.593162393 3rd 
1437403_at Samd5 0.001449756 0.591794872 BOTH (3rd) 
1419271_at Pax6 0.002071286 -0.576068376 3rd 
1441917_s_at Tmem40 0.002233124 -0.572649573 3rd 
1447669_s_at Gng4 0.002300826 -0.571282051 3rd 
1438782_at Axcam 0.003169373 -0.556239316 3rd 
1439633_at Syt7 0.003803452 -0.547350427 3rd 
1436875_at Dnm3 0.003964172 0.545299145 3rd 
1434779_at Cbln2 0.004665976 -0.537094017 3rd 
1442019_at Gas7 0.00512194 0.532307692 BOTH (3rd) 
1434877_at Nptx1 0.005398996 -0.52957265 3rd 
1453771_at Gulp1 0.005470202 -0.528888889 4th 
Air-treated     
1452161_at Tiparp 0.000433941 0.672924901 BOTH (4th) 
1458830_at Fgf14 0.00095138 -0.64229249 3rd 
1459288_at Kcnd2 0.001176552 -0.633399209 3rd 
1456257_at Fam126b 0.001232344 0.631422925 3rd 
1436713_s_at Meg3 0.001727521 -0.616600791 BOTH (3rd) 
1443237_at Ptprd 0.002284704 -0.603754941 BOTH (3rd) 
1420917_at Fnbp3 0.002432929 0.600790514 4th 
1416180_a_at Rdx 0.002698052 0.595849802 BOTH (4th) 
1427351_s_at Ighg 0.002810732 0.593873518 3rd 
1430979_a_at Prdx2 0.004016181 0.576086957 3rd 
1452444_at Napb 0.004094228 0.575098814 BOTH (3rd) 
1426432_a_at Slc4a4 0.004094228 0.575098814 4th 
1437864_at Adipor2 0.004173545 0.574110672 BOTH (4th) 
1442025_a_at Zbtb16 0.004254147 0.57312253 3rd 
1437869_at Ppp2r3a 0.004503832 0.570158103 4th 
*Cycle column: reveals if the probeset was significantly correlated with ethanol consumption after 
the 3rd or 4th cycle.  If the probeset was significantly correlated after both cycles, then the row is 
labeled BOTH and the cycle with the strongest correlation is listed and the cycle is denoted in 
parenthesis.  
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(Fig. 3.4) and as a suggestive eQTL (Supplemental Table 3.12), was also 
significantly correlated to drinking (Fig. 3.7). Table 3.5 shows the top 10 genes 
whose expression in NAC most highly correlates with ethanol consumption in 
CIE-treated and air-treated animals. 
Of note, ethanol intake during the 3rd cycle (GN:12967) strongly 
correlated to ethanol consumption after the other cycles of ethanol vapor 
exposure from this study, giving additional validity to the robustness of the 
dataset and the reproducibility of drinking data across these BXD strains 
(Supplemental Table 3.17). Ethanol intake during the 3rd cycle also correlates 
inversely with drinking phenotypes performed in other labs using drinking 
paradigms without ethanol vapor exposure (GN:12624, R = −0.714, p = 0.0012 
and GN:13578, R = −0.763, p = 0.014). These strong inverse correlations 
suggest that the chronic exposure to ethanol vapor has a distinctly different 
biological effect from simple voluntary ethanol consumption. Importantly, our 
phenotype of interest was positively correlated with change in ethanol 
consumption after a chronic mild stressor relative to control (GN:13573, 
R = 0.700, p = 0.033) and negatively correlated with ethanol consumption in the 
non-stressed control group (GN:13578, R = −0.763, p = 0.014), further 
supporting the notion that chronic stress dramatically alters ethanol consumption 
in mice. Ethanol intake during the 3rd cycle was positively correlated 
corticosterone levels in plasma, 3 days following the 5th and final ethanol vapor 
exposure (GN:13023, R = 0.497, p = 0.006), suggesting that increased levels of 
stress hormones following a chronic stressor may be a potential driving 
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mechanism leading to increased consumption. Ethanol intake during the 3rd cycle 
is also inversely correlated with an anxiety assay (GN:12430, R = −0.499, 
p = 0.0044). Finally, 3rd-cycle ethanol intake inversely correlated with the 
difference in acute ataxia in animals previously exposed to ethanol relative to 
naïve controls, which is a measure of ethanol sensitization and an inverse 
measure of ethanol tolerance (GN:10497, R = −0.821, p = 0.02 and GN:10498, 
R = −0.821, p = 0.02). This suggests that animals which are more likely to be 
sensitized to the acute effects of ethanol, and thus have a lower tolerance, are 
less likely to consume ethanol after repeated exposures to ethanol vapor. Future 
behavioral studies are necessary to directly test this relationship. 
Validation of Dnm3 downregulation by CIE in male DBA/2J mice. Dynamin-3 
(Dnm3) is a member of the dynamin family, which possesses mechano-chemical 
properties involved in actin-membrane processes, predominantly in membrane 
budding. In BXD RI strains, Dnm3 is significantly ethanol-responsive in PFC and 
NAC, in both acute and chronic ethanol treatment paradigms (Supplemental 
Table 3). The direction of ethanol response with CIE showed wide variation 
across the BXD cohort (Fig. 3.8A), with the D2 progenitor strain showing strong 
down-regulation and B6 mice showing little response. The direction of the Dnm3 
response to ethanol across the BXD strains showed a strong relationship with the 
genotype at the Dnm3 gene locus, as expected given the suggestive Dnm3 
cis-eQTL seen in NAc (Table 3.2). We performed qPCR on a larger cohort of 
DBA/2J and C57BL/6J mice following CIE. We noted a down-regulation in CIE 
mice that was led by D2 males (two-way ANOVA for interaction p < 0.05, partial  
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η2 = 0.249, Fig. 3.8B). Dnm3 expression appeared to be unaffected by CIE in B6 
mice (two-way ANOVA p > 0.05, partial η2 = 0.066, Fig. 3.8C), although we 
acknowledge the possibility that these data may be underpowered. 
 
Gsk3b-centric Ethanol-Responsive Gene Network is Associated with Risk 
for Alcohol Dependence 
Previous analyses using graph theoretic modeling (Wolen et al, 2012) identified 
coordinately regulated gene networks following acute ethanol treatment in PFC. 
One network highly enriched for significantly ethanol-responsive genes included 
Gsk3b as an interconnected hub gene. From these data and prior knowledge on 
the role of GSK3B in synaptic plasticity and affective disorders we hypothesized 
that a Gsk3b-centric gene expression correlation network would show genetic 
association with alcohol dependence in humans. We therefore further 
investigated the correlation structure of the Gsk3b ethanol-responsive network 
from our prior microarray data (Wolen et al, 2012) on acute ethanol-induced 
expression changes (S-Scores). Analysis of individual probeset (gene) 
correlations with Gsk3b expression following acute ethanol treatment in mPFC 
(n= 29 mouse strains) showed that 34 genes had correlations ≥ 90% with Gsk3b. 
There was a highly unique degree of interconnectivity in this Gsk3b network (Fig 
3.9A) compared to randomly chosen similar sized networks from the rest of the 
genome (Fig. 3.9B). This illustrates the concept that Gsk3b is a central member 
of a unique gene network in mouse mPFC that is strongly co-regulated by 
ethanol.  
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Figure 3.9 Gsk3b-centered ethanol-responsive network derived from mouse 
PFC is enriched for AUD risk-conferring SNPs in human GWAS data. (A) 
Network of genes with S-Score, a measure of ethanol-responsiveness, 
correlation of r ≥ 0.9 with Gsk3b, found in the PFC of BXD mice (B) Comparative 
histogram of WGCNA-calculated edge weights (gene-gene expression 
correlations) of the 35 genes in the Gsk3b network (green) and edge weight 
values of 10000 permutations of randomly selected groups of 35 genes (grey) 
from the BXD PFC microarray. (C) SNP-set level analyses of human GWAS 
(COGA dataset, n=1205 cases, 700 controls) were performed on groups of 
homologous genes. Results are shown for genes at multiple levels of correlation 
(80-95%) with Gsk3b in mouse PFC. The result of a SNP-set analysis within the 
GSK3B gene alone is also given. NSNP = total number of genotyped SNPs in 
given gene or geneset; NSIG = number of significantly risk-conferring SNPs; ISIG 
= number of independent (non-LD) risk-conferring SNPs; EMP1 = empiric p-
value. 
 
 
78 
 
 
We next queried gene-based human association data from the Collaborative 
Study on the Genetics of Alcoholism (COGA) project (Bierut et al, 2010; Bierut et 
al, 2002) to determine if the uniquely correlated Gsk3b ethanol-responsive 
network informed genetic studies on alcohol dependence. The above mouse  
expression correlation analysis was used to create gene sets based on ≥ 95%, 
90%, 85%, and 80% correlation with Gsk3b S-Score measurement of ethanol 
responsivity. Set-based analyses revealed significant enrichment of risk-
conferring alleles in the groups of human homolog genes correlating ≥85% and 
≥90% with Gsk3b in the mouse BXD study. The latter of these human homolog 
groups showed peak signal, p=0.004 (Fig. 3.9C). Additionally, set-based 
analyses of SNPs within individual genes showed significant enrichment of 
GSK3B (p=0.029), DNAJB14 (p=0.025), G3BP2 (p=0.017), and KCNMA1 
(p=0.0096) (Supplemental Table 3.18). Taken together, these results indicate 
that a significant risk for alcohol dependence may be mediated via GSK3B and 
related pathway genes, particularly as these relate to initial ethanol sensitivity.  
 
3.4 Discussion 
This chapter describes an exploratory genetic and genomic analysis of 
transcriptome responses to chronic ethanol by intermittent vapor chamber and 
consumption in BXD mice, and comparison of these changes to acute ethanol 
transcriptome responses. Our goal was to gain potential insights into conserved 
vs. unique mechanisms of ethanol-induced expression changes. A striking 
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finding in this study was the significant number of ethanol-responsive genes 
regulated by both acute ethanol and CIE across the BXD cohort, indicating that 
the initial transcriptional response from acute ethanol significantly informs long-
term effects of ethanol. Furthermore, while we found significant expression 
changes unique to CIE treatment, our bioinformatics analysis showed a 
remarkable overall conservation of functional groups among the expression 
responses, either unique or shared across CIE vs. acute ethanol and PFC vs. 
NAC. Finally, these initial studies identified provisional expression/behavioral 
correlations and eQTLs, which may lead to identification of novel targets for 
future intervention in abusive ethanol consumption. 
Our use of the BXD panel across two treatment paradigms provided the 
opportunity to compare both acute and chronic ethanol exposure paradigms on 
gene regulation in a genetic panel. A major strength of this approach was that we 
were able to employ 43 BXD strains exposed to CIE and 29 BXD strains exposed 
to acute ethanol, providing a wide range of genotypes. However, our overall 
power was likely reduced since this initial analysis was able to utilize only 1–
2 mice per strain/treatment due to the overall complexity of the animal-treatment 
paradigm. Using the S-score algorithm to directly compare control vs. treated 
samples within strains, together with a statistical comparison of S-scores across 
strains, allowed our analysis to identify large groups of ethanol-responsive 
genes, despite strain-dependent differences in the magnitude or even direction of 
the ethanol regulation. The number of strains employed here also provided 
reasonable ability to identify expression/behavioral correlations. However, a more 
80 
 
definitive analysis of within-strain expression levels or behavioral results will have 
to await an ongoing enlarged study that will provide a more powerful genetic 
analysis of both expression networks and behavioral responses to CIE. Despite 
these caveats, the studies presented here contribute multiple unique findings. 
One of our major assumptions in the experimental design of these studies 
was that by comparing our prior BXD studies on acute ethanol to these CIE-
evoked responses, we would be able to define expression changes more 
explicitly involved in the long-term neuroadaptive events responsive for 
progressive ethanol consumption with the CIE paradigm. Unexpectedly, our 
studies found a striking overlap between CIE and acute ethanol responses, 
extending even across both PFC and NAC. This occurred despite the studies 
occurring nearly a decade apart, employing different investigators doing the 
primary assays, and having very different experimental designs. The CIE 
treatment entailed a chronic vapor exposure and repeated oral consumption with 
a 72-h abstinence period prior to harvesting brain tissue. In contrast, the acute 
ethanol data was a single i.p. injection with brain tissue harvested 4 h later at a 
time when blood ethanol levels would just be reaching non-detectable levels. 
While we did indeed identify gene responses unique to CIE, the overlap between 
acute and chronic ethanol may provide valuable mechanistic clues to major 
mechanisms of ethanol action on the CNS. It would make intuitive sense that 
certain reliable ethanol actions, such as direct receptor or signaling molecule 
interactions (e.g., binding to GABAA receptor subunits), would produce consistent 
downstream responses acutely or chronically. Thus, our list of 88 genes that are 
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ethanol-responsive across both treatments and in both brain regions studied may 
represent these particularly “reliable” downstream ethanol effectors. Indeed, 
when this list was studied for enrichment, synaptic transmission was by far the 
dominant theme, with voltage-gated cation channel activity, and calcium-
regulated responses as over-represented functions (see Supplemental 
Table 3.8). Kcnma1 and Gabra2 were prominent members of the functional 
groups over-represented in these 88 ubiquitously regulated probesets. These 
genes both have substantial biochemical, structural, pharmacological, and 
genetic prior validation as a prominent target of direct ethanol action (Tapocik et 
al, 2014; Treistman and Martin, 2009), at least partially substantiating our 
conclusions regarding this group of 88 genes. 
Genes unique to CIE PFC showed an enrichment of myelin genes, with 
Mag and Mal identified in the pathway shown in Fig. 3.3. The PFC expression of 
two other major myelin sheath components, Mobp and Mbp, correlated with 
drinking data in CIE-treated animals. The CIE PFC geneset also showed 
enrichment for cytoskeletal binding and cell adhesion molecules and overall, 
showed the greatest functional over-representation differences from any of the 
other treatment group analyses (see Supplemental Tables 3.4–3.8). In the eQTL 
analysis of CIE PFC, top QTL candidates at the two major trans-regulated peaks, 
Chr3 and Chr16 (Fig. 3.5), were identified as the cell adhesion molecules Fat4 
and Dscam, respectively. Thus, it is conceivable that a distinct mechanism of 
chronic ethanol response in PFC operates through altered cellular adhesion and 
potentially an interaction with CNS myelin to drive resulting behavioral changes. 
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Except for the gene group uniquely regulated by CIE in PFC as noted 
above, the other comparison groups showed remarkable similarities in the 
highest ranked over-represented functional categories (Supplemental 
Tables 3.4–3.8). Although there were differences in the component genes, these 
categories all concerned synaptic transmission or neuronal structure. In the PFC, 
overlap between acute and chronic treatments showed over-representation of 
genes related to the GABAA receptor, whereas in the NAC, both treatments 
altered genes related to GABA and glutamate transport vesicles. It is interesting 
to consider that ethanol has been shown to potentiate GABA release both 
through altered receptor expression and altered release (Kumar et al, 2010; 
Roberto et al, 2003). As preliminary analyses, our data seem to indicate that 
these alternate mechanisms may show brain-region specific differences in effect 
(both acutely and chronically), though further studies would be necessary to 
confirm this possibility. 
When comparing gene sets unique to treatment condition, brain region, or 
both, there remained a striking similarity in the top upstream regulators identified 
by IPA. This is perhaps not surprising, given the functional group over-
representation overlaps noted above. In particular, HTT and BDNF were 
identified in nearly every set out of the five queried, despite the fact that many of 
these gene sets were completely distinct (by definition). This may be partially 
explained by these genes serving as major regulators of neuronal signaling in 
general, but likely indicates particular relevance of these genes in ethanol-
induced signaling across multiple pathways. BDNF signaling has, in particular, 
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been closely linked to the mechanisms underlying progressive ethanol 
consumption resulting from the CIE model or similar intermittent ethanol access 
models (Darcq et al, 2015; Smith et al, 2016; Tapocik et al, 2014). This extensive 
genomic analysis across the BXD strains serves as strong affirmation of BDNF 
signaling as an important regulatory point for progressive ethanol consumption, 
and may implicate targets for future therapeutic intervention development. 
The eQTL analyses revealed several important points. The first was that 
there are distinct regulatory hotspots in the BXD genome that influence groups of 
CIE-responsive genes, as seen previously with our genetical genomics study on 
acute ethanol (Wolen et al, 2012). However, the majority of observed eQTLs 
were remote to the QTL location (trans-eQTL). No significant cis-eQTLs were 
seen in PFC with CIE, and only several significant or suggestive cis-eQTLs were 
found in NAC (see below). It is possible that our experimental design with limited 
replication and use of the S-score algorithm could have decreased our power to 
detect cis-eQTLs. However, the S-score actually is advantageous in that it 
eliminates confounding false-positive cis-eQTL occurring due to SNPs within 
DNA segments corresponding to microarray probe positions (Wolen et al, 2012). 
RNA-seq analysis in future studies might be an advantageous approach for 
cis-eQTL identification as well as CIE-induced changes in splicing or non-coding 
RNA expression. 
The large number of trans-eQTLs identified in this study and their 
grouping into regulatory hotspots, or trans-bands (see histograms in 
Figs. 3.5 & 3.6), may have implications for future identification of the major 
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regulators of CIE-responsive gene networks. Strikingly, we observed minimal 
overlap in the position of major trans-bands between CIE- and acute-ethanol 
treatments. This suggests that distinct genetic variation underlies ethanol-
induced expression changes from acute to chronic treatment, even if individual 
gene expression or function group changes themselves are conserved. 
The one significant cis-eQTL identified in the CIE NAC condition was also 
found on the largest trans-band, in Chr6:90–95Mb. The cis transcript is Nuclear 
Receptor 2, Group C, Member 2 (Nr2c2), located at Chr6:92091390–92173057 
on the mouse genome. Its eQTL map is shown in Supplemental Fig. 3.6; its peak 
LRS (with S-score) is within 100 Kb of its genomic location. In a genome-wide 
association study (GWAS) of human alcohol and nicotine co-dependent 
participants, the gene region SHE3BP5-NR2C2 was found to be enriched for 
risk-conferring SNPs, with the region being the only to reach genome-wide 
significance in the meta-analysis (Zuo et al, 2012). Nr2c2‘s expression has also 
been shown to be significantly altered by subchronic morphine in adult rats 
(Schwarz and Bilbo, 2013), providing further evidence of its potential role in 
addiction. In our study, Nr2c2 expression did not correlate with drinking behavior 
in the CIE-treated animals; however, its expression did correlate significantly 
among air-treated controls during both free-drinking cycles analyzed, suggesting 
that its expression pattern may confer risk before ethanol use becomes chronic. 
With chronic treatment, its expression is significantly altered, but does not 
correlate with consumption. Significant trans-eQTLs in the Nr2c2 trans-band 
include Gabra1, Homer1, and Slc1a2, indicating that alterations in synaptic 
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transmission could occur via altered Nr2c2 regulation; however, such specific 
mechanisms remain to be elucidated. 
Four suggestive cis-eQTLs were also found in CIE NAC: Pcolce, Dnm3, 
Gfap, and Fbxo39. Of these, Dnm3, located at Chr1:160Mb, was particularly 
interesting. Dnm3 expression in the NAC was correlated with ethanol drinking in 
CIE-treated animals, and appeared as a hub in the top-ranked network of 
CIE NAC and acute-NAC overlapping genes (Fig. 3.4). Its gene expression 
levels varied considerably across BXD strains, and particular strains showed 
greater differences in expression between CIE and control groups than seen in 
progenitor strains (Fig. 3.8A). This finding suggests that transgressive or 
epistatic genetic interactions may be involved in the Dnm3 transcriptional 
response to chronic ethanol. In the DBA2/J strain, Dnm3 showed strong down-
regulation with chronic ethanol, a finding validated by q-PCR (Fig. 3.8). Ethanol-
induced expression changes of Dnm3 (down-regulation in the case of the 
particularly sensitive DBA2/J strain) could represent a major mechanism of 
ethanol neuroadaptation. The expression of 21 other genes shows ethanol 
response at the Chr1:160–170Mb trans-band in which Dnm3 is a suggestive 
cis-eQTL. It is thus reasonable to suggest that these expression changes could 
be mediated via Dnm3. The NAC expression for 15 of 21 of these genes also 
correlated significantly with drinking in CIE-treated animals. This is not overly 
surprising, given that all genes regulated by a common locus would be expected 
to correlate with each other to some degree, but does illustrate the possibility of a 
Dnm3-regulated network affecting ethanol-drinking behavior. As in the case of 
86 
 
Nr2c2, specific mechanisms by which this candidate gene exerts ethanol-
relevant effects are unknown. Our IPA network (Fig. 3.4) indicates an interaction 
between dynamin family members, GTPases involved in endocytosis and 
vesicular trafficking (Urrutia et al, 1997), and the Homer family, involved in 
regulation of glutamatergic post-synaptic densities (de Bartolomeis and Iasevoli, 
2003). Additional targeted studies will be necessary to explore this relationship in 
the context of CIE exposure. 
The application of a Gsk3b-centric network (Fig. 3.9) derived from acute 
ethanol response microarray data in mouse PFC, to human GWAS data, reveals 
that these network genes are enriched for risk-conferring SNPs in alcohol-
dependent patients. This is important for several reasons. For one it serves as an 
example cross-species data integration—using an informed subset of genes to 
test for genetic risk can identify susceptibility loci that may not achieve genome-
wide significance independently. For another it may identify human SNPs with 
mechanistic roles that may eventually inform more targeted treatments. We have 
thus far only tested a network of genes identified in the PFC following acute 
ethanol exposure; other networks or gene sets identified, i.e. region-specific CIE-
responsive genes, may be tested in the future. 
Overall, the genetical genomics studies across BXD strains was intended 
as an initial analysis on genetic factors influencing ethanol-regulated behaviors 
and brain gene expression in the corticolimbic dopamine pathway. Our findings 
show remarkable functional genomics overlap between CIE and acute ethanol 
treatment, but also have identified brain expression changes unique to CIE. Our 
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genetic analysis of expression results provide initial details on a limited number 
of genetic loci that may have an important impact on the molecular adaptations to 
CIE. Future studies on expanding and validating the findings here, including our 
results on candidates such as Dnm3, may lead to identification of novel targets 
for therapeutic intervention in the progression from acute ethanol exposure to the 
compulsive consumption seen in AUD. 
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Chapter 4  
Effects of Acute and Chronic Ethanol on GSK3B 
Activity, Downstream Targets, and Behaviors 
 
4.1 Introduction 
 Acute ethanol (1.8 g/kg, i.p.) causes major expression changes in a 
network of genes centered around Gsk3b in the PFC (Wolen et al, 2012). Results 
from several published studies suggest that ethanol inhibition of the GSK3B 
protein contributes mechanistically to regulation of this Gsk3b-centric expression 
network. In the PFC of drug-naïve male rats, an acute dose of ethanol (1.5 g/kg) 
significantly increased phosphorylation of GSK3B at its inhibitory serine-9 residue 
(Neznanova et al, 2009). The increase in p-GSK3B-S9 was not observed at the 
20 minute time point, but was robust at 45 minutes (Neznanova et al, 2009). In 
the NAC of male C57BL/6J mice, an acute dose of ethanol (2 g/kg) significantly 
increased inhibitory phosphorylation of GSK3B as well as GSK3A, 15 minutes 
after treatment (Neasta et al, 2011). Sachs et al. (2014) similarly found that a 2 
g/kg dose of ethanol increased p-GSK3B-S9 phosphorylation in the NAC 20 
minutes after treatment. However, while this effect was observed in wild-type 
animals, mice with congenital serotonin deficiency (tryptophan hydroxylase 
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knock-in) exhibited a significantly blunted response of ethanol induced GSK3B 
phosphorylation (Sachs et al, 2014). These serotonin deficient mice also 
exhibited reduced ethanol sensitivity and increased ethanol preference in two 
bottle choice tests, illustrating the role of serotonin in ethanol behavioral 
responses and perhaps a serotonin-GSK3B pathway in particular (Sachs et al, 
2014). It should be noted that the tyrosine hydroxylase knock-in was constitutive 
and that many concomitant CNS changes might be expected in the context of 
serotonin deficiency. Regardless, it is interesting that an attenuated response of 
GSK3B phosphorylation to ethanol corresponded to altered behavioral effects, 
including increased ethanol preference. To our knowledge specific manipulation 
of GSK3B and subsequent observations of ethanol-related behaviors have not 
been reported.  
 There is evidence that GSK3 phosphorylation underlies certain behavioral 
effects of another NMDA antagonist, ketamine. A subanesthetic dose of 
ketamine (10 mg/kg, i.p.) robustly increased serine phosphorylation of both 
GSK3A and GSK3B (Beurel et al, 2011). This GSK3 inhibition appears to be 
necessary for the rapid antidepressant effect of ketamine, as evidenced by 
knock-in mice with constitutively active GSK3; these mice showed a completely 
ablated ketamine antidepressant effect as assessed by a learned helplessness 
paradigm (Beurel et al, 2011). On the other hand, treatment with high-dose 
lithium mimicked the effect of subanesthetic ketamine in wild-type mice (Beurel et 
al, 2011).   
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 While ketamine has become well-known for its acute antidepressant effect 
(Andrade, 2017), ethanol has long been known to exhibit an acute anxiolytic 
effect (Ellinwood et al, 1983). Whether GSK3B inhibition might underlie aspects 
of ethanol anxiolysis is unknown. We hypothesized that GSK3B in the PFC of 
male and female mice would show dose-dependent increases in Serine-9 
phosphorylation following i.p. ethanol treatment. As a speculative hypothesis, we 
predicted that this inhibition may contribute to the anxiolytic effect of ethanol, and 
therefore that treatment with a GSK3B inhibitor might potentiate the effect of 
ethanol on anxiolytic behavior. 
 Prior reports of the effect of chronic ethanol treatment on GSK3B activity 
in brain are less consistent. There are two studies which show increased 
inhibitory phosphorylation of GSK3B following repeated ethanol exposure: one in 
the NAC of rats (Neasta et al, 2011), and the other in the dorsomedial striatum 
(DMS) of mice (Cheng et al, 2016). Both of these experiments harvested brain 
tissue 24 hours after last access. Thus it is unclear to what extent this GSK3B 
inhibition is due to repeated, long-term ethanol exposure, or corresponds to the 
state of ethanol withdrawal. These studies did not compare animals currently 
intoxicated with ethanol (following long-term exposure) to animals 24 hours into 
withdrawal, and the temporal profile of ethanol’s GSK3B-inhibiting effects are not 
known. Moreover, it has yet to be determined whether each ethanol exposure 
shows a greater or lesser degree of GSK3B phosphorylation in chronically 
exposed animals as that observed in ethanol-naïve animals given a single dose. 
A greater response would resemble the profile of a sensitizing effect, whereas a 
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diminished response might be described as tolerance to ethanol’s GSK3B 
inhibiting actions. Based on the study described above (Sachs et al, 2014) of 
serotonin deficient mice with a blunted GSK3B phosphorylation response to 
ethanol showing lower ethanol sensitivity and higher drinking, we might expect 
the tolerance-like effect. That is, animals with a history of repeated ethanol 
exposure and escalating use might show blunted ethanol-induced GSK3B 
phosphorylation following an acute dose of ethanol, compared to naïve animals 
receiving the same dose.  
 To establish escalated ethanol consumption, we have used the 
intermittent ethanol access (IEA) paradigm. This model allows for behavioral 
correlates to chronic ethanol exposure which can be studied in themselves. 
Specifically, we will compare the observed escalations in ethanol drinking during 
an initial 2 hour binge period at the beginning of each dark cycle, with the pattern 
of daily (24 h) ethanol drinking week to week. We will also verify binge-like 
ethanol drinking at the 2 hour time point with blood alcohol content readings from 
a subset of animals.  
 In addition to the activity of GSK3B, as determined by the level of 
phosphorylation at the serine-9 (S9) residue, we will assess the alternate isoform 
GSK3A, which is regulated at an analogous inhibitory serine-21 (S21). 
Additionally we will assess levels of synaptic scaffolding proteins, gephyrin and 
PSD-95, both reported targets of GSK3B (Nelson et al, 2013; Tyagarajan et al, 
2011). 
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4.2 Materials and Methods 
Animals. Male and female C57BL/6J mice (aged 8 weeks) were obtained from 
Jackson laboratories (Bar Harbor, Maine). For pilot studies on anxiety-like 
behavior, male C57BL/6J mice were obtained from the VCU transgenic core 
facility at 4 weeks and housed in our vivarium until ≥8 weeks old.  All mice were 
housed in a temperature and light controlled room (12 hr light:dark cycle) with 
free access to Teklad laboratory diet (Envigo, Hungtingdon, UK) and tap water. 
All procedures were approved by the VCU Institutional Animal Care and Use 
Committee and followed the NIH Guide for the Care and Use of Laboratory 
Animals. 
Antibodies. Rabbit anti-phospho-GSK3A/B-S21/9 (#8556), phospho-GSK3B-S9 
(#5558) and total GSK3A/B (#5676) are from Cell Signaling Technology 
(Danvers, MA). Rabbit anti-gephyrin (#720218) and total PSD-95 (#51-6900) are 
from Thermo Scientific (Rockford, IL). Rabbit anti phospho-PSD-95-T19 
(ab17167) is from Abcam (Cambridge, MA). Mouse anti-B-actin (A5441) is from 
Sigma-Aldrich (St. Louis, MO). Mouse anti-NeuN (MAB377) is from Millipore 
(Billerica, MA). Secondary antibodies used for Western blotting were Amersham 
ECL donkey anti-rabbit IgG, HRP-linked antibody, and Amersham ECL sheep 
anti-mouse IgG, HRP-linked antibody, both from GE Healthcare (Chicago, IL). 
Secondary antibodies used for immunofluorescence were goat anti-rabbit 
AlexaFluor 488 (A11008) and goat anti-mouse AlexaFluor 594 (A11005), both 
from Life Technologies (Grand Island, NY).  
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Preparation of Solutions. For the Western blot dose-response (0.5-4.0 g/kg) 
study, ethanol was diluted to 18% v/v in normal (0.9%) saline. For i.p injections in 
behavioral studies and immunohistochemistry (IHC), ethanol was diluted to 20% 
v/v in normal saline. For intermittent ethanol access, ethanol was diluted to 20% 
v/v in tap water. The GSK3B inhibitor tideglusib (Selleck Chemicals, Houston, 
TX) was prepared for gavage by suspension in 26% peg-400 (Sigma), 15% 
Cremophor EL (Sigma), and water.  200 mg/mL tideglusib was homogenized into 
vehicle by vortexing and subsequent bath sonication at 40 degrees Celsius for 
30-60 minutes.   
(Acute) Systemic Administration of Alcohol. For all molecular studies 
(Western blots and IHC) mice were habituated to the i.p. administration 
procedure with daily injections to saline for three days immediately prior to the 
experimental procedure. On the day of the experiments, mice were injected with 
saline or ethanol (0.5 g/kg, 2.0 g/kg, 4 g/kg) and sacrificed 30 minutes later. For 
Western blotting experiments mice were sacrificed by cervical dislocation and 
decapitation; for IHC mice were sacrificed by perfusion under anesthesia 
(isoflurane, Butler Schein, Dublin, OH). See Figure 4.1A for overview of 
experimental design.  
Western Blot Analyses. Tissue was homogenized on ice by suspension RIPA 
buffer containing Halt protease and phosphatase inhibitor cocktail (Thermo), and 
probe sonication for 2-3 short bursts. Immunoblotting was performed using an 
Xcell Surelock Mini-Cell kit (Thermo). Tissue homogenates were denatured with 
NuPage LDS Sample buffer and Sample Reducing Agent (Thermo), and heated 
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at 70 degrees Celcius for 10 minutes. Samples were separated via 
electrophoresis at 120 V on 4%-12% Bis-Tris gels at room temperature in 1X 
NuPage MES Running Buffer (Thermo), followed by transfer onto PVDF 
membrane at 12 V, at 4 degrees Celsius in 1X NuPage Transfer Buffer in 20% 
methanol. Membranes were blocked with bovine serum albumin (5% w/v), and 
incubated overnight at 4 degrees C in primary antibody. Dilutions of antibodies 
for phospho-proteins, gephyrin, and PSD-95 were 1:1000. Dilution of antibody to 
total GSK3A/B was 1:5000. Dilution of antibody to B-actin was 1:20000. 
Following incubation membranes were washed extensively in Tris Buffered 
Saline containing 0.1% Tween-20 (TBS-T) and incubated in the appropriate 
secondary antibody for 1 hour at room temperature. Dilution of secondary 
antibody was 1:15000 for phospho-protein staining and 1:30000 for total protein 
staining. Membranes were again washed in TBS-T 3 times for 5-10 minutes each 
wash. Membranes were incubated in ECL Prime (GE Healthcare) (1:1 in TBS-T) 
before being exposed to GeneMate Blue Ultra Autorad film (BioExpress, Kayville, 
UT). Blots were stripped using Restore Stripping Buffer (Thermo) before re-
staining for total protein (after primary phospho-stain) or B-actin as a loading 
control. Films were scanned using a flatbed scanner and analyzed using 
densitometric analysis with ImageJ (NIH).   
Immunohistochemistry. Thirty minutes after i.p. injection, mice were deeply 
anesthetized with isoflurane and perfused transcardially with 1X phosphate-
buffered saline (PBS) followed by 4% formaldehyde in PBS. Brains were 
removed and post-fixed in 4% formaldehyde overnight at 4 degrees C, then 
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transferred to 30% sucrose in PBS. When brains had sunk to the bottom of the 
sucrose vial (72 hours at 4 degrees), they were snap frozen in isopentane on dry 
ice. Frozen brains were cut (20 micron thick coronal sections) using a Leica 
CM3050 cryostat (Leica Biosystems, Wetzlar, Germany). Sections were collected 
into 24-well plates, floating in PBS with 0.2% sodium azide. Free-floating 
sections containing PFC were selected and incubated in citric acid buffer (10 mM 
sodium citrate in distilled water and 0.05% Tween 20) at 80 degrees Celsius for 
20 minutes, as an antigen retrieval step. Sections were allowed to cool before 
incubation with gentle shaking in 5% goat serum in PBS with 0.2% Triton, for 
blocking and permeabilization. Sections were then incubated in primary 
antibodies in 3% goat serum in PBS with 0.1% Tween-20 (PBS-T) overnight at 4 
degrees Celsius with gentle agitation. Sections were washed 3 times for 5 min 
each in PBS-T on a shaker, before incubation in secondary antibody for 2 hours 
at room temperature, with gentle agitation. Sections were again washed 3 times 
in PBS-T with agitation and placed on slides in one drop of PBS combined with 
one drop of PBS-T. Liquid was wicked off and slides were allowed to air dry 
momentarily. Sections were mounted with VectaShield Antifade mounting 
medium (Vector Laboratories, Burlingame, CA) and a coverslip. Slides were 
assessed using a Leitz DMRD microscope and images were taken using an 
attached Olympus CK40 inverted scope camera.  
Light/Dark Assays. The light-dark (LD) box contains two equally sized 
compartments (30 cm x 15 cm x 15 cm), separated by a black plastic partition 
with an opening in the middle to allow for light-dark transitions (Med Associates, 
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Fairfax, VT). The box is enclosed in a sound-attenuating box equipped with 
overhead lighting and fan ventilation. The system is interfaced with Med 
Associates software that allows for automatic measurement of activity using a set 
of 16 infrared beam sensors along the X-Y plane. The activity chambers contain 
CM1820 28V 170mA (22 lux) light bulbs.   
A pilot experiment was performed to assess the utility of the LD box test 
for assessing ethanol-induced anxiolytic behavior using a repeated-measures 
paradigm. Previously the LD box was used as an anxiolytic assay in animals 
unexposed to the chamber (Putman et al, 2016). In this experiment all mice (n=6, 
males) were habituated to the LD box for 1 hour with no treatment on Day 1. 
Over the course of the next week each mouse received one of 4 pre-treatments 
on Days 2, 3, 4, and 5 of the experiment. Pre-treatments were i.p. saline, 0.5 
g/kg ethanol, 1.0 g/kg ethanol, or 2.0 g/kg ethanol. Doses were given in varied 
order from mouse to mouse. Mice were placed in the light side of the chamber, 
facing the entrance to the dark, immediately following the injection, and their 
activity recorded. 
Subsequently, an additional set of C57BL/6J mice (n=9, males) was tested 
using a similar repeated measures paradigm. All mice were habituated to the LD 
boxes, and subsequently tested with either pre-treatment of Tideglusib (200 
mg/kg) or vehicle, via gavage, followed 30 minutes later by i.p. injection of either 
saline or the highest dose of ethanol previously tested (2.0 g/kg) and then 
immediate placement in the LD box. All mice received both i.p. injections (that is 
saline on Day 1 and ethanol on Day 2, or vice versa) but each mouse received 
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only 1 type of gavage treatment (that is Tideglusib on Day 1 and Tideglusib on 
Day 2, or Vehicle on Day 1 and Vehicle on Day 2).  
Overall, relative time spent in the light was treated as inverse to the level 
of anxiety-like behavior.  
(Chronic) Intermittent Ethanol Access (Two Bottle Choice Paradigm). 
C57BL/6J mice (n=21/group/sex) were allowed one week to habituate to our out-
of-vivarium room (lights on at 0200, lights off at 1400). Mice were then given 
access to bottles of tap water (continuous) or 20% v/v ethanol (intermittent). 
Ethanol bottles were placed on cages immediately before the dark cycle on 
Mondays, Wednesdays, and Fridays (Fig 4.1B). Readings were taken at a 2 
hour (binge) time point using a red lamp. Readings were taken for 5 weeks, with 
blood and tissue collection during week 6. 
Blood Ethanol Content. At the time of the usual binge reading, blood was 
collected via cheek punch using Goldenrod sterile lancets (Braintree Scientific, 
Braintree, MA) from a subset of animals (n=5 EtOH-drinking females, 5 EtOH-
drinking males, and one no-EtOH exposed control mouse of each sex). Blood 
was centrifuged and stored at -20 degrees Celsius until analysis. Analysis was 
performed using an Analox AM1 Alcohol Analyzer (North Yorkshire, UK) 
according to manufacturer’s instructions. One male EtOH sample was excluded 
due to insufficient plasma. 
“Acute-on-Chronic” Ethanol Paradigm. Following the studies on a single 
systemic administration of ethanol (acute) and intermittent ethanol access 
(chronic), these paradigms were combined into a mixed acute and chronic  
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Figure 4.1 Acute and chronic ethanol paradigms for Western blot studies. 
A. “Acute Ethanol” paradigm for Western blots and IHC: 3 days of i.p. habituation 
to saline injections followed by either saline or ethanol. B. “Chronic ethanol” 
paradigm: Intermittent Ethanol Access (IEA) schedule. All mice had access to 
water and food ad libitum. Ethanol (20% v/v) was placed on cages Mondays, 
Wednesdays, and Fridays. The period of ethanol access began with each dark 
cycle (except Sunday, when ethanol was not available). Binge readings were 
taken 2 hours into the dark cycle using a red lamp.  
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Figure 4.2 Acute-on-chronic ethanol paradigm for Western blot studies. 
Male and female mice underwent >6 weeks of intermittent ethanol access (IEA) 
or water-only drinking before i.p treatment with either i.p. saline or ethanol. All 
mice were gavaged for the last 2 weeks to allow for an additional treatment 
condition, the administration of a GSK3B inhibitor (tideglusib).  
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paradigm (Fig. 4.2). Both males and females were given access to either water 
only or continuous water and intermittent ethanol access (IEA) 
(n=20/sex/access). After 3 weeks of free drinking and readings taken at 2 and 24 
hours, all animals were habituated to gavage (3 days of 0.1% saccharin, 2 days 
of vehicle). Gavage occurred prior to ethanol access, Mondays Wednesdays and 
Fridays. Animals subsequently received either gavaged vehicle or tideglusib (200 
mg/kg) in the hour preceding ethanol access during Weeks 6 and 7. Animals 
receiving water-only were on the same gavage schedule. During Week 7 we 
began saline habituation in addition to gavage treatments, for the 3 days prior to 
the day of sacrifice. On the day of sacrifice, a Friday, 24 hours after last ethanol 
access, animals received gavage, an i.p. injection of either saline or ethanol (2 
g/kg) an hour later, and were sacrificed 30 minutes after the injection. Western 
blots were run as in acute and chronic ethanol studies. Studies of the effect of 
tideglusib on ethanol drinking behaviors will be discussed in Chapter 6. 
Statistical Analyses. Quantified Western blot data was normalized to saline 
controls and compared using t-tests when comparing two groups, or ANOVA to 
account for multiple doses or treatments. Thus acute ethanol dose response 
studies used a 1-way ANOVA to compare ethanol doses within each sex (as 
males and females were run as separate experiments). The effect of chronic 
ethanol (IEA) on p-GSK3B and total proteins was compared with t-tests within 
each sex (again, protein studies were run separately).  
The effect of acute ethanol +/- IEA was analyzed via ANOVAs first within 
sex and then with sexes pooled, because throughout this experiment animals 
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and tissue samples were run concurrently. To combine samples run across 4 
membranes, each of which was stained for both phospho- and total GSK3, we Z-
transformed phospho/total scores according to each membrane, to create 
normalized scores that would not be artificially skewed by differences in staining 
intensity between entire membranes. Z-scores were converted to positive values 
by addition of a factor which would bring the Vehicle-Water-Saline sample scores 
to an average = 1. Within sex, a 2 way-ANOVA was run with two factors: (1) 
acute (ethanol vs. saline i.p. injection) and chronic (IEA vs. water-only). A 3-way 
ANOVA was then run which included Tideglusib treatment nested within the 
“chronic” factor (because here we only studied Tideglusib treatment within the 
IEA condition). When sexes were pooled, we first assessed for effect of sex with 
acute and chronic ethanol and found it non-significant as a main effect and 
interaction. We then carried out 2- and 3-way ANOVAs on the pooled sexes as 
just described for within-sex comparisons. For all Western blot analyses, 2-way 
ANOVAs were run in Prism and 3-way ANOVAs were run in JMP Pro 13.  
Ethanol induced anxiolysis used one or two-way ANOVA, the latter when 
Tideglusib was included as pre-treatment. Anxiolytic behavioral assays were 
analyzed in Prism. 
IEA Analyses: Ethanol consumption values over the 2 h and 24 h periods 
were calculated as ratios of grams ethanol consumed over kilograms per animal. 
For weekly analyses, week means were calculated for each animal giving values 
in g/kg/day. The first day of the experiment was excluded from the analyses of 
weekly means, as we have previously observed an immediate escalation on the 
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second day of intermittent ethanol access in C57BL/6J mice (Macleod 
unpublished, van der Vaart unpublished). Statistics were performed using JMP 
Pro 13. We used a Mixed Model repeat measures ANOVA to analyze by sex, 
week, and sex*week. Multiple comparisons of sex*week were performed using 
Tukey’s post hoc test. Blood Ethanol Concentrations were analyzed using linear 
regression with sexes pooled. 
 
4.3 Results 
4.3.1. Acute Ethanol 
Acute ethanol increases inhibitory phosphorylation of GSK3 in PFC of 
C57BL/6J mice. First, we aimed to determine whether an acute dose of 
systemically administered ethanol inhibited GSK3 in the PFC. Levels of 
phosphorylation of GSK3A (Serine-21) and GSK3B (Serine-9) 30 minutes after 
i.p. ethanol (0.5-4.0 g/kg) were assessed via Western blotting in male and female 
mice. As shown in Figure 4.3, male mice showed a significant effect of ethanol 
treatment on phosphorylation of both GSK3A (F3,17=4.80, p=0.0134) and GSK3B 
(F3,17=6.99, p=0.0029). As shown in Figure 4.4, female mice also showed a 
significant effect of ethanol treatment on phosphorylation of GSK3A (F3,20=3.58, 
p=0.032) and GSK3B (F3,20=3.16, p=0.047). A qualitative comparison between 
the male and female blots suggested a difference in the response profile, 
wherein male mice showed the increase in phosphorylation at the 0.5 g/kg dose 
and above, while female mice showed increases in phosphorylation only at the 
2.0-4.0 g/kg doses. This would suggest that while acute ethanol inhibited GSK3A  
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Figure 4.3 Acute ethanol increases inhibitory phosphorylation of GSK3 in 
PFC of male C57BL/6J mice. Male mice (n=5-6/dose) were harvested 30 min 
after i.p ethanol. A. Phospho- and total GSK3A/B were assessed via Western 
blot (representative film). B. p-GSK3A-S21 / total GSK3A shows main effect of 
ethanol (p<0.05), with the 4.0 g/kg dose (p<0.01) differing significantly from 
saline via post-hoc test. C. p-GSK3B-S9 / total GSK3B shows main effect of 
ethanol (p<0.005), with the 2.0 and 4.0 g/kg doses differing significantly from 
saline via post-hoc testing (p<0.05 and p<0.005, respectively).  
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Figure 4.4 Acute ethanol increases inhibitory phosphorylation of GSK3 in 
PFC of female C57BL/6J mice. Female mice (n=6/dose) were harvested 30 min 
after i.p ethanol. A. Phospho- and total GSK3A/B were assessed via Western 
blot (representative film). B. p-GSK3A-S21 / total GSK3A shows main effect of 
ethanol (p<0.05). C. p-GSK3B-S9 / total GSK3B shows main effect of ethanol 
(p<0.05).   
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Figure 4.5 Acute EtOH-induced p-GSK3B-S9 appears to show punctate 
staining. Male mice were perfused 30 minutes after a single 2.0 g/kg ethanol 
dose and stained for p-GSK3B-S9 (green) and the neuronal nuclei marker NeuN 
(red). Signals appeared qualitatively similar at 2.5 and 10X; upon closer 
inspection of PFC at 32X, punctate staining in the p-GSK3B-S9 channel can be 
observed overlaying neurons and appeared qualitatively greater in the ethanol 
treated condition.  
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and GSK3B in both male and female mice, males may be more sensitive to this 
effect.  
To further characterize ethanol-induced GSK3B phosphorylation in the 
PFC, we conducted pilot IHC studies of male mice (n=3/treatment) treated with  
saline or ethanol (2g/kg) for 30 min. and then perfused. Following staining for 
neuronal nuclei (NeuN) and p-GSK3B-S9, qualitative analysis revealed possible 
increased p-GSK3B staining in ethanol treated mice, with a punctate pattern 
(Figure 4.5, 32X) overlaying neurons.  Since Western blot data had confirmed 
the phosphorylation results and GSK3B staining was virtually entirely neuronal, 
we did not pursue a more quantitative analysis of the IHC results. To test the 
effect of acute ethanol on a reported downstream synaptic target of GSK3B, we 
assessed levels of phospho-PSD95-T19 (Figure 4.6). Acute ethanol treatment 
did not show a significant effect on PSD95 phosphorylation in male (F3,17=1.13, 
p=0.36) or female mice (F3,20=0.18, p=0.908). In male mice, we did observe a 
suggestive, non-significant linear trend (p=0.083) of phosphorylated/total PSD95, 
inverse to ethanol treatment. Such a trend toward decreased phosphorylation at 
this threonine-19 residue would be expected, given GSK3B inhibition following 
acute ethanol.  
 
Acute ethanol shows significant effect on anxiety-like behavior. We 
conducted a pilot study on a repeated measures protocol for light-dark (LD) box 
assays. Our intent was to determine whether a cohort of animals could be tested 
on successive days for anxiety-like behavior without confounding effects of day in  
107 
 
 
 
Figure 4.6 Effect of acute ethanol on p-PSD95-T19 levels in PFC. PSD95 did 
not show significant alterations in phosphorylation of its threonine-19 residue in 
either male or female mice as an effect of ethanol treatment. However, a post-
hoc test for linearity showed a suggestive inverse trend with increasing dose in 
male mice.  
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the LD box. Each day, animals were given saline or a dose of ethanol (0.5-
2.0g/kg) and placed in the light side of the chamber. Locomotor behavior was 
recorded for a full hour, but we carried out initial analyses on the first 5-minute 
bin. By one-way RM ANOVA, there was a significant effect of ethanol treatment 
(F1.34,6.70=14.14, p=0.0058) on %Time in the light, with no observable effect of 
day in the box (Figure 4.7A-B). We assessed overall locomotor activity via total 
distance traveled, and found a linear trend across increasing ethanol doses  
(Figure 4.7C). Thus the pilot study determined that using repeated treatment 
over successive days was a viable method of assessing ethanol-induced effects 
on anxiety-like behavior and locomotor activity. 
 
Pre-treatment with the GSK3B inhibitor tideglusib augments the effect of 
acute ethanol on locomotor activity. A separate cohort of C57BL/6J mice 
(n=9, males) was used in assays of the GSK3B inhibitor, tideglusib, to assess its 
potential effect on acute ethanol induced behavioral changes. On a given day, 
each animal received a gavage of either vehicle of tideglusib (200 mg/kg), and 30 
minutes later, an i.p. injection of either saline or ethanol (2 g/kg). The dose of 
tideglusib was determined based on preclinical studies of this drug (Bharathy et 
al, 2017). The dose of ethanol was determined based on the effect of this dose 
observed in the pilot study. The first 10-minute bin in the LD box was assessed 
via 2-way RM ANOVA to test the effects of injection (saline vs. ethanol) and 
gavage (vehicle vs. tideglusib). Results are shown in Figure 4.8. Effects on 
anxiety-like behavior, as determined by %time in light (A), were found to be  
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Figure 4.7 Pilot study of acute ethanol on LD box assay. N=6 male mice each 
received saline or each of 3 ethanol doses over the course of a week. A. Acute 
ethanol (i.p.) shows anxiolytic-like effects.   One-way RM ANOVA of %Time 
in Light shows main effect of treatment (p<0.01); 2 g/kg dose differs from saline 
and each other dose at p<0.05 by Tukey’s post-hoc. B. There is no discernible 
pattern of day in LD box at each dose. C. Significant linear trend of total 
distance traveled with increasing ethanol dose.  
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Figure 4.8 GSK3B inhibition augments acute ethanol locomotor effects. 
Gavage pre-treatment with tideglusib vs. vehicle was given 30 min prior to i.p. 
ethanol vs saline and then animals assayed in LD box for anxiety-like behavior 
and locomotion. First 5-minute bin data shown here. A. Acute ethanol (i.p.) 
shows anxiolytic-like effects. Two-way RM ANOVA of %Time in Light shows 
significant main effect of ethanol (p<0.01), and suggestive but non-significant 
effect of tideglusib (p<0.1). B. Two-way RM ANOVA of Distance Traveled shows 
significant main effect of ethanol and significant main effect of tideglusib (p<0.05 
for each). Difference between tideglusib and vehicle within EtOH treatment 
condition was significant (*p<0.05) by Sidak’s post-hoc test. 
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Figure 4.9 Full hour test data from LD boxes (cumulative bins). A. Total 
distance traveled, B. %distance traveled in the light, C. %time spent in the light. 
Veh/Tid refers to gavage pre-treatment, Saline/EtOH refers to acute i.p. injection. 
The anxiolytic-like effects of ethanol (B & C) appear to occur preferentially in the 
earlier bins, while effects of tideglusib on locomotor behavior appear stable over 
the course of the test.  
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significant for injection (F1,7=15.39, p=0.0057), non-significant for gavage 
(F1,7=4.75, p=0.0657), and non-significant for interaction (F1,7=0.413, p=0.541). 
Effects on locomotor activity, as determined by total distance traveled (B), were 
found to be significant for injection (F1,7=5.77, p=0.047) and gavage (F1,7=11.71, 
p=0.011), and non-significant for interaction (F1,7=0.655, p=0.445). When the 
data is examined over the course of the 1 hour mice spent in the LD box (Figure 
4.9), there appear to be differences in the time course between the effects of 
ethanol and tideglusib. While differences between saline and ethanol injections 
are more pronounced in the early time bins (particularly in C. %time in light), by 
the end of the session the differences between vehicle and tideglusib gavage are 
more apparent (see A. and C.). Qualitatively, there appears to be a more 
sustained effect of tideglusib on locomotor activation and possibly anxiolytic-like 
behavior than that of ethanol. Alternatively, tideglusib could be viewed as 
increasing the acute anxiolytic properties of ethanol. 
 
4.3.2. Chronic Ethanol 
Chronic ethanol (IEA) does not significantly alter phosphorylation or total 
levels of GSK3. After 6 weeks of intermittent ethanol access or water-only 
access, male and female mice (n=8/sex/access) were harvested 24 hours after 
last available ethanol and tissue was assessed via Western blot. Representative 
images and quantifications are shown in Figure 4.10. There was insufficient 
evidence to reject the null hypotheses that chronic ethanol does not alter levels 
of GSK3A/B phosphorylation or total protein. Rather than listing all statistical  
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Table 4.1: Results of t-tests for Western blots of p-GSK3A/B after chronic 
ethanol. 
 
 p-GSK3A-S21 Total GSK3A p-GSK3B-S9 Total GSK3B 
Males t=0.06504  
p=0.9491 
t=0.2635  
p=0.7963 
t=0.4053 
p=0.6914 
t=0.09361  
p=0.9268 
Females t=1.407 
p=0.1813 
t=0.9145 
p=0.3760 
t=0.6402 
p=0.5324 
t=0.04710  
p=0.9631 
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Figure 4.10 Chronic ethanol does not significantly alter GSK3 
phosphorylation or total protein in mPFC. p-Proteins normalized to the total 
form of the same protein; total proteins normalized to B-Actin. A. Representative 
films of p-GSK3, total GSK3, and B-actin in male C57BL/6J mice. B.-E. Analyses 
of quantified Western blots. F. Representative films of p-GSK3, total GSK3, and 
B-actin in female C57BL/6J mice. G.-J. Analyses of quantified Western blots.  
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Figure 4.11 Chronic ethanol significantly alters synaptic scaffolding 
proteins in mPFC. Tissue was harvested after 6 weeks of intermittent ethanol 
access, 24 hours after last access period. A. PSD95 is significantly increased in 
male mice (*p<0.05). B. Gephyrin is not significantly altered in male mice. C. 
PSD95 is not significantly altered in female mice. D. Gephyrin is significantly 
decreased in female mice (*p<0.05).  
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outcomes in the text, results of two-tailed t-tests for all conducted are given in 
Table 4.1.  
 
Chronic ethanol (IEA) significantly alters synaptic scaffolding proteins in 
PFC. We carried out subsequent Western blot analyses on the scaffold proteins, 
PSD95 and gephyrin, in male and female mice. Results are shown in Figure 
4.11. In males, PSD95 was significantly increased following IEA (t=2.32, 
p=0.036), while gephyrin was not significantly altered (t=0.586, p=0.568). On the 
other hand, in female mice, PSD95 was not significantly altered (t=0.453, 
p=0.657) while gephyrin was significantly decreased (t=2.37, p=0.033). Thus 
these may represent alternative means of adaptation of the PFC to chronic 
ethanol exposure, through either upregulation of a glutamatergic anchor protein 
or downregulation of a GABAergic anchor protein, which show sex specificity.  
 
Characterization of Ethanol-Drinking Behaviors in Male and Female 
C57BL/6J Mice. We set out to determine the extent to which C57BL/6J mice will 
undergo an immediate binge period during the first two hours of ethanol access, 
whether there was an escalation in this binge-like consumption, and whether 
male and female mice showed any differences in this behavior or the IEA model 
generally. Daily values of 2 hr and 24 hr consumption and preference are plotted 
out in Figure 4.12.  
 Given fluctuations in the data, we took 3-day averages from ethanol 
access days to obtain weekly means. The first day was dropped from this  
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Figure 4.12 Intermittent Ethanol Access (IEA) behavioral characterization.  
C57BL/6J mice (n=21/sex) were given access to 20% v/v ethanol in addition to 
tap water at the start of their dark cycle on Mondays, Wednesdays, and Fridays 
over the course of five weeks. Changes in fluid volume were measured at 2 
hours and 24 hours after placement of bottles on cages. Consumption is reported 
as g EtOH/kg body weight; preference is reported as mL EtOH / mL total fluid.  
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Figure 4.13 Mean ethanol binge consumption (weekly). A.-B. Within-Sex 
Comparisons: A. Females show significantly greater binge (2 h) ethanol 
consumption at Weeks 2-5 than at Week 1. B. Males show significantly greater 
ethanol consumption at Week 5 than Weeks 1-4. ***p<0.0005, **p<0.005, 
*p<0.05. C. Between-Sex Comparisons: Females show significantly greater 
ethanol consumption at Weeks 2-4 than males, but no significant difference at 
Weeks 1 or 5. †††p<0.0005, ††p<0.005, †p<0.05 
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Figure 4.14 Mean ethanol 24-hour consumption (weekly). D.-E. Within-Sex 
Comparisons D. Females show significantly lower total (24 h) ethanol 
consumption at Weeks 2, 3, and 5 than Week 1. Note that the first reading 
(Access Day 1) was excluded from the weekly analysis, and showed the lowest 
mean ethanol consumption overall. B. Males do not show any significant 
differences in total ethanol consumption from week to week. F. Between-Sex 
Comparisons Females show robustly greater total ethanol consumption over the 
entire course of the experiment.  
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Figure 4.15 Blood Ethanol Content (BEC). A. Blood samples taken at 2 h at 
the end of 5 weeks of IEA from 9 EtOH drinking mice and 2 non-EtOH controls 
show a linear relationship with consumption. B. Mean blood ethanol content in 
ethanol drinking mice is approximately 100 mg/dl in both female and male mice, 
on average, after a 2 h access period.  
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analysis as it is an expected outlier. Drinking data from the last week (Week 6) is 
also not reported because of interventions such as blood draws confounding the 
data. We found that there was significant escalation in binge-like ethanol drinking 
as determined by increases in consumption in the first 2 hours after ethanol 
access (Figure 4.13). In female mice, Weeks 2-5 all showed significantly greater 
ethanol consumption (p<0.005 for Week 3, p<0.0005 for Weeks 2, 4, and 5) than 
was observed in Week 1. In male mice, Week 5 consumption was significantly 
higher than Weeks 1-4 (p<0.05 compared to Week 4, p<0.0005 compared to 
Weeks 1-3). Between male and female mice, females drank significantly more 
ethanol during the 2-hr binge period than males during Weeks 2-4 (p<0.0005 for 
Week 2, p<0.05 for Week 4). There was not a significant escalation in daily 
ethanol consumption based on the 24-hour readings (Fig. 4.14), although the 
first day of ethanol access had the lowest consumption over the course of the 
experiment (see Fig. 4.12). Females drank significantly more than male mice 
during the 24-hour access periods consistently through the experiment (p<0.0005 
Weeks 1-5).  
 
Blood Ethanol Concentration (BEC). After 5 weeks of IEA, blood was drawn at 
the usual 2 hour binge point to verify that mice were achieving binge-like 
consumption. Blood was collected via cheek punch from 9 ethanol-drinking mice 
and 2 non-drinking controls. These values show a significant linear relationship 
when plotted against consumption values obtained from readings at the same 
time point (Fig. 4.15A). Mean BEC values were approximately 100 mg/dl (0.10 
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g%) on average for both male and female mice (Fig. 5.15B). This confirms that 
after 5 weeks of ethanol access, both male and female mice are consuming an 
excessive amount of ethanol. Moreover, the lack of sex difference at this time 
point is in line with our observation that male and female mice were consuming 
similar amounts of ethanol during the binge period by Week 5.  
 
4.3.3. Acute-on-Chronic Ethanol 
It has been shown that a 2.0 g/kg dose of ethanol produces a BEC in 
C57BL/6J of about 180 mg/dl (Crabbe et al, 2003), which is only slightly above 
the highest BECs we recorded at our 2 hour binge time point. We have shown 
that a 2 g/kg ethanol injection in the PFC of naïve mice produces a robust 
phosphorylation at the GSK3B inhibitory residue. We however found no 
significant effect of chronic ethanol on GSK3B phosphorylation 24 hours into 
ethanol withdrawal. We next sought to determine whether long-term ethanol 
exposure might alter the reactivity of GSK3B to an acute dose of ethanol. We 
used the same combined antibodies to the A and B isoforms on GSK3 as 
previously but have focused our analyses on relative p-GSK3B-S9 specifically.  
In the PFC of male C57BL/6J mice (Fig. 4.16)  two-way ANOVA of acute 
and chronic ethanol (excluding Tideglusib treated animals) revealed a significant 
main effect of acute ethanol (F1,15=7.083, p=0.0178), and non-significant effects 
of chronic (IEA) ethanol (F1,15=0.0433, p=0.183) and acute*chronic interaction 
(F1,15=1.19, p=0.293). By Sidak’s post-hoc test, acute i.p. ethanol significantly  
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Figure 4.16 Acute-on-chronic ethanol effects on GSK3B phosphorylation in 
mPFC (males). (Top): Representative films of phospho- and total GSK3 Western 
blots. (Bottom): Quantified results of p-GSK3B. Acute (i.p.) ethanol vs. saline is 
on the X-axis. Chronic ethanol (IEA vs Water) is shown in legend. A 2-way 
ANOVA excluding Tideglusib treated animals found significant main effect of 
acute ethanol. By Sidak’s post hoc, acute ethanol increased p-GSK3B within the 
chronic water condition (*p<0.05), but not within the IEA condition. Subsequent 3-
way ANOVA did not find significant effects of Tideglusib.  
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Figure 4.17 Acute-on-chronic ethanol effects on GSK3B phosphorylation in 
mPFC (females). (Top): Representative films of phospho- and total GSK3 
Western blots. (Bottom): Quantified results of p-GSK3B. Acute (i.p.) ethanol vs. 
saline is on the X-axis. Chronic ethanol (IEA vs Water) is shown in legend. A 2-
way ANOVA excluding Tideglusib treated animals found significant main effects 
of acute and chronic ethanol. By Sidak’s post hoc, acute ethanol increased p-
GSK3B within the chronic water condition (*p<0.05), but not within the IEA 
condition. Subsequent 3-way ANOVA found significant main effect of Tideglusib 
treatment, with Tideglusib-IEA-Ethanol significantly (**p<0.01) different from 
control (Vehicle-Water-Saline) by Tukey’s post-hoc. 
125 
 
increased GSK3B phosphorylation within the water-only drinking (ethanol-naïve) 
mice (adj. p=0.0305, * in Fig. 4.16); within the chronically ethanol exposed (IEA) 
mice the effect of i.p. ethanol was not significant (adj. p=0.506). To include 
Tideglusib treatment in the analysis, we had to account for the unbalanced 
design of these protein assays, wherein only animals in the IEA condition 
received tideglusib (all water-drinking controls analyzed on these blots received 
vehicle). Thus tideglusib treatment was included as a factor, and nested within 
chronic in a three-way ANOVA. There was not a significant main effect from 
treatment (F1,22=0.87, p=0.360), nor any significant interactions.  
In the PFC of female C57BL/6J mice (Fig. 4.17)  two-way ANOVA of 
acute and chronic ethanol (excluding Tideglusib treated animals) revealed 
significant main effects of acute ethanol (F1,16=13.95, p=0.0018) and chronic 
ethanol (F1,16=5.011, p=0.0398) and non significant acute*chronic interaction 
(F1,16=0.563, p=0.464). By Sidak’s post-hoc test, acute i.p. ethanol significantly 
increased GSK3B phosphorylation within the water-only drinking (ethanol-naïve) 
mice (adj. p=0.0118, * in Fig. 4.17); within the IEA mice the effect was not 
significant (adj. p=0.0993). When tideglusib treatment was included as a factor, 
and nested within chronic in a three-way ANOVA, there was a significant main 
effect of treatment (F1,22=9.96, p=0.0046), a significant main effect of acute 
ethanol (F1,22=10.65, p=0.0035), and non-significant effects of chronic[treatment] 
(F1,22=3.86, p=0.0621), acute*treatment (F1,22=0.0247, p=0.877) and 
acute*chronic[treatment] (F1,22=0.434, p=0.517). Tukey’s post hoc testing of the  
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Figure 4.18 Acute-on-chronic ethanol effects on GSK3B phosphorylation in 
mPFC (pooled). Quantified results of p-GSK3B following the acute-on-chronic 
ethanol paradigm in male and female PFC tissue as shown in the figures above 
were pooled together to increase statistical power. Upon finding no significant 
effect of sex on relative p-GSK3B levels, three-way ANOVA found significant 
main effects of acute ethanol and tideglusib treatment (p<0.001, p<0.01, 
respectively). Tukey’s post hoc testing revealed significant differences from 
control (Vehicle-Water-Saline) for the Vehicle-Water-Ethanol group and the 
Tideglusib-IEA-Ethanol group (**p<0.01).    
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three-way ANOVA found a significant difference between Tideglusib-IEA-Ethanol 
and Vehicle-Water-Saline (adj p=0.009, ** in Fig 4.17), as well as differences 
between Tideglusib-IEA-Ethanol and Vehicle-IEA-Saline (adj. p=0.001) and 
between Vehicle-IEA-Saline and Vehicle-Water-Ethanol (adj. p=0.0136).  
Given the relatively low power of conducting within-sex analyses with 6 
groups, and the fact that animals and tissue were run with sexes in parallel, we 
pooled all samples together to achieve an n of 8-10/group (n=56 total). Pooled  
results are shown in Figure 4.18. We first ran a two-way ANOVA with sex and 
the other factors combined into a single acute-chronic-treatment factor. This 
model found a robust effect of acute-chronic-treatment (F5,44=5.78, p=0.0003) but 
no significant effect of sex (F1,44=0.477, p=0.493) or sex*acute-chronic-treatment 
(F5,44=0.677, p=0.643). Given the lack of sex effect this factor was dropped from 
subsequent analysis. In the pooled samples, a two-way ANOVA of acute and 
chronic ethanol (excluding tideglusib treated animals) found significant main 
effect of acute (F1,35=13.14, p=0.0009) and no significant effect for chronic 
(F1,35=0.880, p=0.355) nor acute*chronic (F1,35=1.045, p=0.314). Sidak’s post hoc 
testing found a significant effect of acute ethanol within the chronically water-
drinking controls (adj. p=0.0041); within the IEA animals there was not a 
significant effect of acute ethanol on GSK3B phosphorylation (adj. p=0.150). 
Subsequent three-way ANOVA with Tideglusib treatment included found 
significant main effects of treatment (F1,50=8.34, p=0.0057) and acute ethanol 
(F1,50=12.74, p=0.0008). There were no significant effects from chronic[treatment] 
(F1,50=1.98, p=0.166), acute*treatment (F1,50=0.500, p=0.483), or  
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Table 4.2 Results of Tukey’s pairwise comparisons after 3-way ANOVA of 
p-GSK3B-S9 in the acute-on-chronic ethanol model (sexes pooled). After 
multiple tests corrections, the Tideglusib-IEA-Ethanol group is significantly 
different from Vehicle-treated animals receiving saline i.p., with and without IEA. 
The Vehicle-Water-Ethanol group is significantly different from these same two 
Vehicle-saline groups (+/- IEA).   
 
 
 
 
 
 
 
 
 
 
treatment chronic acute  -treatment  -chronic  -acute t Ratio Prob>|t| Lower 
95% 
Upper 
95% 
Tideglusib IEA Ethanol Tideglusib IEA Saline 1.72 0.5283  -0.49168 1.84414 
Tideglusib IEA Ethanol Vehicle IEA Ethanol 2.25 0.2340  -0.27260 1.99347 
Tideglusib IEA Ethanol Vehicle IEA Saline 4.15 0.0017* 0.44105 2.64975 
Tideglusib IEA Ethanol Vehicle Water Ethanol 0.46 0.9974  -0.93426 1.27444 
Tideglusib IEA Ethanol Vehicle Water Saline 4.04 0.0024* 0.40023 2.60892 
Tideglusib IEA Saline Vehicle IEA Ethanol 0.47 0.9971  -0.98371 1.35211 
Tideglusib IEA Saline Vehicle IEA Saline 2.26 0.2302  -0.27093 2.00926 
Tideglusib IEA Saline Vehicle Water Ethanol  -1.32 0.7752  -1.64624 0.63395 
Tideglusib IEA Saline Vehicle Water Saline 2.15 0.2780  -0.31175 1.96844 
Vehicle IEA Ethanol Vehicle IEA Saline 1.84 0.4517  -0.41938 1.78931 
Vehicle IEA Ethanol Vehicle Water Ethanol  -1.85 0.4429  -1.79469 0.41400 
Vehicle IEA Ethanol Vehicle Water Saline 1.73 0.5202  -0.46020 1.74849 
Vehicle IEA Saline Vehicle Water Ethanol  -3.79 0.0051*  -2.45020  -0.30042 
Vehicle IEA Saline Vehicle Water Saline  -0.11 1.0000  -1.11572 1.03407 
Vehicle Water Ethanol Vehicle Water Saline 3.68 0.0072* 0.25959 2.40938 
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acute*chronic[treatment] (F1,50=1.56, p=0.218). The results of Tukey’s post-hoc 
testing from the three-way ANOVA are given in Table 4.2. There are two groups 
which differ significantly from the Vehicle-treated, water-drinking, saline-injected 
controls: naïve animals injected with ethanol (Vehicle-Water-Ethanol), and 
ethanol-drinking animals pre-treated with Tideglusib and subsequently injected 
with ethanol (Tideglusib-IEA-Ethanol).  These two groups are denoted with 
asterisks in Figure 4.18. We interpret these findings as follows: IEA blunts the 
response of GSK3B inhibitory phosphorylation following an acute dose of 
ethanol. A pharmacologic GSK3B inhibitor could restore this inhibitory 
phosphorylation such that the same dose of ethanol results in a comparable level 
of GSK3B activity as in the ethanol-naïve state. Behavioral correlates of the 
application of a GSK3B inhibitor following a period of IEA will be discussed in 
Chapter 6. 
 
4.4 Discussion 
In agreement with prior literature on acute ethanol’s effects on GSK3 
phosphorylation in rodent PFC (Neznanova et al, 2009), a single i.p. injection of 
ethanol significantly increased p-GSK3A and p-GSK3B in the PFC of C57BL/6J 
mice. This is the first report of the effect being replicated in female mice, as well 
as to characterize multiple doses of ethanol. Moreover, we have provided 
evidence that inhibitory GSK3B phosphorylation may contribute to the locomotor 
effects of acute ethanol, as the GSK3B inhibitor tideglusib augmented the 
locomotor stimulatory effects and appeared to add to the anxiolytic-like effect. As 
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there is evidence of GSK3B phosphorylation mediating the rapid antidepressant 
effects of ketamine (Beurel et al, 2011), GSK3B phosphorylation may account for 
some of ethanol’s short-term effects on mood-related phenotypes.  
 The upstream mechanism of ethanol’s GSK3B inhibition remains to be 
elucidated. One well-characterized kinase known to phosphorylate GSK3B is Akt 
(Beaulieu et al, 2009). Akt is activated downstream of growth factors such as 
BDNF and in turn phosphorylates the S9 residue of GSK3B, an action thought to 
underlie certain mood-stabilizing agents (Mai et al, 2002). If ethanol acutely 
increases BDNF in the PFC, this might account for its inhibition of GSK3B. Co-
administration of a BDNF receptor (TrkB) antagonist with ethanol could serve as 
a test of this hypothesis: if the antagonist (e.g. ANA-12) blocked the ethanol 
induced increase in GSK3B, this would be evidence for an ethanol-BDNF-Akt 
pathway. It should be noted that Akt is only one potential upstream kinase and 
that many pathways converge on GSK3B. For example, Miller et al. (2014) found 
that cocaine inhibited Akt and activated GSK3B by decreasing its 
phosphorylation in the NAC. Blockade of D2 receptors prevented the cocaine-
induced inhibition of Akt, while D1, D2, and NMDA antagonists each blocked 
cocaine-induced activation of GSK3B (Miller et al, 2014).  
 Given the inhibition of GSK3B as well as GSK3A following an acute 
ethanol dose, it might be expected that as a homeostatic response, GSK3 activity 
may basally increase in the PFC. Alternatively, if each ethanol dose perturbs 
GSK3 for much longer than ethanol stays in the bloodstream, a sustained 
decrease in GSK3 activity might be expected following intermittent cycles of 
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ethanol exposure. However we found evidence for neither of these conditions in 
our study of intermittent ethanol access (IEA), with PFC tissue harvested 24 
hours after the last drinking session. Neither p-GSK3A-S21 nor p-GSK3B-S9 
were significantly altered by IEA compared with water-drinking controls. 
However, it is still possible that the single 24-hour time point did not detect 
temporal trends in adaptation via altered GSK3 activity.  
There was evidence for alterations in PFC synaptic scaffolding proteins 
with ethanol treatment. In male mice, the PFC showed an increase in total 
PSD95, while in female mice the PFC showed decreased gephyrin. PSD95 has 
recently been shown to increase in RNA expression in the NAC of male rats after 
8 weeks of IEA compared to water-drinking controls (Liu et al, 2017). Prior work 
on chronic ethanol induced plasticity has shown increased NMDA receptor 
clustering and PSD-95 expression in hippocampal neurons (Carpenter-Hyland 
and Chandler, 2006). As a homeostatic response it is relatively unsurprising: if 
ethanol repeatedly antagonizes NMDA receptors, upregulation of the protein 
which anchors these receptors to the synapse may be a means of restoring 
balance. Interestingly, while we did not see this PSD-95 effect in female mice, we 
saw what might be seen as the parallel inverse: decreased gephyrin. As ethanol 
repeatedly potentiates GABA receptors, downregulation of their anchor protein 
would also restore balance. In male rats, chronic ethanol vapor (CIE) and 
withdrawal were found to increase gephyrin in the amydala (Diaz et al, 2011). 
Chronic ethanol exposure has often been shown to alter the expression of 
GABAA receptors in the cerebral cortex (Krystal et al, 2006), and to enhance 
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internalization of alpha-1 subunit containing GABAA receptors in particular 
(Kumar et al, 2003), but the role of gephyrin in this response has been little 
studied.   
As both PSD-95 and gephyrin contain GSK3B target residues (Nelson et 
al, 2013; Tyagarajan et al, 2011), it is interesting to consider the interplay 
between alterations in the levels of these synaptic scaffolds and GSK3B activity. 
While we did not see a significant effect of acute ethanol on p-PSD95-T19, the 
GSK3B target site, there was a suggestive inverse trend with increasing ethanol 
(p<0.1), specifically in male mice. Phosphorylation by GSK3B normally serves to 
remove a scaffold protein from the membrane. If each ethanol exposure 
decreases GSK3B activity and corresponds to some degree of decreased PSD-
95 phosphorylation, this might be expected to stabilize its expression at the 
synapse. This same logic could apply to gephyrin. Why then, does chronic 
ethanol cause PSD-95 to persist at a higher expression in males while gephyrin 
shows decreases in females? A crucial piece of information might be the rate of 
turnover of each of these scaffolding proteins in comparison with their receptors. 
Does an increase in total PSD-95 necessarily correspond to more stable 
expression, and does this in turn imply enhanced NMDA signaling? Or might the 
increase in total PSD-95 correspond to increased turnover, to allow for insertion 
of new NMDA receptors in place of non-responsive or tolerant channels? If the 
latter, then acute GSK3B inhibition in the context of chronic ethanol could 
actually counter the effects of increased PSD-95, by inhibiting turnover and 
preventing signal enhancement.   
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  Another interesting male-female distinction is observed in the chronic 
(IEA) behavioral results. Females showed a near immediate escalation in binge 
consumption, as soon as Week 2, and drank significantly higher binge amounts 
than male mice until Week 5, when males caught up. Thus male mice escalate 
binge consumption much more slowly than female mice. However, by Week 5, 
the fact that males and females did not significantly differ in binge consumption is 
striking considering the robust differences in total daily consumption through the 
course of the experiment. This means that male mice eventually consume a 
much greater proportionate binge amount relative to their daily consumption. One 
consistent observation across both sexes is that the drinking patterns of the 
overall cohort seem to converge around a mean value. That is, the histograms in 
Week 1 show a much greater spread than those by the end of the 5 weeks under 
investigation. Thus it might be considered that individual differences in inbred 
lines may show up early in long-term IEA experiments relative to later.  
Finally, we used another cohort of male and female mice to investigate the 
relative effects of a single acute (2 g/kg) dose of ethanol on GSK3B 
phosphorylation in naïve versus IEA-exposed mice. We hypothesized that 
repeated cycles of exposure and escalating ethanol consumption might 
correspond to habituation to the effect of ethanol on GSK3B phosphorylation. 
Two-way ANOVAs of males, females, and the pooled samples consistently found 
a main effect of acute ethanol, but that this effect was significant specifically in 
the naïve (non-IEA) condition in post-hoc testing. This supports our hypothesis of 
a blunted response following chronic ethanol exposure. We also included 
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tideglusib-treated mice in subsequent three-way ANOVAs and found a significant 
treatment effect in the pooled sample, and that both (1) the naïve animals 
injected with ethanol and (2) the IEA animals pre-treated with tideglusib and then 
injected with ethanol showed significant (p<0.01) differences from control 
(vehicle-water-saline). Observing Figure 4.18, it would appear that tideglusib 
treatment by itself raises relative p-GSK3B-S9 to similar levels as IEA animals 
given an injection of ethanol. Treatment of acute ethanol on top of tideglusib 
treatment restores levels of p-GSK3B-S9 to those seen in naïve animals treated 
with acute ethanol only. Implications of tideglusib treatment will be further 
discussed in chapter 6. 
Full acute dose responses in the naïve and IEA groups would be 
necessary to conclude that chronic ethanol (IEA) shifts the responsiveness of 
GSK3B inhibitory phosphorylation downward. However we would predict based 
on our selected dose of 2 g/kg and the dose-responses previously performed in 
naïve animals only, that following chronic treatment, a greater dose of ethanol 
would be required to achieve an equivalent inhibitory GSK3B phosphorylation. 
Thus we propose the novel hypothesis that a certain level of GSK3B inhibition in 
the PFC normally serves to counteract the motivation to self-administer ethanol. 
This may correspond to a certain level of positive effects, i.e. anxiolysis, to 
achieve satiety, or to a certain level of dysphoria, which only sets in at higher 
ethanol doses. As more ethanol is required to achieve this same level of GSK3B 
inhibition, escalating consumption ensues.  
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Chapter 5  
Genetic Modulation of Gsk3b and Ethanol Drinking 
 
5.1 Introduction 
 To examine the role of a particular isoform of a ubiquitously expressed 
intracellular kinase, by far the most specific means of functional targeting is at the 
level of the gene. In humans, the GSK3B gene is located on the long arm of 
chromosome 3; in mice the Gsk3b gene is on chromosome 16. These mouse 
and human genes share 92.7% identity in DNA sequence, and the encoded 
proteins share 99% amino acid sequence homology (NCBI, 2017). Homozygous 
disruptions in Gsk3b lead to death around mid-gestation (Patel et al, 2008) or 
neonatally (Liu et al, 2007), consistent with the GSK3B protein playing a crucial 
role in development.  
 Several alternatives to pancellular or constitutive Gsk3b gene deletions 
have been developed and assayed in rodents previously. Transgenic mice 
overexpressing Gsk3b have been proposed as a model for hyperactivity and 
mania (Prickaerts et al, 2006). In this case the overexpression was mediated via 
targeted mutation of the GSK3B-S9 phospho-residue, causing constitutive 
activity of the protein. In addition to hyperlocomotion, these mice were found to 
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show an increased acoustic startle response, despite no differences in basal or 
stress-induced plasma adrenocorticotrophic hormone or corticosterone levels 
(Prickaerts et al, 2006). They also showed increases in Akt1 expression and 
BDNF in the hippocampus, possibly as compensatory responses to constitutively 
active GSK3B (Prickaerts et al, 2006). 
 Conditional genetic deletion of Gsk3b has been carried in neurons 
specifically expressing dopamine D1- vs D2- type receptors (Urs et al, 2012). 
These mice were generated by crossing D1 or D2 promoter driven Cre-lines with 
homozygous floxed Gsk3b mice (Urs et al, 2012). The homozygous Gsk3b-flox 
mice carried alleles with a LoxP site flanking the second exon, allowing for Cre-
mediated excision and an inactivated GSK3B protein product (Patel et al, 2008). 
Thus Urs et al. achieved cellular selectivity as Cre-mediated deletion would only 
occur in cells with active promoter-driven expression (i.e. cells expressing either 
dopamine D1 or D2 receptors). However, there was no temporal selectivity 
outside of that provided by the temporal expression pattern of the D1 and D2 
receptors. The authors found that deletion in neither neuronal type altered 
immobility in the tail suspension test or latency to cross in a dark-light emergence 
test; however D2 specific deletion of Gsk3b significantly attenuated 
amphetamine-induced hyperlocomotion, and deletion in either neuronal cell type 
prevented amphetamine-induced disruption of prepulse inhibition (Urs et al, 
2012). Based on corresponding pharmacologic agents in these same assays, the 
authors concluded that dopamine receptor-dependent GSK3B activation may 
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underlie aspects of antipsychotic, but not antidepressant, actions (Urs et al, 
2012).  
 In another study of specific Gsk3b deletion (Latapy et al, 2012), the gene 
was postnatally deleted in forebrain neurons expressing the alpha isoform of the 
calcium/calmodulin-dependent protein kinase II (CAMKIIα, encoded by CAMK2A 
in humans or Camk2a in mice). These mice were generated via breeding 
Camk2a-Cre mice to the same Gsk3b-floxed line as above. Gsk3b deletion in 
this neuronal population did seem to mimic antidepressant actions, in contrast to 
the D1-/D2- deletions above. The open field test and light-dark emergence test 
revealed a marked reduction in basal anxiety-like behavior in the Gsk3b-deletion 
mice (Latapy et al, 2012).  These findings expound upon previous findings that 
Gsk3b haploinsufficiency or GSK3B pharmacologic inhibition rescues the 
anxiogenic-like phenotype observed in serotonin deficient mice expressing 
tryptophan hydroxylase knock-in (Beaulieu et al, 2008). Of note, these serotonin 
deficient mice have since been found to exhibit increased ethanol preference 
(Sachs et al, 2014). 
 Based on the convergence of neuronal signaling pathways on GSK3B and 
the strong effect of ethanol described in the previous chapter, we investigated the 
role of the GSK3B in alcohol-drinking behavior with both regional and cellular 
specificity, and without the potential confounds of developmental disruptions. 
Here we describe 3 genetic manipulation techniques:  
(1) Viral-mediated over-expression of Gsk3b in the medial PFC (mPFC). 
(2) Viral-mediated deletion of Gsk3b in the mPFC, specifically infralimbic cortex 
(IL) 
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(3) Conditional deletion of Gsk3b in Camk2a-expressing neurons using 
tamoxifen-inducible Cre 
Based on observations in the prior chapter consistent with molecular tolerance to 
ethanol’s inhibitory effects, we hypothesize that GSK3B activity level in frontal 
cortex drives ethanol-seeking behavior. This hypothesis is further supported by 
there being high GSK3B activity specifically in the frontal cortex of serotonin-
deficient mice (Beaulieu et al, 2008) who show high ethanol preference (Sachs et 
al, 2014); and by higher constitutive GSK3B activity in the prefrontal cortex of 
alcohol-preferring vs. non-preferring rats (Neznanova et al, 2009). We test this 
hypothesis using two-bottle choice ethanol drinking paradigms for all genetically 
modified mice.   
   
5.2 Materials and Methods  
5.2.1 Viral-mediated overexpression 
Animals. Male C57BL/6J mice (age 7-8 weeks, Jackson Laboratories, Bar 
Harbor, Maine) were habituated to a climate-controlled vivarium for 1 week prior 
to beginning experiments with ad libitum food and water access unless indicated. 
Animals were kept on a 12-h light cycle (lights on 0600). All injections of the 
overexpression vector and subsequent validation studies and behavioral tests 
were carried out by Annie Meng. Mice were singly housed following surgery and 
for the duration of ethanol-drinking studies.  
Viral vector stereotactic injections. Mice were injected with an AAV2 vector 
containing either Gsk3b cDNA (AAV-GSK3B, n=16) or mock AAV2 (AAV-IRES, 
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n=14) driven by a CMV promoter. Both vectors also expressed hrGFP 
fluorescent reporter protein. For viral injection bilaterally into mPFC, mice were 
anesthetized with ketamine (120 mg/kg, i.p.) and xylazine (12 mg/kg, i.p.) and 
small burr holes were drilled through the skull immediately above the mPFC. Two 
microsyringes were slowly lowered to the following coordinates relative to 
bregma: anterior-posterior +0.1, medial-lateral +0.06 and -0.06, dorsal-ventral -
0.21. At each site, 1 µl of the virus was injected at the speed of 0.1µl per min, the 
needle was left in place for an additional 10 min and then slowly raised. 
Efficiency of viral transduction in anesthetized mice was assessed 2-3 weeks 
following injections using the IVIS200 in vivo imaging system (Xenogen, 
Alameda, CA). Photons emitted from hrGFP-expressing cells in mPFC were 
quantified over a defined period of time ranging from up to 5 minutes using the 
software program Living Image (Xenogen) as an overlay onto the Igor program 
(Wavemetrics, Portland, OR). 
Immunohistochemistry. Mice were heavily anesthetized with pentobarbital, 
perfused transcardially with 0.9% saline for 2 min, and then perfused with a 
solution of 4% paraformaldehyde in 0.1 M PBS, pH 7.4, for 15 min with a flow 
rate of 2.5 ml/min. Brains were removed, post-fixed for 12 h in 4% 
paraformaldehyde, and transferred to PBS containing 30% sucrose. Brains were 
frozen on dry ice, and sections cut at 25 μm using a Leica sliding microtome. 
Sections were then rinsed in PBS, incubated in blocking solution for 30 min, and 
incubated with a rabbit-anti-GSK3B polyclonal antibody (1:100, Abcam, 
Cambridge, MA, USA) and a mouse anti-NeuN monoclonal antibody (1:500, 
140 
 
Millipore, MA, USA), overnight, at 4°C. Sections were then washed and 
incubated in a goat-anti-rabbit FITC-conjugated secondary antibody (1:2000, 
Invitrogen, Grand Island, NY) and a donkey anti-mouse conjugated Texas red 
secondary antibody (1:2000 Invitrogen, Grand Island, NY).  A confocal laser 
scanning microscope (Fluoview FV1000, Olympus, Japan) was used to obtain z-
stacks. All exposure settings were kept constant for each group. 
q-RT-PCR. For quantitative validation of Gsk3b expression, aliquots of total RNA 
(1 µg) from AAV-GSK3B (n=4) or pAAV-IRES (n=6) injected mice were reverse-
transcribed into cDNA according to the manufacturer instructions of the first 
strand cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The primers used in 
this study were synthesized by Operon (Huntsville, AL, USA) and sequences for 
Gsk3b sense and antisense, 5`-tccgattgcggtatttcttc-3` and 5`-
aatgtctcgatggcagatcc-3`, respectively.  
Voluntary ethanol intake. Five weeks post-viral injection, ethanol consumption 
by AAV-GSK3B mice compared to control AAV-IRES mice was assessed using a 
two-bottle choice drinking paradigm (George et al, 2012; Meliska et al, 1995). 
Mice received increasing concentrations of ethanol for 5 days at each dose (3-
15% w/v ethanol). Water was available at all times during the experiment. The 
positions of the alcohol and water tubes were switched every other day (L, L, R, 
R, etc.) to avoid a placement bias. Alcohol solutions were prepared freshly daily. 
Ethanol and water consumption was measured every 24 h, and body weight was 
recorded every 5 days. Ethanol consumption was calculated as grams of ethanol 
per kilogram body weight per 24 h. Percent ethanol preference for individual mice 
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was obtained by dividing volume of ethanol consumption by total fluid 
consumption for daily drinking sessions. Bottles containing ethanol or tap water 
were placed in an empty cage to account for evaporation loss and values were 
subtracted from the amount consumed for each mouse to calculate corrected 
preference ratios and ethanol intake. A schematic of the ethanol drinking 
behavior paradigm used here is shown in Figure 5.1A. 
Blood ethanol determination. For blood ethanol pharmacokinetics, AAV-
GSK3B and control littermates (n=3 per genotype) were injected with ethanol (2 
g/kg, i.p.) and 100 µL of blood sample were obtained from the tail vein at 60 min 
and 120 min post-injection. Blood ethanol concentration was determined using 
the Analox AM1 Analyzer (Analox Instruments, North Yorkshire, UK). 
Taste discrimination. Taste preference for bitter and sweet solutions was 
measured using quinine and saccharin respectively using the two-bottle choice 
paradigm as described above. Mice were allowed to recover for 7 days following 
the voluntary ethanol drinking study. Half of the mice were given two bottles 
containing either a 0.05 mM quinine solution or tap water for 4 days to assess 
bitter taste preference (Wolstenholme et al, 2011). The remaining mice were 
given a choice between saccharin (0.033%) or tap water to measure non-caloric 
sweet taste preference. Bottles were alternated every other day to avoid side 
preferences. Consumption of quinine and water or saccharin and water were 
measured daily after which the other tastant was offered for 4 days in a 
counterbalanced design. 
Lithium diet treatment. After the taste discrimination test, mice were allowed to  
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Figure 5.1 Schemata of drinking paradigms used in genetic modulation 
studies. A-B. Continuous ethanol access at escalating doses, initiated 3-5 
weeks after viral vector injections in PFC or infralimbic cortex (IL). Abstinence 
associated anxiety was assayed via LD box 24 hours after last ethanol access. 
C. Continuous ethanol access at 15%w/v, followed by intermittent ethanol 
access.  
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recover for one week, after which animals were fed chow with or without 0.2% 
lithium chloride (LiCl, Harlan Teklad, Madison,WI) for 4 weeks. Saline (0.45% 
NaCl) was added to the drinking water of lithium fed mice to reduce toxicity as 
previously reported (Smith and Amdisen, 1983). Body weight was monitored 
weekly in both control and lithium fed mice. Blood lithium levels were found to be 
stable 3 weeks after lithium treatment, and then ethanol consumption was 
measured 4 weeks following lithium treatment. Upon completion of the 
experiment, blood samples were collected from the tail vein. The blood was 
collected in a microtube and was immediately centrifuged at 3,000 rpm at 4º for 
10 min. Plasma was then collected and stored at -20°C for lithium level analysis. 
Concentrations of plasma lithium were determined by the VCU Clinical Chemistry 
Laboratory by atomic absorption spectrophotometry. 
Loss of righting reflex (LORR). Three weeks following AAV viral injections in 
C57BL/6J mice, loss of righting reflex was assessed. Ethanol (3.6 g/kg, 20% v/v 
solution) was injected intraperitoneally, and individual mice were placed 
immediately in a clean Plexiglas cage. After mice lost their righting reflex, they 
were placed on their backs in their home cage. The duration of LORR was 
defined as the time from the loss of the righting reflex to the time at which it was 
regained. Recovery was defined as the time at which mice could right 
themselves 3 times in 30 seconds after being placed on their backs. The 
behavioral room was illuminated with a soft light, and external noise was 
attenuated. 
Light-Dark Box. Ethanol tubes were removed 20 days following commencement 
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of the drinking study and 24 hours later, ethanol abstinence associated anxiety 
was assessed using the light-dark (LD) box conflict model as described in 
(Putman et al, 2016). The LD boxes were as described in Chapter 4 with the 
exception that these experiments used CM1820 28V 100mA light bulbs as 
opposed to 180mA “stimulus” bulbs.    
 
5.2.2 Viral-mediated deletion 
Animals. Floxed Gsk3b (Gsk3bfl/fl) mice were generously donated by Dr. James 
Woodgett (Samuel Lunenfeld Research Institute, Toronto) (Patel et al, 2008). 
Male and female Gsk3bfl/fl mice were maintained on a C57BL/6J background by 
the VCU Transgenic Core Facility, and sent to our temperature and humidity 
controlled vivarium at 4 weeks of age. At approximately 12 weeks of age, 
Gsk3bfl/fl mice underwent stereotaxic surgery and were subsequently singly 
housed. All mouse studies were conducted in accordance with the National 
Institute of Health Guidelines for Animal Care and Use and VCU IACUC 
approved protocols. All mice undergoing stereotaxic surgery were given 
ibuprofen (0.2 mg/mL) in their drinking water for the 24 hours pre- and 72 hours 
post-operation for analgesia. 
Robot stereotaxic surgery. Mice were anesthetized with isoflurane (<5% in O2) 
and mounted onto a motorized drill-microinjection robot stereotaxic rig 
(Neurostar, Tubingen, Germany). Isoflurane vapor was maintained at the minimal 
level to achieve full anesthetic effect, assessed by toe pinch every 5-15 minutes. 
The surgical area was cleaned with Betadine and 70% ethanol. Bupivacaine was 
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injected subcutaneously to the scalp. A midline incision was made to allow 
bregma and lambda visualization. The drill-microinjection arm was calibrated 
based on bregma and lambda, as well as points 2 mm on either side of the skull 
to allow for roll/tilt correction. The drill and microinjector were 90 degrees 
perpendicular to the surface of the skull, such that holes were drilled directly 
above the injection target. Injection target coordinates for infralimbic cortex (IL) 
were AP: +1.42, ML: ±30, DV: -2.50 (compare to (Holmes et al, 2012)). A 
screenshot from the Neurostar robot control software is shown in Figure 5.2, 
which gives the predicted placement of these coordinates in an integrated mouse 
brain atlas.  
 Gsk3bfl/fl mice were injected with AAV2-CMV-Cre-eGFP, or as a control, 
the same virus but without Cre: AAV2-CMV-eGFP. The AAV2 serotype was 
chosen based on the relative neuronal tropism of this serotype as well as low 
toxicity (Howard et al, 2008). The CMV promoter was used based on its small 
size, efficient transduction and constitutive expression once within cells (Smith et 
al, 2000).  Cre recombinase is the virally encoded enzyme which accomplishes 
the deletion via excision of the Gsk3b exon. Finally, eGFP allows for a 
fluorescent reporter label to identify and validate successful transduction.  
The Cre or GFP control viruses were injected bilaterally, 0.7 µL per hemisphere. 
The robot was programmed to inject each 0.7 µL volume at a constant speed 
over a duration of 5 minutes. The virus was then given an additional 5 minutes to 
diffuse away from the needle before the microinjector was slowly raised and 
moved to the opposite hemisphere, and the process repeated. Hamilton Gastight  
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Figure 5.2 Stereotaxic target according to Neurostar robot software. 
Screenshot of Neurostar Stereotaxic Drill-Injection Software (StereoDrive) is 
shown. Injection target is top of infralimbic cortex (IL). Virus injection volume per 
hemisphere was 0.7 uL (not shown in figure).  
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10 uL syringes with 33 gauge small hub needles (Hamilton, Reno, NV) were 
used on the automated microinjector. Following bilateral injection, saline was 
applied to rehydrate the scalp and the incision resealed using surgical glue. The 
wound was cleaned with Betadine and ethanol. Sterile field was maintained 
throughout the surgery.  
Immunohistochemistry. Loss of GSK3B expression in the IL was confirmed via 
IHC. At least 3 weeks after injection, mice were transcardially perfused with 4% 
paraformaldehyde and brains were stained according to the same protocol for 
immunofluorescent staining described in Chapter 4.2 (Materials and Methods). 
 Voluntary ethanol intake. As described above in 5.2.1, mice were given 
continuous access to escalating concentrations of ethanol (3%, 6%, 10%, 15% 
w/v) for 5 days at each dose. Ethanol access was begun 3-5 weeks post-viral 
injection. Ethanol-drinking paradigm is depicted in Figure 5.1B. 
Taste preference. An ethanol-naïve cohort was given access to quinine (0.05 
mM) for 4 days and saccharin (2 mM, 0.037% w/v) for 4 days subsequently.  
Light-Dark Box. An ethanol-naive cohort of mice was assessed for basal anxiety 
via LD box. An ethanol drinking cohort (Fig. 5.1B) was tested 24 hours after last 
ethanol access. LD boxes were as described in Chapter 4.   
Novel Object Recognition. A subset of animals from both ethanol-naïve and 
ethanol-drinking cohorts were tested for PFC-dependent working memory via 
novel object recognition (Besheer et al, 1999; Wolstenholme et al, 2017). This 
task consisted of 2 days of testing. On the first day, each mouse was brought into 
the testing room for at least 1 hour. Each mouse was placed into its own clean 
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and empty (without bedding) cage for 30 minutes, and then returned to its home 
cage. On the second day, mice were again habituated to the testing room for at 
least 1 hour. Each mouse was then placed into its own clean, empty test cage for 
20 minutes, then returned to its home cage for at least 2 minutes. During this 
time, two identical objects (two small laboratory funnels or two owl-shaped pencil 
sharpeners) were cleaned with 10% ethanol, dried, and taped to the bottom of 
the test cage in opposite corners, at least 2 inches from the sides. The training 
phase was then begun, wherein the mouse was returned to the test cage and 
allowed to explore the cage containing the identical objects for 5 minutes. The 
time spent exploring each object (nose oriented toward object, less than 2 cm 
away) was recorded using a stopwatch. After the the training phase the mouse 
was returned to its home cage for an interval of 5 minutes. During this interval 
one object was replaced with a clean, novel object. After the 5 minute interval the 
mouse was returned for the testing phase. This consisted of a final 5-minute 
duration during which time the time the mouse spent exploring each object was 
recorded using a stopwatch. 
 
5.2.3 Tamoxifen-inducible Cre 
Animals. The floxed Gsk3b (Gsk3bfl/fl) mice described in 5.2.2 were crossed with 
a transgenic line hemizygous for Tg(Camk2a-CreERT2) allele (Madisen et al, 
2010). This allele encodes a Camk2a promoter driven Cre-ERT2 fusion protein. 
Cre-ERT2 consists of Cre recombinase fused to a triple mutant form of the 
human estrogen receptor which does not bind 17β-estradiol at physiological 
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concentrations but will bind the synthetic estrogen receptor ligand tamoxifen 
(Madisen et al, 2010). The VCU Transgenic Core Facility received the B6;129S6-
Tg(Camk2a-cre/ERT2)1Aibs/J line from Jackson Laboratories (Bar Harbor, ME) 
and subsequently maintained a colony via back-crossing with C57BL/6J mice. 
C57BL/6J genotypic background was confirmed at >95% using GigaMUGA high 
density genotype arrays (GeneSeek, Lincoln, NE). These mice were crossed with 
Gsk3bfl/fl and subsequently inbred to generate mice homozygous for the floxed 
allele and hemizygous for Camk2a-cre/ERT2, which when paired with another 
Gsk3bfl/fl, would generate offspring all of which were homozygous for the Gsk3b 
floxed allele, and half of which carried the Camk2a-cre/ERT2 gene (50% Cre+ 
and 50% Cre-). These offspring were sent to our climate-controlled facility at 4 
weeks of age and treated with tamoxifen upon reaching adulthood (8-12 weeks 
of age).  
Tamoxifen treatment. Upon starting the treatment regimen (Madisen et al, 
2010), animals were moved to single housing. Tamoxifen (Sigma-Aldrich, St. 
Louis, MO) was dissolved in corn oil at a concentration of 20 mg/mL by bath 
sonication. The drug vial was wrapped in foil for to protect from light, and stored 
at 4 degrees C for the duration of injections. Each mouse was injected with 100 
uL of the tamoxifen solution for a per weight dose of approximately 75 mg/kg, 
every 24 hours for 5 successive days. Validation of deletion was performed via 
immunohistochemistry as described above. 
Voluntary ethanol intake. Ethanol access was begun 3-4 weeks post treatment. 
Ethanol-drinking paradigm is depicted in Figure 5.1C. Animals were given 
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continuous access to 15% w/v for 15 consecutive days, and then switched to 
intermittent ethanol access (15% w/v) for 5 weeks, i.e. 15 days of ethanol 
access.  
Taste preference. A subset of animals were given access to quinine (0.05 mM) 
for 4 days and saccharin (2 mM, 0.037% w/v) for 2 days subsequently.  
Light-Dark Box. An ethanol-naive cohort of mice was assessed for basal anxiety 
via LD box, 1 week after tamoxifen treatment. An ethanol drinking cohort was 
tested 24 hours after last ethanol access (after > 5 weeks of IEA). LD boxes were 
as described in Chapter 4.   
 
5.3 Results 
5.3.1 Viral-mediated Over-expression 
AAV-mediated overexpression plasmid increases Gsk3b transcript and 
protein product. Viral vectors co-expressed humanized recombinant green 
fluorescent protein (hrGFP), allowing localization off AAV-GSK3B transduction. 
We observed hrGFP-positive labeling up to 8 weeks following AAV-GSK3B and 
control AAV-IRES (expressing only hrGFP) transduction (Fig. 5.3A). GSK3B 
overexpression was confirmed at the mRNA and protein level (p<0.05) by 
quantitative RT-PCR, ELISA and immunofluorescence (Fig. 5.3B-E). GSK3B 
over-expression was largely limited to NeuN-positive neurons (Fig. 5.3E).  
 
GSK3B overexpression increases ethanol consumption. GSK3B over-
expression in mPFC produced a significant increase in mean daily ethanol  
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Figure 5.3 Validation of Gsk3b overexpression vector. AAV-GSK3B viral 
vector increases Gsk3b expression and GSK3B protein in neurons relative to 
AAV-IRES control. A. Visualization of hrGFP using an in vivo imaging system at 
3 and 8 weeks, in mice injected with AAV with hrGFP tag (right) and controls. B. 
Representative immunohistochemistry of GSK3B-staining in AAV-IRES and 
AAV-GSK3B injected PFC. C. Significantly upregulated Gsk3b mRNA in PFC of 
AAV-GSK3B injected mice as measured by RT-qPCR (n=4-6, *p<0.05). D. 
Significantly higher levels of GSK3B protein in PFC of AAV-GSK3β injected mice 
as measured by ELISA (n=3/group, *p<0.05). E. Representative PFC sections 
from AAV-IRES or AAV-GSK3B injected mice, double-stained with GSK3B and 
NeuN. Overlap reveals largely neuronal localization (yellow) of GSK3B over-
expression in AAV-GSK3β injected mice. 
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Figure 5.4 GSK3B overexpression increases ethanol consumption and 
preference. A. Compared to IRES mice, AAV-GSK3B mice (n=14-16) show 
significantly increased ethanol consumption (g/kg/day) during free access, two-
bottle choice at 10% (p= 0.0005) and 15% (p=0.0147) ethanol concentrations. B. 
AAV-GSK3B mice show increased ethanol preference (EtOH/total fluid) during 
two-bottle choice at 6% (p=0.028) and 10% (p=0.0039) ethanol concentrations. 
C. AAV-GSK3B shifts the dose-response relationship between ethanol 
concentration and mL consumed significantly upward (p=0.0001) D. Addition of 
Lithium diet significantly decreased ethanol consumption in AAV-GSK3B mice 
(n=7-8 per group, #treatment effect of lithium in AAV-GSK3B mice, p=0.0021; 
*genotype effect in untreated mice, p=0.0451 vs. IRES). E. During a 10 minute 
LD box test, AAV-IRES and AAV-GSK3B (n=7-8/group) did not differ in total 
distance traveled. (F) AAV-GSK3B mice showed a significantly decreased time 
spent in the light (*p=0.0365), indicating increased anxiety-like behavior following 
withdrawal from ethanol access.  
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consumption (g/kg/day) using a progressive ethanol dosing regimen (Fig. 5.4A, 
F1,28=20.68, p<0.0001 for viral genotype). AAV-GSK3B mice consumed larger 
(~30-40%) amounts of ethanol (g/kg/day) at 10% (p<0.001) and 15% (p<0.01) 
w/v ethanol concentrations compared to control AAV-IRES mice by Sidak’s 
multiple comparisons test. There was also a significant viral genotype effect on 
mean ethanol preference ratio (Fig. 5.4B, F1,28=19.34, p=0.0001), with AAV-
GSK3B mice displaying an enhanced ethanol preference during access to 6% 
(p<0.05) and 10% (p<0.01) ethanol solutions. We further assessed ethanol 
drinking behavior as a function of ethanol concentration, wherein mean volume 
consumed of ethanol-containing solution was used as a proxy for reinforcers 
delivered. This showed an inverted U-shape dose-effect curve peaking at the 6% 
w/v ethanol (Fig. 5.4C), and with GSK3B mice consistently displaced to higher 
values than controls. Two-way ANOVA revealed a significant effect of viral 
genotype on mean volume of ethanol-containing solution per body weight 
(F1,28=20.44, p=0.0001).  
No significant difference in two-bottle choice voluntary consumption of 
saccharin (0.015% w/v) or quinine (0.05 mM) were observed between AAV-
GSK3B and AAV-IRES mice (Fig. 5.5A, tsaccharin=0.92, p=0.36; tquinine=0.45, 
p=0.66), suggesting taste preferences were not altered (Bachmanov et al, 1996). 
Additionally, blood ethanol levels were not different between AAV-GSK3B and 
AAV-IRES mice at 60 or 120 minutes after injection (i.p.) with 20% v/v ethanol 
(Fig 5.5B, F1,4=1.48 , p=0.29) eliminating pharmacokinetic factors as a potential 
difference between the two viral genotypes. 
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Figure 5.5 Taste preference and BEC show no differences following 
overexpression. AAV-GSK3B and AAV-IRES injected mice did not differ in taste 
preference or ethanol metabolism. A. Quinine and saccharin preferences, as 
determined by volume consumed over total fluid consumption (n=14-16/group, 
p>0.05). B. Blood ethanol levels at 60 or 120 minutes following an i.p. injection of 
ethanol (2 g/kg) (n=3/group, ANOVA p>0.05 for AAV-GSK3b vs. AAV-IRES at 
either time point). 
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To further confirm specificity of GSK3B overexpression on ethanol consumption, 
in a separate experiment we introduced lithium, a well validated GSK3B inhibitor 
(Chou et al, 2012; O'Brien and Klein, 2009), into diets for half of each  
experimental group for 4 weeks while receiving access to ethanol (10% w/v) and 
water (Fig. 5.4D). Lithium treatment (F1,26=15.51, p=0.0005) and viral genotype 
(F1,26=5.483, p<0.05) both significantly altered mean ethanol consumption 
(g/kg/day).   Lithium significantly decreased ethanol consumption in AAV-GSK3B 
mice relative to standard chow (Tukey’s post hoc, p<0.01). AAV-IRES mice fed 
lithium showed a non-significant decrease in ethanol consumption (95% CI: 
0.4908 to -1.859 g/kg difference in mean consumption). Serum lithium levels did 
not differ significantly (F1,2=0.11, p=0.771) between AAV-GSK3B (mean=0.65 
mmol/L) and AAV-IRES mice (mean=0.70 mmol/L) fed lithium diets. Mice fed a 
standard chow had average serum lithium levels <0.3 mmol/L. 
 
5.3.2 Viral-mediated Deletion 
Viral vector mediated Cre recombinase expression completely deletes 
GSK3B from infralimbic cortex. The experimental vector (AAV2-CMV-Cre-
eGFP) expressed Cre fused to enhanced green fluorescent protein (eGFP) to 
allow for visualization under fluorescent microscopy. The control vector encoded 
for eGFP without Cre recombinase. The injection site was confirmed while 
GSK3B staining demonstrated complete ablation of protein expression thereby 
confirming Gsk3b gene deletion. Figure 5.6 shows representative GSK3B-
stained sections from the infralimbic cortex region (box in top of figure), with a  
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Figure 5.6 Rostral portion of Gsk3b deletion in infralimbic cortex. Rostral 
injection site with confirmed Gsk3b deletion. Target is shown at top of figure. 
Anterior Cerebral Artery (ACA) serves as a landmark. Both viruses expressed 
eGFP at green wavelength under fluorescent microscopy, while GSK3B was 
stained in the red channel.  Overlap reveals GSK3B deletion from infralimbic 
cortex (IL).  
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Figure 5.7 Caudal portion of injection site with confirmed Gsk3b deletion. 
GFP and GSK3B were in green and red channels, shown here in B&W. Corpus 
Callosum (CC) serves as landmark. Color added to merged image, again 
showing complete absence of GSK3B staining in region of virus.  
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Figure 5.8 Localization of virally encoded protein in neuronal nuclei. Cre-
eGFP fusion protein (bottom left) localizes in neuronal nuclei (NeuN) (overlap in 
bottom right), compared to cytoplasmic expression of free eGFP (top left). There 
is no evidence of neuronal toxicity in the injection site of either virus, based on 
consistent density of NeuN in injection site and surrounding region. Scale bar = 
50 µM.  
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landmark provided by the notch of the anterior cerebral artery (ACA). Additional 
sectioning in the caudal direction demonstrated viral transduction Gsk3b deletion 
in the anterior cingulate cortex, just dorsal to the decussation of the corpus 
callosum (Fig. 5.7). Co-staining with the marker of neuronal nuclei (NeuN) 
provided visualization of the localization of Cre-eGFP fusion protein to the nuclei 
of neurons, compared to apparent cytoplasmic expression of the free eGFP 
expressed by the control virus (Fig 5.8). Neither virus showed signs of neuronal 
toxicity based on the relative density of NeuN staining through the injection site. 
Despite differences in cellular localization, there did appear to be a similar rate of 
transduction among the neuronal population (based on informal GFP-positive cell 
counting per high powered field). Altogether these findings confirm our injection 
target—with complete transduction of the IL and some additional transduction of 
the mPFC—and that Cre-mediated deletion of the Gsk3bfl/fl allele was 
successful. 
 
Deletion of IL Gsk3b attenuates high-dose ethanol consumption in female 
mice. As above, mice were given continuous access to escalating doses of 
ethanol, ≥3 weeks after viral injection via stereotaxic surgery. Ethanol 
consumption (g/kg) was recorded daily in female and male mice for 5 days each 
at 3%, 6%, 10%, and 15% (w/v) ethanol. As ethanol concentration transitioned to 
the highest dose, we observed qualitatively that the Cre-injected mice, 
particularly females, showed a decrease in consumption and preference relative 
to GFP-injected mice. Daily consumption and preference readings in female and  
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Figure 5.9 Plotted ethanol intake in GFP vs Cre-injected mice. Ethanol 
consumption (intake in g/kg) and ethanol preference (volume EtOH/volume total 
fluid) over 25 days of continuous ethanol access at escalating w/v%. 
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Figure 5.10 Female mice consume less high percent ethanol following 
Gsk3b deletion in IL. Ethanol consumption and preference in female and male 
mice, assessed by 2-way ANOVA finds signification interaction of 
genotype*concentration in female mice. Fisher’s LSD finds significant effect of 
viral genotype at 15% ethanol in consumption (p=0.028) and preference 
(p=0.032).  
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male mice are shown in Figure 5.9. As for the viral-overexpression studies, 5-
day means were calculated at each ethanol concentration and mean 
consumption and preference were analyzed via two-way ANOVA with viral 
genotype and ethanol concentration (within sex) (Fig. 5.10).  
Within females, there was a significant effect of concentration 
(F3,45=65.13, p<0.0001) and genotype*concentration interaction (F3,45=2.81, 
p=0.050) on mean ethanol consumption (g/kg/day). The strong effect of ethanol 
concentration on ethanol consumption in g/kg is unsurprising given the nature of 
the variables—higher ethanol concentrations require lower intake volumes to  
achieve the same consumption by mass. However, ethanol concentration also 
showed a highly significant effect (F3,45=23.05, p<0.0001) on ethanol preference, 
measured in (mL ethanol / (mL ethanol + water). However, in this case the higher 
ethanol concentration corresponded to lower preference. Again, there was a 
signification interaction effect of genotype*concentration (F3,45=2.94, p=0.043). It 
is interesting to note that in the overexpression studies above (Fig 5.4A-B), 
genotype by itself showed a significant effect whereas for the viral deletion 
studies the effect is as an interaction with ethanol concentration. Because the 
increasing concentration, continuous access paradigm has traditionally been 
used to establish high ethanol drinking upon completion of the escalation rather 
than as multiple comparisons across each “dose” (Crabbe et al, 2011) we used 
Fisher’s LSD as a post-hoc test to assess differences at individual 
concentrations. At 15% ethanol, Cre-injected female mice were found to exhibit 
significantly lower ethanol consumption in g/kg/day (p=0.028) and lower  
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Figure 5.11 No significant taste preference differences following Gsk3b 
deletion in IL. Taste preferences were analyzed in a subset of ethanol naïve 
mice (n=8 GFP, 3 Cre). No significant differences were found for average quinine 
preference (p=0.18) over 4 days or saccharin preference (p=0.53) over a 
subsequent 4-day period. 
 
164 
 
 
Figure 5.12 LD Box assays following Gsk3b deletion in IL.. LD Box assays 
were performed on an ethanol-naïve cohort of animals and an ethanol-
experienced cohort after 24 hours of abstinence. Group numbers are given in A. 
Based on there being no observable differences across all males and females 
assessed (B), sexes were pooled in C. No significant differences were observed 
based on genotype, ethanol exposure, or interaction.  
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preference as a ratio over total fluid (p=0.032), than GFP-injected female mice. In 
male mice, ethanol concentration was the only significant effect on either ethanol 
consumption (F3,39=20.12, p<0.0001) or ethanol preference (F3,39=14.41, 
p<0.0001).  
 
Deletion of IL Gsk3b does not affect taste preference or anxiety-like 
behavior. 
 To assess for potential taste differences between viral genotypes, a 
subset of animals were given access to quinine or saccharin (Fig. 5.11). No  
qualitative differences were observed in average preference for either tastant 
over a 4-day period. Across both groups, average quinine preference appeared 
higher in this study than in the overexpression studies above (Fig. 5.5A). This 
appears to be driven by an unusually high quinine preference during Days 1-2 of 
access (Fig. 5.11A), possibly as a novelty-type effect. Regardless, taste 
preference did not appear to play a role in the observed ethanol consumption 
differences.  
 As exploratory studies of the potential role of IL GSK3B in anxiety-like 
behavior with and without ethanol exposure, we tested subsets of virally injected 
animals in the LD box (Fig. 5.12) Studies of basal anxiety (n=5 GFP, 7 Cre) were 
performed in ethanol naïve animals, 3-5 weeks post viral injection. In an 
additional subset of animals (n=9 GFP, 11 Cre), anxiety-like behavior was tested 
24 hours after the last ethanol exposure, following 34 days of continuous ethanol 
access. These studies were unbalanced in terms of sex ratio (Fig 5.12A), so  
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Figure 5.13 Novel object recognition task following Gsk3b deletion in IL. 
Novel Object Recognition tests were performed on an ethanol-naïve cohort of 
animals and an ethanol-experienced cohort after 24 hours of abstinence. Group 
numbers are given in A. Discrimination Index (DI) is the primary measure of the 
task, calculated as [(Time spent with Novel Object)-(Time spent with 
Familiar)]/Total Time. Viral genotype is indicated by “GFP” vs. “Cre,” and ethanol 
exposure by “naïve” vs “EtOH.” Based on observed similarity of DI values in the 
ethanol naïve and ethanol exposed groups (B), these were pooled in C.  
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males and females were compared overall, regardless of ethanol exposure (Fig 
5.12B).  As there appeared to be no evident sex effect, we compared basal and 
abstinence-induced anxiety without regard to sex (Fig 5.12C). There was no 
significant effect of genotype (F1,28=0.016, p=0.90), ethanol exposure (F1,28=1.5), 
or interaction (F1,28=0.466, p=0.50). Thus, unlike in the case of the 
overexpression vector, there is no evidence that Gsk3b deletion in the IL is 
associated with anxiety-like behavior, before or after long-term ethanol 
consumption.  
 
Deletion of IL Gsk3b shows suggestive impairment in Novel Object 
Recognition Task. As an additional exploratory experiment, we assessed PFC-
dependent memory function using the novel object recognition task, also in 
ethanol naïve and ethanol experienced mice (Fig. 5.13) These studies were 
underpowered to include sex as a covariate (Fig 5.13A) but as above there was 
no difference in sexes overall (t18=0.95, p=0.36) and so data was analyzed 
collapsed across sexes. We hypothesized there might be ethanol-induced 
impairments in working memory showing interaction with GSK3B deletion. 
However, observation of the data from the 4 groups shown in Figure 5.13B 
revealed qualitatively similar discrimination indexes between Cre-injected and 
GFP-injected mice regardless of ethanol exposure. Thus groups were 
additionally collapsed across ethanol exposure to compare the two genotypes 
(Fig 5.13C) and a suggestive effect (p<0.1) was found by t-test. This finding 
could indicate that GSK3B in the infralimbic cortex might be necessary for normal 
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working memory function, and in theory a learning-related mechanism could be 
related to a potential role for GSK3B in addiction. However additional 
investigation would be necessary to determine whether this is a meaningful effect 
rather than a speculative hypothesis. Overall, these studies were underpowered 
but are not the major focus of work and so we will not discuss them further.  
 
5.3.3 Tamoxifen-mediated Gsk3b Deletion 
 Having observed a subtle but significant effect on ethanol drinking in 
female mice following Cre-mediated Gsk3b deletion by a viral vector in the IL, we 
wanted to investigate an alternative approach to Cre-mediated deletion. While 
viral vectors afford a high degree of regional specificity, their cellular specificity is 
limited due to size constraints of the promoter. Selective breeding of tamoxifen-
inducible promoter-driven Cre lines with homozygous floxed animals allows for 
the ability of selective cell-specific deletion, with regional specificity dependent 
upon regional expression of the promoter. Here we compare Camk2a-Cre+ and 
Camk2a-Cre- mouse strains, both homozygous the Gsk3b-floxed allele, and both 
treated with tamoxifen. The Cre+ mice would be expected to show GSK3B 
deletion in Camk2a-expressing neurons (located throughout the forebrain) while 
the Cre- would be expected to show wild-type GSK3B expression. 
 
Validation of tamoxifen-induced Camk2a-Cre mediated deletion. 
Confirmation of GSK3B deletion was carried out after ethanol access and a 
subsequent wash-out (>1 week of ethanol abstinence). Effective Camk2a-Cre 
action had been previously validated by our group in a genetic cross with the  
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Figure 5.14 Validation of Gsk3b deletion in Camk2a+ neurons of Cre+ mice. 
GSK3B and Camk2a immunostaining in Cre+/Gsk3b fl/fl vs. Cre-/Gsk3b fl/fl mice. 
Results show highly selective loss of GSK3B staining in Camk2a+ cells of Cre+ 
mice (red arrow). GSK3B expression remained in Camk2a- cells (white arrow). 
Sections are oriented with dorsal surface of the brain upwards.  
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TdTomato reporter strain (Harris et al., unpublished). Immunostaining revealed 
highly selective loss of GSK3B in Camk2a+ neurons of Cre+ mice (Fig. 5.14). 
Cre- animals showed extensive Camk2a-GSK3B co-localization (yellow) while 
Cre+ mice showed very little overlap between green staining neurons (GSK3B-
expressing) and red neurons (Camk2a-expressing). 
 
Deletion of GSK3B in Camk2a+ forebrain neurons decreases ethanol 
consumption and preference. Given previously observed differences in GSK3B 
deletion specifically at higher concentration ethanol (15% w/v), we utilized this as 
the starting concentration animals were given in this study. Further, we were 
interested in a potential role for GSK3B in escalated drinking behavior, as seen 
under the intermittent ethanol access (IEA) paradigm (see Chapter 2.3). All mice 
were given 15% (w/v) ethanol under a continuous access schedule for 15 days 
and then switched to intermittent access 2-bottle choice for 15 days of ethanol 
access, i.e. 5 weeks of the IEA paradigm (see Fig. 5.1C).  
  Daily consumption values in g/kg were recorded for each 24-hour ethanol 
access period and are shown in Figure 5.15. Throughout this experiment, males 
and females were run concurrently and the data is shown as collapsed across 
sexes as well as split by sex (n=5-7 females per genotype, 8-10 males per 
genotype). Surprisingly female Cre- mice displayed average ethanol 
consumption at levels relatively similar to male Cre- mice through the course of 
this experiment. The potential antagonistic effect of 5-day high-dose tamoxifen  
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Figure 5.15 Daily consumption values plotted in Camk2a-Cre+ vs. Cre- 
mice. Daily consumption (g/kg EtOH) was recorded over the 30 ethanol access 
days of the experiment. The latter 15 access days of the experiment were 
recorded over 5 weeks, with 3 24h recordings per week according to the IEA 
protocol.  
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Figure 5.16 Daily preference values plotted in Camk2a-Cre+ vs Cre- mice. 
Daily preference (mL EtOH / mL total fluid) was recorded over the 30 ethanol 
access days of the experiment. The latter 15 access days of the experiment were 
recorded over 5 weeks, with 3 24h recordings per week according to the IEA 
protocol. Female Cre- mice show a high degree of variability (and the lowest n) 
but qualitatively seem to show a delayed escalation in preference following the 
switch to IEA. Overall Cre+ mice appear to drink less across both paradigms 
while still showing an escalation during the IEA paradigm.  
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treatment on subsequent ethanol drinking behavior in females is beyond the 
scope of this work but is under investigation as a separate project. 
 
 Daily preference values showed a similar pattern and are plotted in Figure 
5.16. There appear to be qualitative differences between the two genotypes 
throughout the experiment but also in the slope of escalation seen following the 
switch to IEA beginning on Access Day 16. The Cre- female mice also appeared 
to show a delayed escalation following the switch to IEA relative to the Cre+.  
 To analyze the data we attempted to maximize power while maintaining 
rigor. As an initial step we took calculated mean consumption and preference 
values per mouse during windows of interest in the experiment. For the 
continuous access period, average consumption and preference values were 
calculated over Access Days 2-15 (two weeks of continuous access). The first 
day of access is commonly dropped from ethanol-drinking studies due to novelty-
type factors leading to consistently observed outlier behavior (Chester et al, 
2006). For the intermittent access period, average consumption and preference 
values were calculated from the final week of ethanol access, to allow for 4 
weeks of potential escalation in drinking behavior. As preliminary analyses, mean 
values within males and females and within paradigms were compared in a 
series of unpaired t-tests. These comparisons are shown in terms of 
consumption in Figure 5.17A-D and preference in Figure 5.18A-D. There is a 
trend for Cre+ animals to show lower ethanol consumption and preference 
across sexes and paradigms, but the strongest differences are seen in females 
under a continuous access paradigm (t(consump, df=10)=2.43,p=0.035; t(pref,  
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Table 5.1 Results of 2-way ANOVAs of sex and genotype (Camk2a Cre+ vs 
Cre-) on ethanol drinking measures.  CONT=continuous ethanol access. 
IEA=intermittent ethanol access. GENO= genotype. Nparm=number of 
parameters.  
 
CONT 
CONSUMP 
Nparm DF Sum of 
Squares 
F Ratio Prob > F 
GENO    1 1 75.995105 4.7786 0.0380* 
SEX    1 1 26.689876 1.6783 0.2065 
GENO*SEX    1 1 2.332289 0.1467 0.7049 
 
IEA 
CONSUMP 
Nparm DF Sum of 
Squares 
F Ratio Prob > F 
GENO    1 1 75.995105 4.7786 0.0380* 
SEX    1 1 26.689876 1.6783 0.2065 
GENO*SEX    1 1 2.332289 0.1467 0.7049 
 
CONT 
PREF 
Nparm DF Sum of 
Squares 
F Ratio Prob > F 
GENO    1 1 0.18525127 6.6911 0.0156* 
SEX    1 1 0.00749241 0.2706 0.6073 
GENO*SEX    1 1 0.08025681 2.8988 0.1006 
 
IEA 
PREF 
Nparm DF Sum of 
Squares 
F Ratio Prob > F 
GENO    1 1 0.35163048 9.9205 0.0041* 
SEX    1 1 0.00008508 0.0024 0.9613 
GENO*SEX    1 1 0.00054501 0.0154 0.9023 
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Figure 5.17 Mean ethanol consumption comparisons in Camk2a-Cre+ vs 
Cre- mice. Average ethanol consumption (g/kg/day) values were compared 
during the first two weeks of the experiment (continuous access) and during the 
last week of intermittent ethanol access (IEA). A.-D. Independent unpaired t-tests 
were run within males and within females, with significant differences observed 
between Cre+ and Cre- males during IEA and females during continuous access 
(Cont) (*p<0.05). Because males and females were run together and sex was 
found not to exert a significant effect on ethanol drinking, groups were then 
analyzed by RM ANOVA with sexes pooled (E). Cre+ animals consumed 
significantly less ethanol than Cre-, during both Cont and IEA (*p<0.05). 
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Figure 5.18 Mean ethanol preference comparisons in Camk2a-Cre+ vs Cre- 
mice. Average ethanol preference (volume EtOH/total fluid) values were 
compared during the first two weeks of the experiment (continuous access) and 
during the last week of intermittent ethanol access (IEA). Independent unpaired t-
tests were run within males and within females, with significant differences 
observed between Cre+ and Cre- males during IEA and females during 
continuous access (cont) (*p<0.05). Groups were then analyzed via RM ANOVA 
with sexes pooled, and overall Cre+ animals showed significantly lower ethanol 
preference than Cre-, during both Cont and IEA (*p<0.05, **p<0.01). 
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df=10)=3.10, p=0.011) and in males under an intermittent access paradigm 
(t(consump, df=16)=2.26, p=0.038; t(pref, df=16)=2.88, p=0.011). To analyze the data 
more formally, we performed 2-way ANOVAs of genotype and sex on 
consumption and preference values within each paradigm. Results of the 2-way 
ANOVAs are shown in Table 5.1. 
 As there were no significant effects of sex or sex*genotype on any of the 
dependent variables of interest, we pooled the sexes and dropped the factor 
“sex” from our analyses, thus providing additional power to perform a 2-way RM 
ANOVA on genotype and paradigm (IEA vs CONT). These results are displayed 
in terms of consumption in Figure 5.17E and preference in Figure 5.18E. Mean 
consumption was found to be significantly affected by genotype (F1,28=6.48, 
p=0.017), paradigm (F1,28=29.08, p<0.0001), and not significantly affected by the 
paradigm*genotype interaction (F1,28=0.052, p=0.82).  Similarly, mean preference 
showed significant effects of genotype (F1,28=11.11, p=0.0024), paradigm 
(F1,28=22.56, p<0.0001), and no significant effect of the interaction (F1,28=1.31, 
p=0.26).  Fisher’s LSD post hoc comparisons found significantly lower ethanol 
consumption in Cre+ mice under continuous access (p=0.026) and IEA (p=0.046) 
and significantly lower ethanol preference in Cre+ mice under continuous access 
(p=0.027) and IEA (p=0.0011). Taken together, we conclude that GSK3B 
deletion in Camk2a expressing neurons decreases ethanol-drinking behavior 
across ethanol access paradigms. However GSK3B function in Camk2a-
expressing neurons does not appear to be necessary for an escalation in 
drinking under IEA paradigm relative to continuous ethanol access.  
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Deletion of GSK3B in Camk2a+ forebrain neurons does not alter taste 
preference, ethanol metabolism, or anxiety-like behavior.  
As described in above sections, subsets of animals under this deletion protocol 
were assessed for quinine and saccharin taste preference when provided in 
conjunction with a water bottle under a two-bottle choice, continuous access 
model (n=4/genotype) (Fig 5.19A). By unpaired t-tests, there was no significant 
difference in average quinine preference (p=0.49) but a slight suggestive 
difference in saccharin preference (p=0.093). In the latter case the mean values 
were very similar (Cre- mean±SEM: 0.928±0.006, Cre+ mean±SEM: 
0.944±0.005) but the low variance in each group might indicate that additional 
saccharin preference tests should be run with lower concentrations than 2 mM 
(0.03% w/v) to assess whether a difference in sweet preference emerges. The 
fact that the Cre+ group showed, if anything, a suggestively higher preference 
would indicate that general reward-seeking type behavior is not impaired 
following Camk2a+ neuron GSK3B deletion. 
 Blood ethanol content was measured at two time points 
(n=4/genotype/time) following an i.p. ethanol (2 g/kg) injection (Fig. 5.19B). A 2-
way RM ANOVA revealed a significant effect of time (F1,6=6.175, p=0.048) but no 
significant effect of genotype (F1,6=0.35, p=0.57) or time*genotype (F1,6=0.46, 
p=0.53). Thus tamoxifen-induced Cre expression and subsequent GSK3B 
deletion shows no evidence of altering the metabolic profile of ethanol, and 
metabolic differences do not account for ethanol consumption differences.  
 Finally, a subset of animals were tested in the LD box basally (1 week 
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Figure 5.19 Camk2a-Cre+ and Cre- mice do not differ in taste preference or 
ethanol metabolism. A. Quinine and saccharin preferences, as determined by 
volume consumed over total fluid consumption (n=4/group, p>0.05). B. Blood 
ethanol levels at 60 or 120 minutes following an i.p. injection of ethanol (2 g/kg) 
(n=4/group, ANOVA p>0.05 for Cre- and Cre+ at either time point). 
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Figure 5.20 Camk2a-Cre+ and Cre- mice do not differ in locomotor 
behavior. Cre- and Cre+ mice do not show significant differences in locomotor 
behavior. LD Box assays were performed on an ethanol-naïve cohort of animals 
and an ethanol-experienced cohort after 24 hours of abstinence. Group numbers 
are given in A. Based on there being no observable differences across all males 
and females assessed (B), sexes were pooled in C.  
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after completion of tamoxifen treatment) and a separate cohort tested upon 
ethanol abstinence (24 hours after last ethanol access, following >5 weeks of 
IEA). These experiments are displayed in Figure 5.20. As before, sexes were 
unbalanced but we did not see any evident differences by sex, and subsequently 
pooled the animals to again find no significant differences in anxiety-like behavior 
(Fgenotype(1,15)=0.032, p=0.86; Ftreatment(1,15)=0.38, p=0.55; Fgenotype*treatment=0.84, 
p=0.37), as measured by %time in the light. There is a notable qualitative 
difference in the mean %time in light in the tamoxifen-treatment experiment 
overall, compared to mean %time in light of the virally injected animals overall 
(see Figure 5.12).  
 
5.4 Discussion 
 While the magnitude of effect varied across methods of gene modulation 
and the specifics of the paradigm used for assessment, there was a striking 
consistency in the directionality of the effect of GSK3B expression on ethanol-
drinking. When expression was increased by use of an exogenous-Gsk3b gene 
expressing vector applied to mPFC of male mice, ethanol consumption and 
preference increase markedly at multiple ethanol concentrations (6%, 10%, 15% 
w/v). When expression was decreased by Gsk3b deletion in the IL portion of the 
mPFC via viral-mediated Cre expression in floxed animals, ethanol consumption 
and preference decrease selectively at high ethanol concentration (15% w/v), in 
female mice specifically. When Cre was induced in a specific forebrain neuron 
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population (Camk2a-positive) via tamoxifen induction, ethanol consumption and 
preference decreased at a high ethanol concentration (15% w/v) among male 
and female mice, whether ethanol was administered continuously or under an 
IEA schedule. 
 The effects of viral deletion in the IL were rather minimal when compared 
with the effects seen with mPFC over-expression. While it may be that there is 
simply a fundamental difference between increasing GSK3B and deleting it, there 
are several specific contributing factors that could account for the difference in 
effect magnitude. The overexpression vector was injected (by Annie Meng) at a 
volume of 1.0 µL per hemisphere, while the Cre-expressing deletion vector was 
injected at 0.7 µL per side, in an effort to increase specificity of the injection site. 
As a rough estimate, an injection results in a bolus of about 1 mm3/uL, and so in 
total 0.6 mm3 of additional cortex might be expected to have been exposed to the 
overexpression virus. Similarly, the target site used by Meng was selected to be 
the anterior cingulate cortex (ACC) portion of the mPFC, with tracking into the 
rostral mPFC (IL cortex) whereas the deletion vector was injected directly into the 
IL. Both the ACC and IL have been implicated in ethanol-seeking behavior (Gass 
et al, 2014; Gremel et al, 2011), but it may be that GSK3B function in the ACC 
exerts a stronger effect on ethanol-drinking behavior than the IL. Alternatively, it 
could be that GSK3B overexpression in male mice allowed for stark increases in 
consumption and preference, whereas GSK3B deletion, particularly in males, 
was simply subject to a floor effect. As pointed out in the text, male mice in the 
viral deletion study showed atypically low drinking for C57BL/6J mice. To this end 
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it may also be noted that possible subtle genetic effects can be carried in 
transgenic animals, given unintentional effects of LoxP site insertion or persistent 
loci from other lab strains despite several generations of inbred back-crossing. All 
this aside, it remains remarkable that both overexpression and deletion of 
GSK3B in mPFC produced significant effects on ethanol drinking, and in opposite 
(complementary) directions.  
 The mPFC is a component of the mesocorticolimbic reward pathway, 
receiving dopaminergic input from the ventral tegmental area (VTA) as well as 
thalamic-mediated input from other subcortical basal ganglia structures 
(Tzschentke, 2000). In turn, the mPFC projects efferents to the nucleus 
accumbens and back to the VTA (Sesack and Pickel, 1992). Given that GSK3B 
has been shown to be activated by dopamine signaling, particularly downstream 
of D2-receptor activation (Beaulieu et al, 2004), it could be asked if increasing 
prefrontal cortical GSK3B is effectively a means of amplifying the dopaminergic 
signal as it cycles through the mPFC along the reward pathway. That is, if certain 
actions of ethanol which produce increases in dopaminergic signaling through 
the mPFC are responsible for its induction of ethanol-seeking behavior, and 
increased GSK3B serves to somehow enhance these actions, ethanol-seeking 
behavior is in turn increased. Similarly, GSK3B deletion in the IL could effectively 
blunt any dopamine-dependent signal which traverses through the IL, based on 
the inability of D2 receptors in this region to activate GSK3B. A similar 
mechanism could also explain the suggested impairment in the novel object 
recognition task following GSK3B deletion in the IL (Fig 5.13), given the crucial 
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role of dopaminergic signaling in the IL, and mPFC generally, for working 
memory (Cassaday et al, 2014). 
If this model accounts for the effects observed here, then selective means 
of increasing or deleting GSK3B in dopamine D2 receptor expressing neurons in 
the mPFC would be expected to show identical or very similar to the effects on 
drinking behavior as those observed here. As discussed in the introduction, mice 
with D2-receptor positive deletion of GSK3B show an attenuation of 
amphetamine-induced hyperlocomotion (Urs et al, 2012) but have not been 
tested for ethanol-related behaviors. Additionally, the mice described in Urs et al. 
express GSK3B deletion through all D2-positive neurons in the brain, without 
region specificity. Therefore these mice would only be expected to mimic the 
PFC-deletion mice insofar as GSK3B in other brain regions is not antagonistic to 
its role in the PFC.  
Dopamine D2 receptors could identify an afferent pathway to the mPFC. 
Questions remain as to how the dopamine signal is translated intracellularly and 
how it is propagated to efferent projections. CAMKIIα (encoded by Camk2a) may 
provide at least a partial answer. CAMKIIα is a marker of pyramidal glutamatergic 
neurons, which make up the principle output of the mPFC (Warthen et al, 2016). 
CAMKIIα autophosphorylation has been found to contribute to ethanol-drinking 
behavior, as mice expressing CAMKIIα with a mutation in its autophosphorylation 
site show decreased initial ethanol preference and an absent locomotor-
activating effect, compared to wild-type mice (Easton et al, 2013). Moreover 
these αCaMKIIT286A mice show no dopamine response in the nucleus 
185 
 
accumbens following acute or subchronic ethanol administration. It may be 
concluded that this protein plays a crucial part in the dopaminergic reward 
pathway via the functioning of glutamatergic projection neurons from the mPFC. 
Is it possible that active GSK3B normally serves to modulate the afferent signal 
of glutamatergic projections? There is only evidence of CAMKII-mediated 
phosphorylation of GSK3B (Song et al, 2010), not the reverse. We would 
speculate that feedback phosphorylation of GSK3B onto CAMKIIα is a possible 
means of regulation open to exploration. However, GSK3B could serve to 
modulate glutamatergic projections onto the reward circuit whether it is via 
CAMKIIα or some other downstream target which is also expressed in pyramidal 
projection neurons. It would be interesting to assess the ethanol-induced 
dopamine response in the NAC of mice with a Camk2a-neuron GSK3B deletion, 
as described by Easton et al. (2013) to determine whether GSK3B deletion 
exerts a similar effect to CAMKIIα autophosphorylation deficiency.  
 Altogether the data presented in this chapter make a compelling case that 
the high levels of ethanol drinking observed in C57BL/6J mice depend to some 
degree on intact cortical GSK3B function. Active GSK3B may contribute to the 
maintenance of ethanol reward-related behavior, such that its overexpression 
corresponds to sustained increases in consumption and preference, and its 
deletion corresponds to relatively low levels of ethanol self-administration.  
Notably we have identified a substantial role for GSK3B function specifically in 
Camk2a-positive, glutamatergic pyramidal neurons in mediating ethanol drinking 
behaviors.  
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Chapter 6  
Potential Translational Application of GSK3B Inhibitors 
 
6.1 Introduction 
 It is generally agreed that current treatments for Alcohol Use Disorder 
provide only modest efficacy (Batman and Miles, 2015; Franck and Jayaram-
Lindstrom, 2013). While there are varied definitions of treatment efficacy, such as 
strict abstinence vs. avoidance of problem-drinking (Sanchez-Craig and Lei, 
1986), all major AUD treatment studies have reported a treatment nonresponse 
rate of at least 30% (Naqvi and Morgenstern, 2015). It would seem a major 
portion of patients with AUD are lacking any effective therapy.  
 A better understanding of the neurobiology of alcohol’s effects on the brain 
is what has allowed for the incremental progress in pharmacologic treatment 
options to date (Batman et al, 2015). Naltrexone and Acamprosate were 
developed into AUD treatments due to their targeting receptors in the ethanol-
reward pathway—u-opioid receptors in the former case, NMDA-receptors in the 
latter—with the effect of blocking aspects of craving and withdrawal induced by 
ethanol’s dysregulation of this circuitry (Franck et al, 2013). Based on the 
observations outlined in Chapters 4 and 5, we propose that GSK3B might itself 
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underlie aspects of ethanol’s dysregulation of the mesocorticolimbic reward 
circuitry. Therefore specific GSK3B inhibitors represent a novel avenue of 
investigation for AUD treatment.  
 Thiadiazolidinones (TDZDs) were developed as the first non-ATP 
competitive GSK3B inhibitors (Martinez et al, 2002). Non-ATP competitive refers 
to the fact that TDZDs do not target the ATP-binding pocket, which is highly 
conserved across protein kinases (Garuti et al, 2010). TDZDs are instead 
thought to interact directly with the GSK3B enzymatic active site, possibly 
through covalent bonding with Cys-199 (Dominguez et al, 2012; Eldar-Finkelman 
and Martinez, 2011), and stabilization of the inhibitory phosphorylation of Ser-9 
(Zhang et al, 2003).  
 One member of the TDZD family, TDZD-8, has been used extensively in 
the literature with findings relevant to neuropsychiatric dysfunction (Beaulieu et 
al, 2008; Storozheva et al, 2015; Yen et al, 2015). Beaulieu et al. (2008) found 
that TDZD-8 reversed behavioral deficits observed in Tph2 knockin mice showing 
serotonin deficiency, without exerting significant effects on wild-type (WT) mice. 
Observed behavioral effects included reduction in immobility times in the tail 
suspension test and a decrease in anxiety-like behavior in the light-dark 
emergence test (to levels comparable with WT) (Beaulieu et al, 2008). While 
these Tph2 mice have subsequently shown increased ethanol preference (Sachs 
et al, 2014), the effect of GSK3B inhibition has not been assessed in relation to 
this behavior. 
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 Previous work by our laboratory demonstrated significant effects of TDZD-
8 on ethanol-related behaviors. Angela Batman and Michael Scott Bowers tested 
multiple doses (1, 3, 10 mg/kg, i.p.) of TDZD-8 in operant responding 
experiments in Wistar rats (van der Vaart et al, 2018). The 3 mg/kg and 10 mg/kg 
doses decreased responding for ethanol as measured by active (ethanol-paired) 
lever presses. TDZD-8 was also found to inhibit sucrose responding as 
measured by sucrose-paired lever presses during the reinforcement period. 
However, following a 3-week abstinence period, both ethanol-trained and 
sucrose-trained rats were reintroduced to the operant chamber for a cue-induced 
reinstatement task. TDZD-8 (3 mg/kg) essentially abolished cue-induced 
responding in the ethanol trained animals while showing no significant effect on 
responding in the sucrose trained animals. Thus, in the context of cue-induced 
reinstatement, TDZD-8 showed ethanol-specific effects. This finding carries 
strong potential implications, given the relation between cue-induced 
reinstatement and relapse-like behavior (Vengeliene et al, 2006).  
Intermittent ethanol access (IEA) also relies on repeated cycles of ethanol 
exposure and abstinence, and has been shown to increase consumption relative 
to continuous access (Rosenwasser et al, 2013). We have used the IEA model in 
experiments on the Phase II approved TDZD-family drug tideglusib (Lovestone et 
al, 2015). These experiments are described in the following chapter, beginning 
with a pilot study using the effective doses of TDZD-8 derived from the Batman 
studies (3, 10 mg/kg), and followed by oral tideglusib at 200 mg/kg, the gavage 
dose used in other pre-clinical studies of this drug (Bharathy et al, 2017; Sereno 
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et al, 2009) that have, for example, shown alterations of GSK3B-dependent tau 
protein phosphorylation. We set out with the hypothesis that tideglusib would 
decrease self-administration of ethanol, based on results described in Chapters 
4-5, with corresponding alterations in synaptic function. Thus, we have also 
tested the effects of tideglusib (200 mg/kg) on phospho-PSD95-T19 and 
GABAAα1 expression. GABAAα1 expression was chosen as a proxy for 
measuring the effects of GSK3B on GABAAR trafficking  (Tyagarajan et al, 2011).  
  Finally, as a human correlate to our studies of small molecule inhibitors in 
pre-clinical AUD treatment studies, we discuss here the employment of publicly 
available gene expression data from human alcoholic patients (McClintick et al, 
2014) combined with the NIH Library of Integrated Network-Based Cellular 
Signatures (LINCS) Characteristic Direction Signature Search Engine 
(L1000CDS) (http://www.lincsproject.org/) and the integrated pathway 
enrichment tool Enrichr (http://amp.pharm.mssm.edu/Enrichr/) (Duan et al, 2014; 
Duan et al, 2016). The NIH LINCS consortium catalogs changes in gene 
expression across cell-lines occurring following a variety of perturbing agents, 
including small molecule inhibitors (Keenan et al, 2018). The L1000CDS allows 
for input gene expression data in the form of up- and down- regulated gene lists, 
and searches the database for perturbing agents which either mimic or reverse 
the input gene expression profile (Duan et al, 2014). We performed unbiased 
analyses using gene expression data from lymphoblastic cell lines (LDLs) from 
alcoholic vs non-alcoholic patients (McClintick et al, 2014) and the L1000CDS2 
under advisement from Dr. Matthew Reilly, who also provided the author with 
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generous support during the F grant application process. Dr. Reilly used 
McClintick et al. (2014) gene lists in queries of the initial LINCS database, and 
contacted us about GSK3A/B inhibitors as highly ranked candidates for “reversal” 
of the alcoholic gene expression signature. We subsequently queried the 
updated L1000CDS2 (Duan et al, 2016) and found that kenpaullone, a GSK3B 
and cyclic-dependent kinase inhibitor, showed the highest reversal score in the 
database. At the time of this writing tideglusib has not been profiled in the LINCS.  
 
6.2 Materials and Methods 
Preparation of Solutions. In the pilot study using i.p. tideglusib, drug was 
suspended in a vehicle of 10% DMSO, 5% Tween-80 and 85% phosphate-
buffered saline, to final volumes of 0.3 mg/ml and 1 mg/mL. In gavage studies, 
tideglusib was suspended in 26% peg-400, 15% Cremophor, and water, to 20 
mg/mL. In both cases vials were placed in a sonicator heat bath (Branson) and 
heated to 40 degrees with sonication for 30-60 min. The formulations used for i.p. 
studies would show initial dissolution, but precipitated into uniform suspension 
after several minutes at room temperature.  The formulation used for gavage was 
vortexed and large clumps of drug manually dispersed if necessary (using a 
spatula) before placement in the bath sonicator. Ethanol was prepared weekly to 
20% v/v in tap water for use in IEA experiments. 
Intermittent Ethanol Access (IEA). The IEA paradigm has been discussed 
previously (See Figures 4.1 and 4.2. The latter outlines the precise paradigm 
used in the gavage study on ethanol-drinking described here). Briefly, all animals 
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in ethanol-drinking studies received access to water during the entire course of 
the experiment. On Mondays, Wednesdays, and Fridays, at the beginning of the 
dark cycle, one ethanol tube was placed directly beside one water tube for a 24 
hour access period. Placement sides were alternated to avoid side preference 
interactions. A recording of volume change on each tube was always made at the 
end of the 24 hour access period. During the tideglusib-gavage study, there were 
also 2-hour readings recorded.  
Tideglusib Treatments. In the i.p. study, habituation to saline injections was 
begun after 4 weeks of ethanol consumption. Mice were injected with 10 mL/kg 
(0.01 mL/g) of saline as before each ethanol access for 5 ethanol access days, at 
which point ethanol-drinking volumes were confirmed as returning to near 
baseline. Beginning at week 6, mice (n=6-7/treatment group, all male) received 
either tideglusib (3, 10 mg/kg), vehicle, or saline. The saline group was included 
to assess for potential effects of the DMSO- and Tween-80- containing vehicle. 
I.p. injections were administered 30 minutes before each ethanol access period 
began, over 5 ethanol access days. One mouse had an adverse reaction to i.p. 
(vehicle), was euthanized, and all data was excluded from the experiment. Upon 
analyzing the data, one mouse was found to be an outlier based on average 
ethanol consumption over the first 4 weeks of the experiment (Grubbs test, 
p<0.05) and was removed from all analyses. 
 In the gavage study, habituation to gavage was begun after 3 weeks of 
IEA. Saccharin (0.2% w/v) was initially used to train the mice to accept the 
feeding tube. Gavage needles were stainless steel, 20 gauge animal feeding 
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needles (Cadence Science, Cranston, RI). After 3 days of saccharin gavage 
before each ethanol access period, vehicle was administered as pre-treatment 
for two ethanol access days. Tideglusib treatment began at the 6th week of IEA. 
Male and female mice (n=10/sex/treatment) all received tideglusib (200 mg/kg) or 
vehicle. Tideglusib was delivered as a 20 mg/mL solution at approximately 0.01 
ml / g body weight. For example a mouse of 25.0 g (0.025 kg) would be gavaged 
0.25 mL. Ethanol bottles were placed all mouse cages for the 30 min – 1 hr 
period after all mice were gavaged. One mouse (female, tideglusib) had an 
adverse reaction to gavage and was excluded from the experiment.  
 A separate cohort (n=7/treatment, all male) of C57BL/6J mice were 
treated with either tideglusib (200 mg/kg) or vehicle exactly as described above, 
but kept completely ethanol-naïve. Tideglusib treatments were administered on 
Mondays, Wednesdays, and Fridays for two weeks, to assess for the effect of 
repeated tideglusib treatment by itself on phospho-protein levels in PFC. These 
mice were harvested over a 2 hour period, beginning 2 hours after the last 
tideglusib gavage on the sixth treatment day (end of week 2).  
Tissue Collection. Mice were sacrificed by cervical dislocation and decapitation. 
Brains were extracted and submerged in PBS on ice for 1 minute. Brains were 
then rapidly dissected into regions of interest including the medial PFC as a 
wedge surrounding the sagittal fissure, after having made vertical coronal cuts 
just rostral to the optic chiasm and just caudal to the frontal poles (Kerns et al, 
2005a). The PFC and other regions were immediately frozen on liquid nitrogen 
and subsequently stored at -80° C until further studied.   
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Western Blotting. Tissue was homogenized on ice by suspension RIPA buffer, 
made up of 50 mM Tris, 150 nM NaCl, 1% NP40, 5 mM EDTA, and 0.5% sodium 
deoxycholate in distilled H2O, with 1X Halt protease and phosphatase inhibitor 
cocktail (Thermo Fisher, Waltham, MA) added immediately before 
homogenization on ice with probe sonication. Total protein concentration for all 
samples was determined using a Pierce BCA Protein Assay Kit (Thermo), to 
allow for equal protein loading. Immunoblotting was performed using an Xcell 
Surelock Mini-Cell kit (Thermo). Tissue homogenates were denatured with 
NuPage LDS Sample buffer and Sample Reducing Agent (Thermo) and heated 
at 70° C for 10 minutes. Samples were separated via electrophoresis at 180 V for 
X hours on precast NuPage 4%-12% Bis-Tris 1 mm 17-well gels (Thermo) at 
room temperature, followed by transfer onto PVDF membrane at 12 V, at 4° C. 
Membranes were blocked with bovine serum albumin (5%). They were then 
incubated overnight at 4° C in primary antibody: 1:500 rabbit anti phospho-PSD-
95-T19  (Abcam ab16496, Cambridge, MA), 1:1000 rabbit GABAAα1 (Synaptic 
Systems cat# 224 203, Goettingen, Germany), or 1:1000 rabbit p-GSK3B (Cell 
Signaling cat# 5558, Danvers, MA). Following incubation membranes were 
washed extensively in TBS-T and incubated in 1:15000 (in 1% BSA in TBS-T) 
Amersham ECL donkey anti-rabbit IgG, HRP-linked antibody (GE Healthcare, 
Chicago, IL) for 1 hour at room temperature. Membranes were again washed in 
TBS-T. Membranes were incubated in ECL Prime (GE Healthcare) for 5 minutes 
before being exposed to GeneMate Blue Ultra Autorad film (BioExpress, Kayville, 
UT). Multiple exposure were obtained to insure linearity of the response. Blots 
194 
 
were stripped using Restore Stripping Buffer (Thermo) before re-staining for total 
proteins using 1:1000 rabbit anti-PSD95 (Thermo cat# 51-6900), 1:2000 total 
GSK3B (Cell Signaling cat# 9315), and 1:10000 mouse anti-B-actin (Sigma-
Aldrich cat# A5316, St. Louis, MO). Subsequent steps were repeated exactly as 
before except in the case of the B-actin stained membrane, which being a mouse 
antibody required the HRP-linked secondary antibody Amersham ECL sheep 
anti-mouse IgG (GE Healthcare). All films were scanned using a flatbed scanner 
and analyzed using densitometric analysis with ImageJ (NIH).   
Ethanol Metabolism. Male C57BL/6J mice (n=25) were treated with 200 mg/kg 
tideglusib or vehicle and 30 minutes later injected with 2.0 g/kg ethanol, and 
blood was collected via submandibular cheek punch at 10, 30, 60, and 90 minute 
time points (n=3-4/treatment/time). Blood was collected in BD microtainer tubes 
containing EDTA (Fisher Scientific, Waltham, MA) to prevent clotting and stored 
at -20 degrees Celsius until analysis. Blood Ethanol Concentrations assessed in 
this Chapter were obtained by Justin Poklis and the VCU Analytics Core using 
headspace gas chromatography (O'Neal et al, 1996).  
NIH LINCS Analysis of Alcoholic Patient Cellular Signatures. McClintick et al. 
(2014) collected and cultured lymphoblastoid cell lines (LCLs) derived from 
peripheral blood mononucleocytes of alcoholic patients and controls 
(n=21/group). Cultured cell lines were assessed for differentially regulated genes 
by subsequent microarray profiling (McClintick et al, 2014). Ninety-nine percent 
of differentially regulated genes were also found to be expressed in brain. The 
authors generated lists of up- and down-regulated genes and annotated those 
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which were also previously identified in expression studies in post-mortem brain 
samples of alcoholic patients (McClintick et al. 2014, Supplementary Table 2). 
We filtered the table for all genes with at least one annotation to create “master-
lists” of externally validated genes, which were used as our input lists of up- and 
down-regulated genes in L1000CDS2 (http://www.lincsproject.org/). The 
L1000CDS2 is a search engine which treats the input as a gene expression 
signature, and then searches the LINCS database for signatures which reverse 
the input signature. To identify signaling pathways overrepresented in our input 
data, we ran the Enrichr tool (http://amp.pharm.mssm.edu/Enrichr/) on our input 
gene lists . PubChem (https://pubchem.ncbi.nlm.nih.gov/) was used to identify 
targets of output compounds.      
 
6.3 Results 
Tideglusib (i.p.) decreases ethanol consumption from baseline. Male 
C57BL/6J mice (n=6-7/treatment group) were given 4 weeks of IEA before 
habituation to saline injections was begun. Baseline consumption was calculated 
as the mean consumption over the 3 weeks before saline habituation (Fig 6.1A, 
“Baseline”). During saline habituation, ethanol consumption dropped but returned 
to baseline levels or above after more than a week (data not shown). Animals 
were then pre-treated with either saline, vehicle, or tideglusib (3 mg/kg or 10 
mg/kg) before each ethanol access period for 5 ethanol access days. Mean 
consumption and preference values are shown in Figure 6.1A-B. To assess the 
effect of tideglusib during the treatment period as well as relative to baseline 
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consumption for each group, we used a two-way RM ANOVA to test the effects 
of “group assignment” and “treatment period.” The effect of tideglusib is therefore 
the measured as the interaction between group assignment and treatment 
period. The effect of i.p. injection by itself regardless of treatment type is 
assessed by “treatment period”. Groups were assigned randomly and thus there 
would be no expected effect of “group assignment” during baseline. Two-way RM 
ANOVA of ethanol consumption (Fig. 6.1A) revealed a significant effect of the 
interaction (F3,21=7.67, p=0.0012), as well as treatment period (F1,21=7.07, 
p=0.014). There was no effect of group assignment (F3,21=0.082, p=0.97). By 
Sidak’s post hoc test, there was a significant effect of the 10 mg/kg tideglusib 
dose during treatment compared to baseline (p<0.001). Two-way RM ANOVA on 
mean ethanol preference (Fig. 6.1B) did not find a significant effect of treatment 
period (F1,21=2.90, p=0.10), group assignment (F3,21=0.41, p=0.74), or the 
interaction (F3,21=2.24, p=0.11). Because of the observed variation in mean 
ethanol consumption during baseline (no-treatment) drinking, we calculated 
mean %change from baseline consumption values for each mouse and took the 
means of these by group (Fig. 6.1C). One-way ANOVA of mean %change from 
baseline found a highly significant effect of treatment (F3,21=10.12, p=0.0003). 
Sidak’s multiple comparisons test found significant differences between the 3 
mg/kg dose and vehicle (p<0.05) and the 10 mg/kg dose and vehicle (p<0.001).  
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Figure 6.1 Results of i.p. tideglusib during the 6th week of IEA. (n=6-7/group). 
Baseline is average daily ethanol intake for the 3 weeks prior to the habituation 
period. Treatment is mean ethanol intake over 5 days of i.p. tideglusib pre-
treatment. A. Two-way RM ANOVA on mean consumption finds significant effect 
on the interaction of “group assignment” and “treatment period” (p<0.005). 
Sidak’s post hoc test finds that 10 mg/kg tideglusib significantly decreases 
consumption relative to baseline (***p<0.001). B. Two-way RM ANOVA on mean 
preference finds no significant effect of group assignment, treatment period, or 
the interaction. C. One-way ANOVA of % change from baseline finds significant 
effect of treatment (p<0.001). Sidak’s post hoc tests find that the 3 mg/kg dose 
and 10 mg/kg dose both differ significantly from vehicle (*p<0.05, ***p<0.001).  
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Daily consumption and preference show altered trends during gavage 
treatment. Because of potential confounds from insolubility of tideglusib powder 
in an i.p. suspension as well as increased preclinical applicability of an oral drug  
delivery, we used gavage as an alternative administration approach. For this oral 
tideglusib experiment, mice (n=9-10/sex/treatment) were given a 3-week baseline 
consumption period, and subsequently gavaged with saccharin (0.2% w/v) for 3 
days and vehicle (26% peg-400, 15% cremophor) for 2 days subsequently. 
Ethanol bottles were placed on cages immediately upon the start of the dark 
cycle (Mondays, Wednesdays, and Fridays). Through the course of the 
experiment, ethanol (20% v/v) and water intake were recorded 2 hours into the 
ethanol access period using a red lamp, and again at 24 hours after access (the 
end of the following light cycle).  
Consumption and preference values at the 2-hour, “binge,” time point are 
plotted in Figure 6.2., and the 24-hour daily consumption and preference values 
are plotted in Figure 6.3. Across all measures it can be observed that at the 
beginning of each gavage (saccharin on day 10, vehicle on day 13) there is a 
trend of decreased ethanol intake for all animals. By the second day of each 
gavage these values generally restore to within the range previously observed. 
However it can be seen from the binge preference data (Fig. 6.2C-D) that there 
is an overall decrease in ethanol preference beginning with vehicle habituation 
through the remaining course of the experiment. Because this effect is much 
more pronounced in the preference data than the ethanol consumption data (Fig 
6.2A-B), it could be inferred that increased water consumption following vehicle  
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Figure 6.2 Daily consumption and preference during the 2-hour binge 
(gavage study). Mice (n=9-10/treatment/sex) were monitored over 19 ethanol 
access days. Mice assigned to the Vehicle group are in black, the Tideglusib 
group in green. Color coding on X-axis is also given in key. Treatment period is 
Access Days 15-19. A. Ethanol intake (g/kg) in male mice. B. Ethanol intake 
(g/kg) in female mice. C. Ethanol preference (mL ethanol / mL total fluid) in male 
mice. D. Ethanol preference (mL ethanol / mL total fluid) in female mice.  
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Figure 6.3 Daily consumption and preference during 24-hour access 
(gavage study). Mice (n=9-10/treatment/sex) were monitored over 19 ethanol 
access days. Mice assigned to the Vehicle group are in black, the Tideglusib 
gavage group in green. Color coding on X-axis is also given in key. Treatment 
period is Access Days 15-19. A. Ethanol intake (g/kg) in male mice. B. Ethanol 
intake (g/kg) in female mice. C. Ethanol preference (mL ethanol / mL total fluid) in 
male mice. D. Ethanol preference (mL ethanol / mL total fluid) in female mice.  
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pre-treatment may be driving this effect (see Figure 6.4, discussed in following 
section).  
Groups had been assigned to minimize potential chance group differences 
based on rank order of ethanol consumption (24-hour) during baseline drinking 
(first 3 weeks of experiment). During the gavage habituation period, group 
members were selectively re-assigned in an attempt to minimize group 
differences both during baseline and during subsequent gavage habituation, so 
that groups were roughly equivalent on as many measures as possible when 
tideglusib vs. vehicle treatment began.   
Oral tideglusib markedly decreases binge-like ethanol consumption. 
Analyses were performed using a two-way RM ANOVAs to determine the effects 
of group assignment, treatment period, and the [group assignment * treatment 
period] interaction. The last of these effects is the variable of interest: the effect 
of tideglusib (200 mg/kg by gavage) during the treatment period. A main effect of 
treatment period indicates the effect of oral gavage by itself relative to baseline, 
regardless of treatment.  
 All results from the 2-hour binge period are displayed in Figure 6.4. In 
male mice, 2-hour binge consumption (Fig. 6.4A) showed significant effects from 
the interaction (F1,18=15.71, p=0.0009), treatment period (F1,18=14.05, p=0.0015), 
and group assignment (F1,18=11.03, p=0.0038). Sidak’s post hoc revealed no 
effect of tideglusib group assignment during baseline (p=0.99) and a highly 
significant effect of tideglusib during the treatment period (p<0.0001). In female 
mice, 2-hour binge consumption (Fig. 6.4B) showed significant effects from the  
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Figure 6.4 Tideglusib (200 mg/kg) decreases mean binge ethanol 
consumption. Mean binge (2 h) consumption and preference (n=9-
10/treatment/sex) during baseline (3 weeks of IEA prior to gavage habituation) 
and treatment (5 days of pre-treatment with tideglusib before each access 
period). A. Tideglusib attenuates binge consumption (g/kg/day) in male mice. 
There was a significant effect (p<0.01) of “group assignment * treatment period” 
by 2-way RM ANOVA. Tideglusib group assignment showed no effect during 
baseline consumption and a significant effect during the treatment period 
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(****p<0.0001). B. Tideglusib attenuates binge consumption (g/kg/day) in female 
mice. There was a significant effect (p<0.01) of “group assignment * treatment 
period” by 2-way RM ANOVA. Tideglusib group assignment showed no effect 
during baseline consumption and a significant effect during the treatment period 
(**p<0.01). C. Tideglusib attenuates ethanol preference (mL ethanol / mL total 
fluid) during the binge period in male mice. There was a significant effect 
(p<0.05) of “group assignment * treatment period” by 2-way RM ANOVA. 
Tideglusib group assignment showed no effect during baseline consumption and 
a significant effect during the treatment period (*p<0.05). D. Tideglusib does not 
alter significantly alter ethanol preference during the binge period in female mice. 
The effect of treatment period (gavage itself) was highly significant (p<0.0001) 
but the interaction with tideglusib was not significant (p=0.28). E-F. Significant 
increases in water consumption during the binge period after gavage pre-
treatment. Males (E) show significant effect of treatment period (p<0.0001) but no 
interaction with group assignment (p=0.95). Females (F) also show significant 
effect of treatment period (p<0.0001) but no interaction with group assignment 
(p=0.90).  
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interaction (F1,17=9.58, p=0.0066) and treatment period (F1,17=10.61, p=0.0046), 
and non-significant effect of group assignment (F1,17=4.13, p=0.058). Sidak’s post 
hoc revealed no effect of tideglusib group assignment during baseline (p=0.97) 
and a significant effect of tideglusib during the treatment period (p=0.0027).  
 In male mice, 2-hour binge preference (Fig. 6.4C) showed significant 
effects from the interaction (F1,18=6.60, p=0.019), treatment period (F1,18=63.56, 
p<0.0001), and no effect of group assignment (F1,18=2.77, p=0.11). Sidak’s post 
hoc revealed no effect of tideglusib group assignment during baseline (p=0.99) 
and a significant effect of tideglusib during the treatment period (p=0.012). In 
female mice, 2-hour binge preference (Fig. 6.4B) showed a highly significant 
effect of treatment period (F1,17=27.64 p<0.0001), but no significant effects of 
group assignment (F1,17=2.14, p=0.15), or interaction (F1,34=11.44, p=0.337). 
Thus in both cases the pre-treatment with gavage, regardless of whether it 
contained tideglusib or vehicle, altered ethanol preference markedly compared to 
baseline. During baseline treatment, ethanol preference approached 1.0, 
indicating no water intake in the first 2 hours after ethanol access. However pre-
treatment with gavage seemed to induce significant water intake during the binge 
period. Indeed volume of water consumed during the binge period is plotted in 
Figure 6.4E-F, and shows significant effects of treatment period in males 
(F1,18=33.83, p<0.0001) and females (F1,17=27.34, p<0.0001). Importantly, in 
neither group was there an effect of tideglusib on water consumption. Males 
showed no effect of group assignment (F1,18=0.062, p=0.81) or the interaction of 
group assignment * treatment period (F1,18=0.0042, p=0.95). Females similarly  
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Figure 6.5 Effects of tideglusib (200 g/kg) on mean daily ethanol 
consumption.  A. In male mice there was a significant effect of treatment period 
(gavage itself, p<0.001), but no significant effects of group assignment or the 
interaction. B. In female mice there was also a significant effect of treatment 
period (p<0.001) but no significant effect of group assignment or the interaction. 
C. When males and females were collapsed and assessed by 2-way ANOVA of 
sex and treatment (within the treatment period only), both sex (p<0.0001) and 
tideglusib treatment (p<0.05) were significant effects. Fishers post hoc test found 
a suggestive effect of tideglusib in male mice (p<0.1) but not within female mice.  
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showed no effect of group assignment (F1,17=0.0075, p=0.93) or the interaction 
(F1,17=0.016, p=0.90). Thus either the act of gavage or the vehicle used to 
administer the drug induced significant water intake in the 2-hour period after 
ethanol access, but this effect was unrelated to tideglusib.  
 
Oral tideglusib slightly decreases 24 hour ethanol consumption. From 
Figures 6.2-6.4 it can be seen that there is a less pronounced effect of tideglusib 
gavage on ethanol consumption measured at the end of each 24 hour access 
period compared to the effect in the 2 hour binge period. We first analyzed 24 
hour binge consumption using the same two-way RM ANOVA design described 
above.  Results are displayed in Figure 6.5A-B. In male mice, there was a 
significant effect of treatment period (F1,18=20.34, p=0.0003) and no significant 
effects of group assignment (F1,18=2.55, p=0.13) or the interaction (F1,18=2.28, 
p=0.15). In female mice there was also a significant effect of treatment period 
(F1,17=22.56, p=0.0002) and no significant effects of group assignment 
(F1,17=0.39, p=0.54) or the interaction (F1,17=1.91, p=0.18). As both females and 
males showed a decrease in mean ethanol consumption during the treatment 
period, and the animals were run concurrently, we collapsed across sexes to 
increase our power for detecting the effect of tideglusib (Fig. 6.5C). We 
performed a two-way ANOVA to test sex and treatment within the treatment 
period. This analysis showed a highly significant effect of sex (F1,35=37.74, 
p<0.0001) and a significant effect of treatment (F1,35=5.12, p=0.030). Post hoc 
testing using Fisher’s LSD found a suggestive effect in males (p=0.072) and no 
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significant effect in females (p=0.19). Overall there was an effect of treatment 
across all sexes (n=19-20/group) but this did not reach significance within sex. 
 
Tideglusib (200 mg/kg) does not alter ethanol metabolism. To assess 
whether the gavaged dose of tideglusib described above may alter ethanol 
metabolism in the two hours following treatment, we took blood a separate set of 
ethanol-treated animals +/- tideglusib pre-treatment. Tideglusib was delivered via 
gavage and mice (n=12-14/treatment) were injected with ethanol (2 g/kg, i.p.) 30 
minutes afterward. Blood was collected at four time points (n=3-4/treatment/time 
point) and assessed for ethanol content via gas chromatography. Results are 
plotted in Figure 6.6. 2-way ANOVA found a significant effect of time 
(F3.18=13.02, p<0.0001) and no significant effect of treatment (F1,18=0.027, 
p=0.87) or treatment*time interaction (F3,18=0.31, p=0.82). Thus there was no 
evidence that tideglusib altered the pharmacokinetics of ethanol.  
 
Tideglusib (200 mg/kg) decreases GSK3B-mediated PSD95 
phosphorylation in PFC. Response of GSK3B target PSD95 to repeated 
tideglusib (200 mg/kg) treatment in ethanol-naïve animals (n=6-7/treatment) was 
assessed via Western blotting of microdissected PFC. Results are shown in 
Figure 6.7. Unpaired t-tests were used to measure all quantified densitometric 
ratios. In the case of p-PSD95-T19, a one-tailed t-test was used to test whether 
tideglusib effectively inhibited GSK3B activity at this phospho-residue. Other 
phospho-proteins and total proteins were assessed using two-tailed t-tests to  
208 
 
 
 
Figure 6.6 Tidegusib (200 mg/kg) does not affect ethanol metabolism. 2-way 
ANOVA found a significant effect of time (p<0.0001) and no significant effect of 
treatment (p=0.87) or treatment*time interaction (p=0.82). 
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Figure 6.7 Repeated tideglusib decreases PSD95 phosphorylation. A. 
Representative films of Western blots of PFC following repeated Tideglusib (200 
mg/kg) or vehicle treatment (n=6-7/treatment, males). B.-E. Relative ratios of p-
PSD95-T19, total PSD95, p-GSK3B-S9, and total GABA(A) α1 based on 
unnormalized densitometric values. Results of t-tests are given below each 
graph. F. Linear regression of p-GSK3B-S9 expression against GABA(A) α1 
shows suggestive inverse trend. Throughout figure Tideglusib treatment is in 
orange, vehicle in blue.  
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determine the potential effect and direction of the drug on their expression. 
Phospho-PSD95-T19 was found to be significantly decreased (p=0.033), while 
tideglusib did not show significant effects on p-GSK3B-S9/total (p=0.19), total 
PSD95 (p=0.57), or total GABAAα1 (p=0.24). However an interesting inverse 
relationship could be observed between band intensity of p-GSK3B-S9 and that 
of GABAAα1. When this relationship was plotted (Fig. 6.7F) I,t was found to have 
a suggestive inverse linear relationship by regression (p=0.059). These findings 
hint at the regulation of CNS excitatory/inhibitory balance by GSK3B via synaptic 
proteins, with tideglusib significantly altering PSD95 regulation via phospho-T19.   
 
Interrogation of the NIH LINCS predicts reversal of alcoholic gene 
expression by the GSK3B inhibitor kenpaullone. Output from the L1000CDS2 
is shown in Figure 6.8. Gene lists obtained from McClintick et al. (2014) are 
shown at the left of the figure. Along the top are the highest ranked small 
molecule inhibitors in the LINCS database at the time of query. Ranking was 
according to the predicted “reverse” signature of the inhibitors, i.e. a significant 
effect on gene expression in the opposite direction across the multiple (human) 
cell lines used in the LINCS. The top two inhibitors, radicicol and kenpaullone, 
show the same degree of overlap (indicated by height of bars atop Fig. 6.8). The 
top-ranked small molecules and their targets are listed in Table 6.1. 
Enriched pathways based on the up- and down- regulated gene lists were 
also predicted by the program Enrichr as part of the L1000CDS2 query. The top 
pathway among genes increased in alcohol LCL lines was related to nerve  
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Table 6.1. Top ranked small molecule inhibitors according to the 
L1000CDS2 and their targets (IC50s reported by PubChem) 
Experimental Molecule     Targets 
radicicol Hsp90 (Kd=0.0027uM) 
Kenpaullone GSK3β (IC50=0.023uM), CDK-1 (IC50=0.035uM) 
geldanamycin Hsp90-alpa (IC50=0.02uM), Hsp90-beta 
(IC50=0.022uM) 
598226  TDP1 (IC50=4.11uM) 
T8902 TDP1 (IC50=4.11uM) 
BRD-A68065211 GSTO (IC50=0.038uM), SRC3 (IC50=0.503uM), 
TDP1 (IC50=2.06uM) 
Chemistry 2804 VDR (IC50=1.99 uM), ROR gamma (IC50=3.54uM) 
17757146 PDE4 (IC50=0.0067uM), PDE10 (IC50=0.823uM) 
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growth factor (NGF) signaling, while pathways enriched for the downregulated 
genes were largely related to heat shock and cellular stress. It may be that 
alcoholism is associated with an impairment in response to heat shock and 
stress and that overall the inhibitors ranked by this tool are predicted to restore 
the expression of genes related to this pathway (e.g. HSPE1, HSPA8, 
HSP90AB1). 
6.4 Discussion 
 Here we have described the use of an FDA Phase II approved GSK3B 
inhibitor, tideglusib, as an intervention in a mouse model of excessive alcohol 
intake. When tideglusib was administered i.p., both the 3 and 10 mg/kg doses 
significantly attenuated daily ethanol consumption in terms of %change from 
baseline. When tideglusib was administered by gavage (200 mg/kg) it profoundly 
decreased ethanol consumption during a 2 hour binge-like ethanol drinking 
period, in both male and female mice. This gavaged dose was not found to alter 
the metabolic profile of ethanol. It was found to significantly decrease PSD95 
phosphorylation in the PFC and to show a suggestive inverse relationship with 
total GABAAα1 protein levels.   
 
6.4.1 Limitations/Alternatives 
By the end gavage treatment period, 2 male and 2 female tideglusib 
treated, ethanol drinking mice had become evidently ill, based on poor 
grooming/feeding/locomotor activity. Such adverse outcomes may have been 
due to poor feeding due to esophageal/gastric irritation, fluid aspiration into the 
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lungs from gavage, or tideglusib specific effects such as liver toxicity. Overall 
there were 28 vehicle and 28 tideglusib-treated mice as part of this study, 20 of 
each of which were receiving ethanol access. We collected liver samples from all 
mice for the purposes of assessing potential liver toxicity of tideglusib +/- ethanol; 
analyses are being performed by a collaborator and results are pending. An 
additional caveat is that for the last 3 days of the experiment (which included 1 
ethanol-drinking day) all mice were habituated to daily saline injections as 
outlined in Figure 4.2, so that by the day of harvest we could test for acute 
ethanol challenge in these animals (Figures 4.16 and 4.17) without the injection 
itself being a novel intervention. However, the amount of interventions occurring 
simultaneously at this study’s end may have increased the risk of potential 
confounds overall. It should be noted that other preclinical studies have reported 
daily tideglusib (200 mg/kg) by gavage for up to 3 months with no significant 
effects on survival (Sereno et al, 2009). 
In this study, significant effects of the treatment period (i.e. any gavage vs. 
baseline, see Figures 6.4-6.5) on mean ethanol intake also reflect the overall 
difficulties in using gavage delivery to study a behavior that relies on the 
esophagus. Gavage administration irrespective of treatment interfered with 
ethanol drinking behaviors, particularly in regards ethanol preference by inducing 
water drinking in the hours after gavage was administered.  This is in contrast to 
the i.p. study, wherein control (vehicle and saline groups) actually showed 
relative non-significant increases in mean ethanol consumption and preference 
during the “treatment period.” This could indicate that escalation in ethanol-
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drinking behaviors was still occurring undeterred by i.p. injections; and that this 
delivery method shows less interference with ethanol-drinking behavior. However 
i.p. injection delivery has other potential problems, particularly in the case of CNS 
penetrant molecules which must often be non-polar and hydrophobic. Moreover 
oral delivery has the benefit of clinical applicability, given the vast preference for 
oral delivery of drugs in human patients. Therefore alternative oral routes of 
administration should continue to be explored in animal work (Turner et al, 2011), 
particularly in pre-clinical studies of AUD.  
  Regardless of the above limitations, an inhibitory effect on ethanol 
consumption by tideglusib was replicated across routes of administration. 
Tideglusib has been used in human patients with Alzheimer’s disease at doses of 
up to 1000 mg (approximately 14 mg/kg for a 70 kg person) with no significant 
increase in adverse events over placebo except for a reversible increase in liver 
enzymes (del Ser et al, 2013; Lovestone et al, 2015). If it can be further 
determined that tideglusib does not pose a threat of liver toxicity in the context of 
alcoholism, then it might represent a novel treatment option. The fact that clinical 
trials for other neuropsychiatric diseases are ongoing (Anagnostou, 2018) make 
it an attractive option for its practical accessibility alone. However, as Mathuram 
et al. point out, due to GSK3B’s ubiquitous expression and involvement in 
numerous essential pathways, inhibitors such as tideglusib carry a high risk of 
off-target effects (Mathuram et al, 2018). While it is possible that off-target effects 
would be mild compared to its on-target effects, as in the case of the non-specific 
GSK3B inhibitor lithium (Patel et al, 2006), it is worth continuing to explore the 
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GSK3B pathway as it is pertains specifically to the neurobiology of alcoholism. 
There could be other members in this pathway that show dysregulation specific 
to AUD in the CNS and that could be targeted with therapeutic agents.  
 
6.4.2 Conclusions 
 Tideglusib showed striking effects on ethanol consumption across two 
modes of delivery. Via i.p. injection, the 3 mg/kg and 10 mg/kg doses which 
decreased ethanol consumption as a percent of baseline consumption (Fig. 
6.1C), were equivalent to doses of the “tideglusib progenitor” molecule TDZD-8 
which decreased operant responding for ethanol in Wistar rats (van der Vaart et 
al, 2018). A significantly higher gavage dose (200 mg/kg) decreased ethanol 
consumption markedly during a 2-hour binge but less robustly over the 24-hour 
period of IEA. Tideglusib has recently undergone pharmacokinetic profiling in 
male mice (Saini et al, 2018) at an i.p. dose of 10 mg/kg: plasma levels peaked 
at 0.25 h (Tmax) and the terminal half-life (t1/2) in vivo was determined to be 5.12 
hours. Tideglusib was also found to be highly metabolized in mouse liver 
microsomes (t1/2 =16 min) (Saini et al, 2018). Both i.p. and gavage routes of 
administration would be expected to undergo significant first-pass metabolism, 
with complete delivery to the portal vein in the case of gavage. The preferential 
effect of tideglusib on binge ethanol consumption may be explained by an early 
peak plasma concentration and quick drop-off after several hours.  Thus, in a 
mouse model repeated or extended-release dosing might be necessary to more 
accurately assess actions on prolonged ethanol intake. 
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An alternative GSK3B inhibitor, SB216763, has been found to abrogate 
cocaine-induced conditioned place preference (CPP), particularly upon re-
exposure to an environment previous paired with cocaine (Shi et al, 2014). This 
suggests that GSK3B activity is necessary for the memory reconsolidation and 
subsequent drug-seeking behavior modeled by CPP upon reintroduction to a 
cocaine-paired environment. Interestingly, we observed a significant inhibitory 
effect of TDZD-8 on cue-induced reinstatement (van der Vaart et al, 2018). This 
abrogation was observed specifically in ethanol-trained rats re-introduced to 
ethanol-associated cues, while sucrose-trained rats reintroduced to sucrose-
associated cues did not show an effect of TDZD-8. It has not been tested 
whether TDZD-8 would also attenuate cue-induced reinstatement of cocaine. If 
this were the case it would suggest that there is something fundamentally 
different about re-introduction to cues associated with drugs of abuse (alcohol 
and cocaine) as compared to cues associated with “natural reinforcers” (i.e. 
sucrose).  
In the studies described in this chapter, intermittent ethanol access (IEA) 
was used to induce an escalated level of ethanol consumption compared to 
constant ethanol access. This paradigm is theorized to work based on the 
induction of a kindling-type transition from moderate to excessive use, based on 
cycles of exposure and withdrawal (Hwa et al, 2011). It is interesting to consider 
that pre-treatment with tideglusib before an ethanol access period might serve to 
abrogate this kindling-type effect, either through diminishment of withdrawal-
related symptoms or impaired reconsolidation of ethanol-related learning. A study 
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of tideglusib in the context of ethanol-induced CPP might help elucidate this type 
of effect.  
 As a corollary analysis we have described a data-mining expedition using 
genes identified by McClintick et al. (2014). Their goal of using LCLs cultured 
from peripheral blood mononucleocytes of alcohol-dependent and control 
patients was to work toward the complex but necessary task of identifying 
biomarkers for AUD. Given the impossibility of brain biopsies from living patients, 
McClintick et al. used the logic that gene expression in precursor cells is a 
practical read-out of DNA sequence, and could identify genes with predisposition 
to alterations in their expression in brain (Hu et al, 2006). The authors included 
annotations identifying which differentially regulated genes identified in LCLs had 
previously been reported as differentially expressed in post-mortem brain tissue 
of alcoholic patients. We filtered their gene lists based on these external 
validations as a type of quality control. The prediction that kenpaullone would 
reverse the expression signature identified by McClintick et al. was particularly 
interesting to us given our ongoing work on small molecule inhibitors of GSK3B 
in preclinical models of AUD. Tideglusib is not currently in the NIH LINCS small 
molecule database but would be a useful addition in our opinion given its clinical 
approval. There are a handful of in vitro studies which investigate kenpaullone in 
the context of neuropsychiatric disorders, e.g. its effect of GSK3B regulation of 
serotonin 1B receptors (Chen et al, 2009), but reports of its in vivo use are limited 
(Eldar-Finkelman et al, 2011). Overall we consider that our use of the NIH LINCS 
thus far demonstrates a rather subtle measure of internal validity, as findings 
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from disparate modes of investigation are in broad agreement over the 
applicability of GSK3B inhibitors in the context of alcoholism.  
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Chapter 7  
Concluding Discussion and Future Directions 
 
 An enduring mystery of alcoholism is why some individuals progress from 
occasional to compulsive use of alcohol, to the point of destruction of their health, 
families, and functioning. The pathogenesis of AUD is widely believed to manifest 
upon neuroadaptive responses to repeated ethanol exposures, in predisposed 
individuals (Harris and Koob, 2017). To form an integrative picture of AUD with a 
view to effective treatment, both the neurobiology of repeated ethanol exposures 
and the predisposing factors in human alcoholic patients must be understood.  
 In this dissertation we began with large-scale, genome-wide expression 
analyses of acute vs. chronic ethanol’s effects on gene expression along the 
mesocorticolimbic reward pathway (NAC and PFC). We found a surprising 
degree of overlap between acute and chronic ethanol in terms of significant gene 
expression perturbations. Overall, pathway enrichment analyses for ethanol-
responsive genes across both exposure types and brain regions identified genes 
related to synaptic transmission and neuronal structure. Genes uniquely 
regulated after chronic ethanol in the PFC did converge on Akt as a predicted 
pathway hub (Fig. 3.3), an interesting finding in light of later chapters which 
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describe the GSK3B pathway for which AKT is a prominent upstream kinase.  A 
major candidate gene arising from this chapter was Dnm3, which was identified 
as significantly ethanol-responsive across both treatments and brain regions. In 
the NAC particularly, its expression in the context of chronic ethanol was reliably 
altered based on presence of the D2 vs. B6 allele (see Fig 3.8, red vs. black 
bars). Because its expression in the NAC was also correlated to ethanol drinking 
after repeated ethanol-vapor exposure (Fig 3.7) Dnm3 may represent a genetic 
locus which interacts with chronic ethanol allostatically to produce genotype-
dependent ethanol-drinking behavior. The dynamics of the dynamin-III protein 
have not, to our knowledge, been studied in the context of ethanol. Dynamin 
proteins, of which there are 3 mammalian isoforms (I, II, III) have the conserved 
function of regulating membrane endocytosis, i.e. of synaptic vesicles (Ferguson 
and De Camilli, 2012). Effects of ethanol on dynamin-related mechanisms could 
conceivably be regulated via GSK3B, given its control of dynamin I mediated 
activity-dependent bulk endocytosis (Clayton et al, 2010). However there is no 
evidence currently for direct interaction between GSK3B and dynamin III.  
 Gsk3b emerged as a candidate gene for alcoholism based on our 
laboratory’s initial studies of acute ethanol’s effects on networks of genes (Wolen 
et al, 2012). Gsk3b was a highly interconnected node in a network of genes 
showing significant ethanol response across the BXD panel. Human homologs of 
genes this network (with the highest correlations with Gsk3b) were investigated 
in a SNP-set based analysis of human alcohol-dependent patients (Edenberg et 
al, 2005), and found to be enriched for risk-conferring SNPs (Fig. 3.9). The  
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Figure 7.1 Working model of GSK3B involvement in ethanol signaling. 
“Competing pathways” downstream of ethanol converge on GSK3B 
phosphorylation. We observe acute ethanol-mediated phosphorylation of 
GSK3B-S9, but this effect diminishes after long-term IEA. BDNF expression in 
the mPFC is found to be protective against excessive ethanol use and also 
decreases following IEA (Darcq et al, 2015). An alternate upstream pathway is 
dopamine (DA) mediated, and would be expected to activate GSK3B via type 2 
dopamine receptor recruitment of β-arrestin. 
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Gsk3b gene and its encoded protein GSK3B were the focus of subsequent 
studies on alcohol-related signaling and behaviors, described in Chapters 4-6.  
GSK3B showed notable changes in activity and responsiveness to ethanol 
as assessed by phosphorylation of its inhibitory Ser-9 residue. Acute ethanol was 
found to markedly increase phosphorylation at this residue with apparent 
differences in threshold dose between males and females (Fig. 4.3-4.4). This 
finding is generally consistent with prior literature indicating GSK3B 
phosphorylation following acute doses of ethanol (1.8-2.0 g/kg) in PFC 
(Neznanova et al, 2009), NAC (Neasta et al, 2011; Sachs et al, 2014), and 
hippocampus (Sachs et al, 2014). However in contrast to prior work which also 
showed increased p-GSK3B-S9 after chronic ethanol in NAC (Neasta et al, 2011) 
and dorsomedial striatum (Cheng et al, 2016), our study of PFC after >5 weeks 
of IEA did not show a significant effect of ethanol on GSK3B phosphorylation 
(Fig. 4.10). We tested tissue harvested 24 hours after last access, as was done 
in the prior work cited. It is possible these studies of ours were underpowered 
(n=8/sex) as a trend toward increased p-GSK3 was observed in males and 
females. Regardless, while GSK3B activity did not appear to be altered basally at 
this time point, its responsiveness to ethanol was decreased, as assessed by an 
i.p. injection of 2.0 g/kg in IEA-exposed animals compared to ethanol-naïve 
controls (Fig. 4.15—4.17). Interestingly, decreased responsiveness of GSK3B to 
ethanol-induced phosphorylation has been observed in serotonin-deficient mice, 
which also exhibit increased ethanol consumption (Sachs et al, 2014). Therefore 
it may be that the decreased level of ethanol-induced inhibition of cortical GSK3B 
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is an underlying factor in the tendency of IEA-exposed mice to escalate their 
ethanol consumption relative to naïve mice (Fig. 4.12—4.13, also see 
(Rosenwasser et al, 2013)).  
 One potential upstream mechanism consistent with the blunting of GSK3B 
phosphorylation in PFC following long-term ethanol exposure would be via 
decreased BDNF-mediated signaling. BDNF has been found to inhibit GSK3B via 
Akt (Smillie et al, 2013). Moderate ethanol consumption has been shown to 
activate BDNF signaling, and this protects against the development of excessive 
ethanol intake (Jeanblanc et al, 2009; McGough et al, 2004). However, Darcq et 
al. (2015) found that intermittent ethanol access (IEA) produced a robust 
reduction of Bdnf expression in the mPFC. A microRNA targeting BDNF, mIR-
30a-5p, was found to be concurrently increased. Inhibition of this miRNA using a 
targeted nucleic acid sequence in the mPFC restored BDNF expression and 
decreased drinking, while overexpression of the miRNA further escalated ethanol 
consumption (Darcq et al, 2015). This data is integrated into our findings on 
GSK3B in Figure 7.1. We propose that there are converging pathways on 
GSK3B following a given ethanol exposure. One of these is a BDNF-mediated 
pathway in the mPFC, likely through TrkB receptor activation and subsequent 
Pi3K-dependent Akt signaling intracellularly (Smillie et al, 2013), serving to inhibit 
GSK3B. This pathway might serve to self-regulate ethanol use under normal 
conditions, but is weakened following intermittent ethanol exposure, due to 
decreased expression of BDNF via miR-30a-5p targeting. Another pathway 
downstream of ethanol is dopamine release into the mPFC (Trantham-Davidson 
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and Chandler, 2015). Dopamine, particularly upon binding to D2 receptors (D2R) 
activates GSK3B, likely through beta-arrestin recruitment of protein phosphatase 
2-alpha (PP2A) (Beurel et al, 2015). This pathway could act antagonistically to 
the BDNF-dependent pathway, promoting drug-seeking behavior as is often seen 
with activation of corticolimbic dopamine signaling (Tzschentke, 2000). 
Neuroplastic changes underlying addiction-related learning may rely on a pool of 
active GSK3B in the context of alcohol exposure, as has been observed with 
cocaine (Miller et al, 2014). Our proposed pathway includes a feedback loop 
wherein activated GSK3B can itself serve to inhibit BDNF (Jope et al, 2006; van 
der Vaart et al, 2018), which would further promote excessive ethanol intake.  
 Although still speculative, the mechanism proposed in Figure 7.1 is 
consistent with a number of our observations of GSK3B modulation and ethanol 
drinking behavior. There is an interesting corollary between male-female 
differences in the qualitative profile of GSK3B phosphorylation and escalation in 
binge-like drinking. It appeared to require a higher dose of ethanol to induce 
GSK3B phosphorylation in female mice than males (compare Fig. 4.3-4.4), and 
female mice escalated their binge ethanol consumption almost immediately (Fig 
4.13) while male mice escalated by the fifth week. This would be consistent with 
an initial “protective effect” of GSK3B inhibition. As discussed previously in 
Chapter 4, co-administration of a TrkB inhibitor such as ANA-12 with acute 
ethanol is essential in determining whether BDNF signaling is upstream of the 
ethanol-GSK3B phosphorylation effect (Cazorla et al, 2011).  
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In the case of GSK3B overexpression (Fig. 5.3-5.4), the pool of active 
GSK3B potentially mediating dopaminergic effects in the mPFC would have been 
increased. Moreover, although not discussed in this dissertation, Dr. Annie Meng 
found a decrease in Bdnf mRNA and BDNF protein in the mPFC of mice 
following viral vector GSK3B overexpression (van der Vaart et al, 2018). 
Together these findings suggest a strengthening of the dopaminergic pathway 
proposed in Figure 7.1. Conversely in the case of GSK3B deletion, dopaminergic 
signaling to the PFC (or at least the IL portion of it) could not activate GSK3B, 
and any effects of this pathway downstream from active GSK3B would be 
eliminated. However an important future step is characterizing any potential 
compensatory increases in GSK3A expression or activity following GSK3B 
deletion. Similarly in the case of tideglusib, an irreversible GSK3B inhibitor 
(Dominguez et al, 2012), dopaminergic effects mediated through GSK3B would 
presumably be abrogated so long as the drug is bound.  
Could dopamine-dependent synaptic remodeling be mediated by GSK3B? 
Much of the ethanol-GSK3B downstream pathway remains to be elucidated, but 
there are some interesting considerations in light of GSK3B’s established roles in 
cytoskeletal reorganization and targeting of synaptic anchor proteins (Salcedo-
Tello et al, 2011). Overactive GSK3B promotes PSD95 mobilization by 
phosphorylation of its threonine-19 residue (p-PSD95-T19) (Nelson et al, 2013). 
We observed a suggestive inverse trend of p-PSD95-T19 level with increasing 
ethanol dose—the direction expected given GSK3B inhibition—but this was not 
significant (Fig. 4.6). There was also a significant increase in total PSD95 protein 
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following long-term IEA in male mice (Fig. 4.11). An upregulation of PSD95 could 
represent a compensatory increase in NMDA-receptor scaffolding following 
chronic exposure to ethanol. Increased PSD95 expression has been found to 
enhance NMDA receptor surface expression (Lin et al, 2006). Thus, increased 
PSD95 could contribute to the well-known phenomenon of NMDA receptor over-
activation during periods of ethanol withdrawal. However, this finding presents 
something of a paradox in light of our findings on GSK3B. The inhibitor tideglusib 
decreases PSD95 phosphorylation at T19 (Fig. 6.7). According to Nelson et al. 
GSK3B-induced PSD95 phosphorylation is necessary for its internalization, and 
so a decrease in this phosphorylation would serve to stabilize PSD95 at the 
neuronal surface (Nelson et al, 2013). If this corresponded to increased surface 
expression of NMDA receptors, this should further exacerbate the hyper-
excitable state associated with ethanol withdrawal and might serve to increase 
self-administration during each access period. Contrary to this logic, lithium and 
TDZD-8 have both previously been found to reduce NMDA currents (Chen et al, 
2007) and tideglusib has been found to protect against NMDA-induced 
excitotoxicity (Armagan et al, 2015). In neither of these studies was the level of p-
PSD95-T19 assessed for its relation to the GSK3B inhibitors’ effects on NMDA 
expression. It is possible that GSK3B-mediated PSD95 phosphorylation 
regulates not only receptor internalization, but also receptor insertion, i.e. overall 
receptor dynamic turnover. Certainly PSD95 has been found to regulate both 
aspects of NMDA receptor function membrane localization (Lin et al, 2004). The 
Nelson et al. (2013) studies were performed only in cultured neurons, and so the 
228 
 
true in vivo effect of p-PSD95-T19 on NMDA surface expression is unknown. 
Useful future studies would include characterizing the p-PSD95-T19 surface 
expression in the PFC, with and without GSK3B modulation, and overlapping 
staining for NMDA receptors. Electrophysiological studies would also contribute 
greatly to our understanding of the effects of GSK3B on excitatory balance in 
neurons. In this dissertation, p-PSD95-T19 served as a useful readout for 
GSK3B activity at the synapse (Fig. 6.7) but with unclear implications 
downstream at the present time.  
GSK3B activity shows an analogous function in regulation of inhibitory 
balance in neurons via its regulation of gephyrin (Tyagarajan et al, 2011), the 
scaffold protein of GABAA receptors. Given its dual effects on PSD95 and 
gephyrin, the regulation of excitatory-inhibitory balance via GSK3B is likely highly 
complex and depends upon cellular and temporal context for its combinatorial 
effect on neuronal signaling. Again, based on cell culture experiments, inhibition 
of GSK3B would be expected to increase surface GABAA receptor expression 
due to decreased gephyrin-dependent internalization. In the context of chronic 
alcohol in the dorsomedial striatum, GSK3B inhibition has been found to increase 
GABAA receptor expression with corresponding electrophysiological effects 
(Cheng et al, 2016). Here we found a suggestive inverse relationship between 
GSK3B phosphorylation and overall GABAAα1 subunit expression in the PFC 
(Fig. 6.7). This particular subunit has been associated with alcohol-induced 
tolerance and dependence (Werner et al, 2009), and its overall expression could 
be subject to regulation by gephyrin activity (Tyagarajan and Fritschy, 2014).  If 
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overall GABAergic signaling is increased in the mPFC via GSK3B inhibition, this 
could represent one means of self-regulation against excessive ethanol 
exposure. The mPFC sends glutamatergic projections to the nucleus accumbens 
to maintain reward-seeking behavior via the corticolimbic circuit (Tzschentke, 
2000). An upregulation of GABAA receptors in the mPFC could serve to decrease 
the intensity of firing of these glutamatergic projection neurons. Thus, analysis of 
GABA receptor expression in the PFC of mice with GSK3B overexpression or 
deletion could provide insight into a potential mechanism of the behaviors 
observed and described in Chapter 5. While lacking regional specificity of the 
viral studies, all glutamatergic projection neurons in the PFC would be Camk2a+, 
and so Camk2a-Cre*Gsk3bfl/fl mice could show a similar mechanism of PFC 
GABAA upregulation decreasing excessive ethanol consumption.  
While regulation of PSD95 and gephyrin would each provide a means of 
regulating excitatory or inhibitory signaling, their dual regulation also suggests an 
overall regulation of dendritic spine stability. It is possible that ethanol-related 
learning requires not just changes in excitation/inhibition, but changes in dendritic 
morphology along ethanol-responsive circuits to promote behavioral adaptation. 
Active GSK3B allows for changes in dendritic morphology while its inhibition may 
serve to increase the stability of the spine (Cymerman et al, 2015) thereby 
resisting ethanol-related changes. Golgi-Cox staining and analysis of dendritic 
length, branching, and spine density as has been done in medium spiny neurons 
of the NAC (Peterson et al, 2015) would serve as a useful measure in the mPFC. 
We hypothesize that repeated ethanol exposure would alter spine density 
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selectively, such as increased density of mushroom-type spines in glutamatergic 
neurons (Kroener et al, 2012), but that the extent of such morphologic change 
might depend upon the level of GSK3B activity. Based on the requirement of 
GSK3B activity to induce morphological change, lower levels of GSK3B activity 
would be expected to show resistance to alterations in synaptic structure.  
To achieve high levels of GSK3B activity, a useful transgenic line for 
future studies would be GSK3B-S9A mice, which have previously been proposed 
as a model of hyperactivity and mania (Prickaerts et al, 2006). The serine to 
alanine mutation encoded in this Gsk3b allele prevents its inactivation via S9 
phosphorylation. This mutation serves to increase baseline GSK3B activity, 
which may predispose toward bipolar type symptoms but also toward increased 
susceptibility to excessive ethanol intake. Certainly in humans these 
predispositions appear to be linked (Regier et al, 1990). In addition to the 
possibility of phenotypic differences these mice might provide associated 
network-level changes in gene expression +/- alcohol. The GSK3B transgene is 
also available as a plasmid (Gozdz et al, 2017) which would allow regional and 
temporal specificity based on viral vector mediated expression.  
Network-level investigations are overall an open-ended avenue for 
investigation in light of all that was outlined in this dissertation. We began this 
endeavor with the exciting observation that the Gsk3b gene transcript 
represented a molecular hub for ethanol induced changes in PFC gene 
expression across a genetically diverse panel of mice (Wolen et al, 2012). 
Studies on the level of protein phosphorylation provided very strong evidence 
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that acute ethanol greatly affects the activity of the GSK3B kinase in PFC. 
Inhibition at this functional level could influence genomic changes in many genes 
regulated by ethanol. The network of acute-ethanol related genes has shown 
important consequences in terms of predisposition to alcohol dependence (Fig. 
3.9), and so further study of this network is warranted. Given the phenotypic 
effects observed following GSK3B deletion in Camk2a positive neurons, these 
transgenic animals could also allow for further resolution of the Gsk3b gene 
network. We would propose that following tamoxifen treatment, rather than 
beginning free access to ethanol, Cre+ and Cre- mice are injected with saline or 
ethanol and the PFC harvested as described in Wolen et al. (2012). This would 
allow for comparisons in gene expression at baseline (via comparison of the 
saline groups) and ethanol-induced expression changes (via saline-to-ethanol S-
Scores). The latter of these is where changes in the previously identified Gsk3b 
network might be seen, but both could provide crucial insights into the 
relationship between GSK3B functional expression and the genomic outcome. It 
is through this type of analysis that human genetic panels may in turn be 
interrogated for specific gene expression signatures and we may begin to predict 
more effective treatments based on an informed prediction of a patients’ 
neurobiology. 
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Appendix 
 
 
Supplemental Fig. 3.1. REVIGO treemap of Gene Ontology Biological Processes 
enriched in genes significantly regulated by CIE only in the PFC. GO categories 
clustered by semantic similarity. 
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Supplemental Fig. 3.2. REVIGO treemap of Gene Ontology Biological Processes 
enriched in genes significantly regulated by CIE only in the NAC. GO categories 
clustered by semantic similarity. 
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Supplemental Fig. 3.3. REVIGO treemap of Gene Ontology Biological Processes 
enriched in genes significantly regulated by CIE and acute EtOH in the PFC. GO 
categories clustered by semantic similarity. 
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Supplemental Fig. 3.4. REVIGO treemap of Gene Ontology Biological Processes 
enriched in genes significantly regulated by CIE and acute EtOH in the NAC. GO 
categories clustered by semantic similarity. 
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Supplemental Fig. 3.5. REVIGO treemap of Gene Ontology Biological Processes 
enriched in genes significantly regulated by CIE in the PFC and NAC. GO categories 
clustered by semantic similarity. 
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